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CHAPTER 1: INTRODUCTION  
1.1 Bacterial keratitis 
Infection of the cornea caused by replicating bacteria is known as bacterial 
keratitis. It is a serious ocular condition that can cause significant long term visual 
morbidity.
1-5
  
 
1.11 Epidemiology 
The epidemiological patterns of bacterial keratitis vary with the demographics of 
the population, socioeconomic factors, geographic location and associated 
climate. Bacteria are responsible for a larger proportion of corneal ulceration in 
temperate climates such as the United Kingdom (UK) and the northern United 
States of America (USA), than in tropical regions such as south India, where 
fungal infections predominate.
6
 An estimated 1500 cases are seen annually in the 
UK (approximately 250 per year for a city the size of Liverpool or Manchester) 
and 14,000 in the USA.
7
 Complete epidemiological information for developing 
countries is lacking, however, it is considered to be the leading cause of corneal 
blindness in developing nations.
8
 Whitcher et al,
9
 describe bacterial keratitis as the 
silent epidemic in developing countries. 
1.12 Risk factors 
Bacterial keratitis rarely occurs in the normal eye because of the cornea’s natural 
and innate resistance to infection (chapter 1.21). Risk factors for keratitis can be 
categorised into extrinsic factors, corneal disease and systemic disease. Table 1 
shows the differences in predisposing risk factors for keratitis in studies from 
different geographic locations. For example, the proportion of cases of keratitis 
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associated with contact lens wear was 3% in India compared to 50%, 36%, 22% in 
France, Switzerland and Australia respectively. 
 
Table 1. Studies that describe risk factors for keratitis. n= number of cases of 
keratitis 
 Bharati
10
 
(India)  
n=1043 
Bourcier
2
 
(France) 
n=300 
Schaeffer
5
 
(Switzerland) 
n=85 
Green
11
 
(Australia) 
n=253 
contact lens 
trauma 
corneal disease 
corneal surgery 
other causes 
3% 
28% 
67% 
N/A 
2% 
50% 
15% 
21% 
4% 
N/A 
36% 
20% 
29% 
5% 
N/A 
22%  
16%  
18% 
11% 
3% 
N/A = risk factor not mentioned in study 
1.121 Extrinsic factors  
1.1211 Contact lenses  
Contact lens wear is the major risk factor for the development of bacterial keratitis 
in developed countries.
2, 5, 12
 Lam et al
12
 reported that the incidence of bacterial 
keratitis was six-fold higher in contact lens wearers than in the general population. 
There are approximately 36 million contact lens wearers in the USA
13
 and 3.7 
million in the UK.
14
 The annual incidence of bacterial keratitis in contact lens 
wearers has been reported as being between 10 to 30 per 100,000 in the USA.
15, 16
 
Contact lens associated keratitis is rarer in developing countries due to a lower 
frequency of contact lens use.
10, 17, 18
 For example Bharati et al,
10
 described 
contact lens wear as only being identified as a cause of keratitis in 3% of a large 
case series of patients in India, whereas Bourcier et al
2
 found contact lens wearers 
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to constitute 50% of keratitis cases in France. Extended continuous wear soft 
contact lenses have become increasingly popular, offering increased convenience 
than daily wear lenses. Extended wear lenses, however, are associated with a 
higher risk of bacterial keratitis. In the UK, the incidence of keratitis has been 
estimated at 3.5 per 10,000 in daily disposable users and 20 per 10,000 extended-
wear contact lens.
15, 19-21
 A case-controlled study by Dart et al
22
 showed that the 
relative risk of keratitis for overnight wear for any lens type, was 5.4 higher than 
daily use. They also found the risk of vision loss, was lower in the daily 
disposable group.  
 Contact lenses invariably cause a degree of corneal hypoxia. This can lead 
to suppression of epithelial proliferation, reduced corneal integrity,
23, 24
 and an 
increased risk of infection. In addition to contact lens induced corneal changes, 
some studies suggest that bacterial virulence is enhanced through contact lens use 
(chapter 4.14). Pseudomonas aeruginosa is the most commonly isolated bacterial 
species in contact lens associated keratitis.
25, 26
 It has been shown to adhere to a 
wide variety of contact lenses
27
 and contact lens cases.
28
 Choy et al
29
 determined 
that P. aeruginosa isolated from patients with keratitis had variations in the type 
III secretion toxin encoding genes (chapter 4.1222) and Tran et al
30
 describe the 
adhesion to contact lenses by bacterial flagella and pili. Another mechanism 
which predisposes contact lens wearers to keratitis is by biofilm formation. 
Bacterial biofilms are structured, surface-associated communities of bacteria 
which are less susceptible to antimicrobial agents and are protected from the host 
immune response, giving rise to chronic infections that are difficult to eradicate. 
The moist conditions in which contact lenses are worn or kept and their storage 
cases, are ideal for biofilm formation.
31
 This allows bacteria to persist on contact 
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lenses despite the use of disinfecting solution.
32
 McLaughlin-Borlace et al
33
 
evaluated biofilm formation on contact lenses and contact lens cases in 20 patients 
with bacterial keratitis. 11/20 contact lenses and 17/20 contact lens cases had 
evidence of bacterial biofilm formation. Biofilm formation occurred with equal 
frequency with hydrogen peroxide and chlorine release care systems.  
1.1212 Trauma 
In developing countries however, ocular trauma is the commonest predisposing 
factor for keratitis.
9
 Studies from India and Nepal describe trauma to be causative 
in keratitis in over 65% of cases.
17, 34
 Common causative mechanisms of injury 
include; corneal abrasions, corneal foreign bodies and corneal lacerations.
35
 There 
is a strong association between agricultural work and the occurrence of bacterial 
keratitis.
6
  
1.1213 Surgery 
Corneal surgery is a less common predisposing factor in bacterial keratitis, with 
reported rates varying between 4%
2
 and 11%.
11
 Bacterial keratitis after corneal 
transplantation can severely compromise the survival of a corneal graft (figure 
1).
36, 37
 Das et al
38
 reported that the major risk factors for the development of 
bacterial keratitis following corneal transplantation are; suture related, failed graft, 
ocular surface disease and previous Herpes simplex keratitis (HSK).  
Bacterial keratitis is a rare complication of laser refractive surgery with an 
estimated incidence between 1 in 1000 and 1 in 5000.
39, 40
 Cataract surgery
41
 and 
corneal cross linking have also been reported as rare causes of cause bacterial 
keratitis.
42
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1.122 Ocular disease 
A variety of ocular diseases can predispose a patient to bacterial keratitis.  
1.1221 Ocular surface and lid disease 
Ocular surface disease (OSD) is a term used to describe disease resulting from 
failure of mechanisms responsible for maintaining a healthy ocular surface.
43
 It 
comprises of a range of overlapping conditions that are associated with damage 
and disruption to the corneal epithelium. OSD can also lead to corneal 
neovascularisation (CoNV) and predisposes to bacterial keratitis.
2, 10
  
Inflammation of the eyelids known as “blepharitis” is commonly present 
in OSD. The most clinically useful classification of blepharitis subdivides it into 
anterior and posterior disease. The former is thought to be a product of bacterial 
overgrowth and/or sebaceous gland activity, whereas the latter is almost always 
associated with dysfunction of the meibomian glands. Anterior and posterior 
blepharitis often co-exists. Blepharitis may result in inflammation, altered 
meibomian gland secretions, dry eye and the development of keratitis.
44
 
Abnormalities of eyelid position predispose to keratitis. Inward turning of 
the eyelid, known as entropion, can be caused by involutional ageing changes or 
cicatrizing disease such as pemphigoid. The resultant misdirected eyelashes may 
abrade the cornea, leading to epithelial breakdown and subsequent infection. 
Other lid position abnormalities that can cause ocular surface problems are 
ectropion (outward turning of the eyelid) and lagophthalmos (inability to close the 
eyelid). All of these predispose to the development of bacterial keratitis. 
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1.1222 Corneal disease 
A neurotrophic cornea is a significant risk factor that may predispose to bacterial 
keratitis.
45
 Common causes of a neurotrophic cornea include previous viral 
infection (e.g. HSK), topical anaesthetic abuse and trigeminal nerve palsy.  
Similarly, corneal dystrophies such as lattice and epithelial basement membrane 
dystrophy, can result in a recurrent corneal erosion and a poor ocular surface. This 
may predispose the cornea to bacterial infections.
46
 
Conditions that damage the corneal limbal stem cells can result in 
epithelial defects and subsequent corneal ulceration.
47
 Hereditary causes of limbal 
stem cell disease include; aniridia, ectodermal dysplasia and keratitis-ichthyosis-
deafness syndrome.
48
 Acquired causes of limbal stem cell deficiency are more 
common and include chemical and thermal burns, multiple ocular surgeries 
involving the limbal region, contact lens wear and ocular surface inflammatory 
diseases. Systemic inflammatory diseases that cause limbal stem cell failure 
include Stevens-Johnson syndrome
49
 and mucous membrane pemphigoid.
50,47, 51
   
1.123 Systemic disease 
A wide range of systemic diseases are thought to predispose patients to bacterial 
keratitis.
2
 Diabetes mellitus was shown in various studies to predispose to 
bacterial keratitis.
52, 53
  Diabetes mellitus can lead to OSD through a reduction in 
the quality and quantity of the tear film, conjunctival squamous metaplasia and  
goblet cell loss, and neurotrophic keratopathy.
53
 Bourcier et al
2
 found that diabetic 
patients presenting with keratitis were significantly more likely to  have “very 
poor” visual outcomes, compared to non-diabetic patients. 
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Connective tissue disorders such as rheumatoid arthritis, systemic lupus 
erythematosus, polyarteritis nodosa and granulomatosis with polyangiitis 
(formally called Wegener’s disease54) have all been implicated in bacterial 
keratitis.
55, 56
 The exact pathogenesis of keratitis in these disorders is not yet clear, 
but circulating immune complexes are thought to result in peripheral corneal 
melting and a predisposition to severe corneal inflammation and infection. Other 
systemic diseases predisposing to bacterial keratitis include disorders such as 
rosacea and atopy. Systemic causes of limbal stem cell failure have been 
previously discussed. 
 
1.13 Clinical features 
1.131 History 
Obtaining a detailed history is essential in evaluating patients with clinically 
suspected bacterial keratitis. Pertinent information that should be elicited include; 
ocular symptoms such as pain, redness, discharge, blurred vision, photophobia, 
duration of symptoms and circumstances surrounding the onset of symptoms. If 
contact lenses have been worn, a detailed history is essential, in particular the type 
of contact lens worn, wearing schedule and contact lens hygiene. A review of the 
ocular history may point to underlying aetiology of keratitis, for example, 
previous viral or bacterial keratitis, trauma, ocular surface disease and previous 
ocular surgery. The use of current and recently used ocular medications such as 
topical steroids, antimicrobials and anaesthetics is pertinent. A review of general 
medical history should be obtained including immune status, and the presence of 
underlying inflammatory conditions such as rheumatoid arthritis.  
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1.132 Physical examination 
Physical examination of a patient with suspected bacterial keratitis should include 
measurement of visual acuity, an external examination, and slit-lamp 
biomicroscopy. Although visual acuity is often compromised due to tearing, 
discharge, photophobia and patient discomfort, it is essential that it is 
documented. External examination should be performed, starting with the general 
appearance of the patient. Skin conditions such as acne rosacea may suggest 
Staphylococcus aureus infection.  
Slit-lamp biomicroscopy should be proceed in a systematic “front to back” 
manner. The lid margin should be examined for the presence of meibomian gland 
dysfunction and blepharitis. Conjunctiva should be examined noting the extent 
and position of any inflammation, discharge, follicles, papillae, foreign bodies, 
and evidence of previous surgery such as blebs or glaucoma drainage devices. 
Scleral inflammation and thinning may be associated with connective tissue 
disorders. Corneal sensation should be tested, the absence of which is a significant 
risk factor and may be suggestive of neurotrophic diseases such as previous HSK.  
The corneal epithelium should be examined before and after the application of 
fluorescein or other vital dyes (figure 1). The presence and extent of stromal 
infiltration and thinning should be assessed. Severe keratitis may result in corneal 
thinning, descemetocele and even frank corneal perforation. Signs of previous 
surgery (including refractive), foreign bodies, sutures and underlying corneal 
dystrophies should also be looked for. The anterior chamber should be assessed 
for depth and the presence of inflammation including cell, flare, fibrin and 
hypopyon. The anterior vitreous should be examined for the presence of 
inflammation. The contralateral eye should be examined in a similar manner, 
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which may uncover asymptomatic disease and clues to the aetiology. Chapters 3 
and 4 describe the characteristic features of S. aureus and P. aeruginosa 
associated keratitis.   
1.133 Documentation  
Accurate documentation of the clinical appearance of bacterial keratitis is 
essential in order to monitor the patient’s response to treatment. Management 
decisions are often made on the basis of documented changes in the examination 
findings. Furthermore accurate documentation is invaluable when investigating 
new therapies or virulence factors in the disease (chapters 3 and 4). Documenting 
the clinical characteristics of a patient with pathological corneal disease was 
standardised by a colour coding system described in 1977 by Warring et al
57
 
(figure 2). Using this system allows particular features to be documented in 
patients with bacterial keratitis; measurement of epithelial defect (mm), distance 
from the limbus (mm), stromal infiltration, corneal oedema, anterior chamber 
activity, CoNV and corneal thinning. 
 
1.134 Differential diagnosis 
Pathogens other than bacteria need to be considered as causative agents in 
keratitis. Specific clinical features may point to other aetiologies, for example: 
reduced corneal sensation in HSK and perineural infiltrates in acanthamoeba 
keratitis. Ring infiltrates are most consistently associated with acanthamoeba 
keratitis, but they have also been described in fungi, HSK, varicella zoster, 
immune related conditions such as rheumatoid arthritis and Gram negative bacilli 
infection such as P. aeruginosa and Moraxella.
58-60
 In more than half of patients 
with a clinical diagnosis of keratitis a causative microorganism is not isolated.
61
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This may be either due to limitations in diagnostic techniques, or due to the ulcer 
being truly “sterile”. In the absence of a positive culture it may be difficult to 
differentiate the two. 
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(b) 
 
(b) 
 
 
 
 
 
 
 
 
Figure 1. (a) photograph of severe bacterial keratitis in a patient with a previous 
corneal transplant due to P. aeruginosa. Clinical features; dense conjunctival 
injection, dense stromal infiltration and abscess, hypopyon, corneal 
neovascularisation and meibomian gland disease. (b) photograph under cobalt 
blue light illumination showing a large epithelial defect highlighted by the 
application of fluorescein.  
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Figure 2. Schematic of a corneal ulcer adapted from Warring et al.
57
 A: anterior 
posterior view, B: cross section through ulcer.  Black continuous circle, corneal 
limbus; outer dashed line, contact lens.  Blue shade, stromal oedema; blue dots, 
epithelial oedema.  Green dots, punctate keratopathy; green line, epithelial defect.  
Red straight hashed lines, ghost vessels; straight lines, deep stromal vessels; wavy 
lines, superficial vessels. Grey oval shapes: light grey, old scar; dark grey recent 
scar.  Orange and brown dots: new and old keratic precipitates. Yellow shade: 
hypopyon, corneal infiltrates and abscess formation.  Brown hashed circle: pupil.  
 
1.14 Investigations 
1.141 Corneal scrape 
Sampling of the ulcer in a patient with keratitis is necessary to identify the 
causative microorganism and plan treatment. This is typically done by “corneal 
scraping”, which is described in chapter 2.11. In addition to its diagnostic value, 
scraping may enhance antimicrobial penetration and the therapeutic debridement 
2.3 x 3.1mm   
major and minor 
axes of ulcer 
2mm hypopyon 
A B 
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of infected tissue. The need to detect bacterial, fungal, and amoebic pathogens, 
coupled to the fact that there may be only a few organisms in a corneal ulcer, 
means that adequate clinical material must be obtained and cultures must be 
grown on a variety of media. This has led to the traditional practice of taking 
multiple scrapes from the ulcer and directly plating onto several culture media. 
Allen and Dart,
62
 for example, suggest that scrapes should be put on a glass slide 
for Gram staining, an agar plate for aerobic incubation and other culture media to 
identify less common pathogens.  
Collecting multiple scrapes from the eye of an uncooperative patient is not 
always easy and growing samples in culture on an agar plate is technically 
difficult. In addition, a full range of fresh culture media is not always instantly to 
hand. Kaye et al
61
 investigated a method of indirect inoculation of brain heart 
infusion (BHI) liquid media followed by plating on solid media, to recover 
bacteria. BHI broth has the advantage of a longer shelf life than solid media. Kaye 
et al
61
 found that there were no significant differences in the number of positive 
cultures of the indirect inoculation BHI method compared to direct inoculation of 
bacteria onto solid media. They suggested that where there is difficulty to collect 
multiple scrapes with plating onto several media, the use of BHI with subsequent 
laboratory plating followed by an enrichment broth for organisms that are difficult 
to culture, may be sufficient to isolate the causative microbe. 
Some authors have investigated using polymerase chain reaction (PCR) 
techniques in order to improve the sensitivity of diagnosing and characterising 
keratitis.
63, 64
 Kim et al
64
 showed that out of 108 samples taken from patients with 
bacterial or fungal keratitis, 25 were culture-positive for bacteria and 37 were 
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positive for PCR. The majority of sequenced PCR products matched the positive 
culture results.    
Microbiological methods of identifying bacteria isolated from patients 
with keratitis are discussed in chapter 2.12. Chapter 6.412 discusses novel 
molecular diagnostic techniques that can be used to identify bacteria.       
1.142 Corneal biopsy  
In severe progressive keratitis, where corneal scrape techniques have failed to 
identify causative microorganisms, a corneal biopsy is indicated. Allen and Dart
62
 
suggest that biopsies should be excisional (remove in total) in the case of 
peripheral lesions, and incisional (remove in part) in the case of larger lesions 
involving the visual axis. Bacteria, fungi, and protozoa can all be visualised in 
biopsy specimens using light microscopy. Histological analysis is normally 
available within 48 hours, whereas culture of fastidious organisms may take 
several weeks. An important secondary role of a corneal biopsy is the 
debridement of necrotic tissue, which in itself can be a significant aid to healing. 
Corneal biopsy may lead to irregular astigmatism, although this needs to be 
weighed against potentially much greater complications in untreated keratitis.  
 
1.143 Corneal imaging 
1.1431 Scanning confocal microscopy 
Scanning laser confocal microscopy is used to image the various levels of the 
cornea from epithelium through the stroma to the endothelium in vivo. Recent 
advances have enhanced the resolution and microscopic power of the confocal 
microscope, which has extended its use as a diagnostic tool in keratitis, 
particularly to detect the presence of fungi and acanthamoeba.
65, 66
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1.1432 Angiography 
CoNV is commonly associated with exudation and the development of corneal 
scarring during and following bacterial keratitis. It has been estimated that in the 
United States, 1.4 million patients per year develop CoNV; 12% of them also 
experience a decrease in visual acuity.
67
 A variety of methods have been proposed 
to reduce their formation or to enhance regression for example, topical steroids,
68
 
photodynamic therapy,
69
 and vascular endothelial growth factor inhibition.
70
 
Proper documentation of CoNV is therefore important. CoNV associated with 
keratitis is is commonly analysed by observing photographic images of the 
cornea. This technique, however, is relatively insensitive and many of the blood 
vessels, particuarly the thin afferent vessels are not visible. In addition, the 
presence of corneal scars limits the the detection of CoNV on photographic 
images. The use of corneal angiography, using fluorescein and indocyanine green 
dyes, has recently been shown to be a valuable tool in determing the extent of 
CoNV and its response to treatment.
71
 
72
 Figure 3a shows a picture of a cornea 
with CoNV. Fluorescein angiography of the same cornea shows more extensive 
vascularisation that was observed on the colour picture. Angiography is also 
useful in deliniating the major feeder or afferent vessels in a patients with CoNV 
and in assessing vessel maturity and activity.
13,14
 These afferent vessels may then 
be ameanable to treatments such as fine needle diathermy, which may help reduce 
the leakage and exudation of lipid and other substances into the corneal stroma. 
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(a) 
 
(b) 
 
Figure 3: (a) Colour photographs of corneal neovascularisation (CoNV) 
following bacterial keratitis. (b) Corneal  fluorescein angiography showing extent 
of CoNV. Example of an afferent vessel indicated by a red arrow. The larger 
vessels (yellow arrow) are efferent draining vessels and are more numerous. Note 
apical leakage (green arrow) from immature blood vessels. 
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1.15 Management 
The management of bacterial keratitis is multifaceted. It includes preventative 
measures, medical treatment (mainly in the form of topical antimicrobials) and 
surgical intervention in severe cases. An excellent approach to management of 
microbial keratitis has been described by Allen and Dart
62
 which will be discussed 
below. 
1.151 Prevention 
Avoiding or treating predisposing factors may reduce the risk of bacterial 
keratitis. Dart et al
22
 found 30% of 813 daily disposable users to be incorrectly 
using their lenses for overnight wear. Overnight wear of daily disposable lenses is 
an off-label use that increases the risk of developing bacterial keratitis. This 
emphasises the importance of educating patients regarding the correct use of 
contact lenses,
7, 73,74
 which may in turn reduce their incidence of bacterial 
keratitis. 
 Early detection and appropriate treatment of bacterial keratitis are 
important to minimize permanent visual loss.
75
 OSD, blepharitis, lid position 
abnormalities and predisposing systemic diseases should be all be treated to 
reduce the risk of bacterial keratitis. Patients with predisposing risk factors should 
be educated about their increased risk, be acquainted with symptoms of infection, 
and be informed that they should consult an ophthalmologist promptly if they 
experience these symptoms.
76
 
1.151 Medical treatment 
Frequent application of a topically applied antimicrobial, is the mainstay of 
treatment for bacterial keratitis. The initial antimicrobial used is selected based on 
the most likely causative bacteria from contemporaneous clinical and laboratory 
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data (bacterial spectrum and antimicrobial studies) and knowledge of the 
pharmacokinetics and pharmacodynamics of the agent. Treatment is then 
modified based on the actual bacterium identified, antimicrobial susceptibility 
assay data and clinical response. Combination therapy, where two antimicrobials 
are simultaneously used in a patient, is sometimes used. The advantages of 
combination therapy over monotherapy are; (1) increased bacterial coverage and 
(2) the possibility antimicrobial synergy (chapter 5.126). Antimicrobials used in 
keratitis are discussed in chapter 5. 
 Allen and Dart
62
 suggest that the initial therapy in bacterial keratitis may 
be divided into two distinct phases:  
Phase 1, known as the sterilisation phase, is a period of intensive antimicrobial 
treatment designed to sterilise the cornea. Antimicrobial therapy should be given 
hourly for 5 days followed by 4 times a day until epithelium healed. In severe 
cases, topical antimicrobials should continue through the night and systemic 
antimicrobials should be given. Patients should be reviewed at 48 hours and 1 
week, except for those with rapidly progressing disease who should be seen daily.  
Phase 2, known as the healing phase, aims at limiting further inflammatory 
damage, preventing re-infection, and promoting epithelial healing. During this 
phase, Allen and Dart
62
 recommend reducing antimicrobial treatment to 
prophylactic levels, in order to reduce corneal toxicity of drops. They also suggest 
using unpreserved medication and treating predisposing features such as OSD. 
The cautious use of topical steroids may also be considered at this stage. 
Srinivasan et al
77
 randomised 500 patients with bacterial keratitis in India, to 
receive either placebo or topical steroid. They all had previously been treated with 
intensive topical moxifloxacin for 48 hours. They found that there was no overall 
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difference in 3-month best corrected visual acuity and no safety concerns with 
adjunctive topical steroid therapy for use in bacterial keratitis. It is important to 
note that steroids may increase the pathogenicity of keratitis caused by 
acanthamoeba.
78
 The treating clinician must ensure the absence of these 
pathogens prior to commencing topical steroid treatment.   
1.152 Surgical treatment 
Patients with severe bacterial keratitis, especially those at risk of corneal 
perforation, may require surgical intervention. Impending or small perforations 
can be sealed by cyanoacrylate tissue adhesive. As well as providing tectonic 
support, cyanoacrylate has been shown to have bacteriostatic properties which 
may be beneficial in a patient with bacterial keratitis.
79
 Amniotic membrane may 
also be used to cover an impending or small perforation.
80
  
In patients with large corneal perforations corneal transplantation is 
occasionally needed. Bacterial keratitis accounts for approximately 8% of corneal 
transplants undertaken in the UK [Ocular Tissue Advisory Group to NHS-BT, 
UK] and 1% in the USA [Eye Bank Association of America]. An emergency 
penetrating keratoplasty performed at the acute stage of bacterial keratitis is 
associated with a higher complication rate and lower graft survival. If it is 
possible, penetrating keratoplasty is deferred until the acute infection has 
responded to treatment. 
 
1.2 Structure and function of the ocular surface 
The cornea is a specialised transparent tissue situated at the front of the eye 
(figure 4). It provides structural integrity to the globe, protects the inner 
components of the eye from injury and focuses light onto the retina. The cornea 
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covers the anterior 15% of the surface area of the eye and is continuous 
posteriorly with the white opaque sclera. When viewed anteriorly the cornea 
appears elliptical, its largest diameter is typically in the horizontal meridian 
(approximately 11 mm) and its smallest is in the vertical meridian (approximately 
10 mm). The cornea has an average thickness of 550 µm and is arranged into five 
layers, distinct in both structure and function; epithelium, Bowman’s layer, 
stroma, Descemet’s membrane and endothelium. The cornea is composed of three 
major cell types: epithelium, keratocyte and endothelium which vary considerably 
in their capacity to regenerate. Epithelial cells have the highest rates of cell 
division and endothelial cells are the least renewable.  
The external surface of the cornea is covered by a 4-6 cell layered 
stratified squamous epithelium. Epithelial cells are formed from limbal stem cells 
and upon maturation they migrate from the limbal region towards the centre of the 
cornea and the apical surface. The corneal epithelium is a smooth, non-keratinized 
50 μm thick layer, allowing it to function as a transparent, avascular surface. 
Basal epithelial cells actively secrete a basement membrane, composed of type IV 
collagen fibrils, laminin, heparin sulfate, and fibronectin. The cytoplasm of all 
epithelial cells contains mainly cytoskeletal intermediate filaments and has sparse 
cytoplasmic organelles, which aid in maintaining transparency. The epithelial 
cells are adherent to each other by desmosomes, while the basal surface of the 
epithelium adheres to the basal lamina and underlying Bowman’s layer through 
hemidesmosomes. Zonula occludens tight junctions are also present between 
epithelial cells in both apical and basal cells.
81
 They are made up of the tight 
junction proteins occludin, and claudin which eradicate the intercellular space. 
These tight junctions provide an almost impenetrable barrier for invading 
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pathogens, which explains why the healthy cornea is resistant to infection despite 
it being in a constant state of regeneration. The corneal epithelium is also the most 
important layer when considering the penetration of topically applied drugs into 
the eye. This is discussed in chapter 5.  
The stroma accounts for 90% of the corneal thickness. It is predominantly 
composed of water and contains a structured network of collagen, keratocytes, 
proteoglycans, corneal nerves and glycoproteins. Corneal transparency is 
attributed to the regular lattice-like arrangement of collagen fibrils in the stroma. 
Keratocytes are interconnected by cellular processes divided by gap junctions that 
only allow very small molecules to penetrate to its neighbouring cells. 
Keratocytes may secrete matrix metalloproteinase when activated by 
microorganisms, which coupled with a damaging immune response may cause the 
degradation of the corneal stroma.
82
 
The cornea is bathed in the tear film and comprises an outer lipid layer 
produced by the meibomian glands, a middle aqueous layer produced by the 
lacrimal gland and an inner mucin layer produced by conjunctival goblet cells. 
The tear film plays a critical function in the health of the cornea, supplying it with 
oxygen and nutrition as well as protecting it from invading pathogens. Indeed the 
tear film possesses many nutrients that could potentially foster bacterial growth, 
however, the corneal surface, unlike the skin, contains relatively few bacteria. 
Mucins, defencins, immunoglobulins, complement and surfactants present in the 
tear film create an environment that is inhospitable for bacteria to survive.
83,
 
84,
 
85
 
Moreau et al
86
 postulated that the tear film enzyme phospholipase A2, may be the 
most important barrier protecting the eye from bacteria. They found that the 
amount of phospholipase A2 increases in the tear film in a rabbit model of 
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keratitis, thus enhancing protection against bacteria. The protective properties of 
the tear film against bacteria is highlighted by the observation that certain bacteria 
can easily invade multi-layered corneal epithelial cells grown in vitro in the 
absence of the tear film.
87, 88
  
 
 
Figure 4: schematic cross section of a human cornea and histological section of 
the cornea with hematoxylin and eosin stain.  
 
1.3 Bacteria  
1.31 What are bacteria? 
Bacteria are unicellular microorganisms measuring a few micrometres in length 
that belong to the kingdom Protista. Bacteria are extremely successful colonisers 
being present in even the most inhospitable conditions such as the deep ocean and 
hot springs.
89
 Many bacteria live in symbiosis with a host, some however, are 
parasitic. 
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Figure 5. Approximate size of prokaryotes in relation to other cells and particles  
 
Bacteria do not contain mitochondria, endoplasmic reticulum, golgi bodies, 
nuclear membrane or a true nucleus and are therefore considered to be prokaryotic 
(Figure 5). The bacterial cell wall is essential in providing protection to the 
organelles against the host’s immune system and antimicrobials. Two major cell 
wall types exist which subdivide bacteria into two main groups: Gram-negative 
and Gram-positive. Figure 6 illustrates the main differences between the two 
groups. Gram-positive bacteria have a cell wall that contains a thick 
peptidoglycan layer (50-90% of the cell envelope). Their walls also contain 
teichoic and lipoteichoic acids, which are also unique to these bacteria. Gram-
negative bacteria, however, have a thinner peptidoglycan layer (10% of the cell 
envelope). Their walls also possess a phospholipid outer membrane, which forms 
an extra protective barrier conferring resistance to enzymes, toxic substances and 
some antimicrobials. The periplasm, a layer between the inner and outer walls of 
the cell membrane, is also unique to Gram-negative bacteria, containing enzymes 
that cause the inactivation of some antimicrobials. The outer membrane of Gram-
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negative bacteria contains the lipopolysaccharide endotoxin, which contributes to 
bacterial virulence.  
Pili (also known as fimbriae) are hair-like appendages found on the 
surface of many Gram positive and Gram negative bacteria.
90
 They are long 
filamentous structures containing oligomeric pilin proteins. Flagella are whip like 
extensions that act as locomotive organelles, allowing bacteria to move toward 
favourable environments. Pili
90
 and flagella
91
 have been implicated in bacterial 
virulence (chapter 1.333).   
 
  
 
 
 
  
 
 
 
 
 
Figure 6. Schematic of Gram-positive and Gram-negative bacteria 
 
The bacterial genome is mostly found in a singular circular chromosome located 
in the cytoplasm. The bacterial ribosome consists of a 70S ribosome which is 
significantly different from the eukaryotic 80S ribosome. This difference is 
exploited by some antimicrobials, such as macrolides, which specifically target 
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the bacterial ribosome. Mobile bacterial genetic elements, known as plasmids and 
phages, may also be present in bacterial cells. Plasmids are circular extra-
chromosomal molecules of deoxyribonucleic acid (DNA) that are replicated 
within the cell independently of the main bacterial chromosome. Some smaller 
plasmids utilise the host cell's own DNA replicative enzymes in order to make 
copies of themselves, but most plasmids carry genes encoding the ability to 
replicate themselves. The genes present in plasmids are often responsible for 
pathogenic characteristics displayed by the host bacterium, such as resistance to 
antimicrobials. Bacteriophages are viruses that specifically infect bacteria. Like 
all viruses, phages have a simple structure, consisting of a DNA molecule 
carrying a small number of genes, surrounded by a protective protein coat. The 
phage attaches to the outside of the bacterium and injects its DNA into the cell. 
The DNA molecule is then replicated by specific phage enzymes, followed by 
protein synthesis. Temperate phages are able to incorporate their DNA into the 
main bacterial genome in a process called lysogeny, which may then exist for 
thousands of cell divisions. Both plasmids and phages contribute to bacterial 
virulence (chapter 1.33). 
1.32 Taxonomy 
The taxonomy of bacteria is complex, having undergone frequent revisions in the 
past. Revisions now require the approval of an official international body: the 
International Committee on Systematic Bacteriology. Bacteria are subdivided in 
the following successively smaller groups: division, class, order, family, genus 
and species.  A species can be further sub-divided into individual strains. Table 2 
describes the taxonomy of three genera containing bacteria that commonly cause 
keratitis; Staphylococcus, Streptococcus and Pseudomonas.  
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Bacteria are classified according to their Gram-staining properties and 
morphological form (chapter 2.121). The two main morphological forms are 
spheres (cocci) and rods (bacilli).  Biochemical reactions, such as activity by the 
enzymes catalase, coagulase and oxidase (section 2.12), and the ability to utilise 
different carbon and nitrogen sources for growth, are used to further classify 
bacteria. Bacteria can also be characterised using molecular approaches, targeting 
components such as nucleic acids or amino acids. DNA typing and sequencing 
has further highlighted the heterogeneity of bacteria within their various sub-
groups. 
Table 2: Taxonomy of the bacterial genera; Staphylococcus, Streptococcus and 
Pseudomonas.  
Phylum Firmicutes Proteobacteria 
Class   Bacilli Gammaproteobacteria 
Order  Bacillales Pseudomonadales 
Family  Staphylococcaceae Streptococcaceae Pseudomonadaceae 
Genus  Staphylococcus Streptococcus Pseudomonas 
Species S. aureus*  
S. epidermidis* 
S. hyicus-intermedius 
S. delphini, 
S. lutrae, 
S. pseudintermedius 
S. saprophyticus 
S. auricularis 
S. carnosus 
S. haemolyticus 
S. lugdunensis 
S. pneumoniae* 
S. pyogenes 
S. agalactiae 
Enterococcus* 
 
P. aeruginosa* 
P. alcaligenes 
P. anguilliseptica 
P. argentinensis 
P. borbori 
P. citronellolis 
P. flavescens 
P. mendocina 
P. nitroreducens 
P. oleovorans 
P. pseudoalcaligenes 
* = common causes of keratitis 
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1.33 How do bacteria cause disease? 
Most bacteria live harmlessly in the environment and have nothing to do with 
living organisms. Furthermore, there are a large numbers of bacteria known as 
commensals, that live on the surface of humans and animals without causing any 
impairment of function or disease. A small proportion of bacteria, however, 
known as pathogens, have the capacity to cause disease. 
1.331 Definitions: pathogenicity and virulence 
The ability for a bacteria to cause disease is known as its pathogenicity. Virulence 
is defined as the degree of pathogenicity as indicated by the ability of the bacteria 
to invade the host and/or the severity of disease outcome. Virulence is dependent 
on virulence factors; a large array of molecules secreted by pathogens, that 
enhance their potential to cause disease by enabling host colonization, evasion of 
host immunity and entry into the host cell. Some virulence factors are 
chromosomally encoded and intrinsic to the bacteria, whereas others are obtained 
from mobile genetic elements like plasmids and bacteriophages. Virulence factors 
encoded on mobile genetic elements spread through horizontal gene transfer, and 
can convert harmless bacteria into dangerous pathogens.
92
 Such factors include 
bacterial toxins, proteases, cell surface proteins, cell surface carbohydrates and 
hydrolytic enzymes.
93
 
Mechanisms of virulence factors will now be described. Virulence factors 
particular to S. aureus and P. aeruginosa will be discussed in detail in chapters 
3.12 and 4.12 respectively. 
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1.332 Evasion of the host immune system 
The human host immune system presents a formidable challenge for any invading 
bacteria. It consists of a non-specific or innate system as well as an adaptive or 
cell-mediated system.
94-96
  
Most infectious agents induce inflammatory responses by activating innate 
immunity. Local inflammation and the phagocytosis of invading bacteria may also 
be triggered as a result of the activation of complement on the bacterial cell 
surface. Macrophages and neutrophils of the innate immune system provide a first 
line of defence against many bacteria. The innate immune response relies on the 
recognition of molecules associated with pathogens, such as peptidoglycans and 
flagella. These are knows as pathogen-associated molecular patterns (PAMPs), 
which are structures essential for the survival of the pathogen and distinguishable 
from the host. Upon PAMP recognition, the innate system triggers pro-
inflammatory and antimicrobial responses by activating a multitude of 
intracellular signalling pathways, including adaptor molecules, kinases, and 
transcription factors.
94
 The innate immunity also initiates the adaptive immune 
responses. The lymphocytes (T and B cells) of the adaptive immune system 
provide a more robust means of defence, which also provides increased protection 
against reinfection with the same pathogen via memory.
95
 Pathogenic bacteria 
have various strategies to evade both the innate and adaptive immune systems. 
Strategies specific to S. aureus and P. aeruginosa will be described in chapters 
3.12 and 4.12 respectively. 
1.333 Bacterial adhesion, invasion and toxicity 
For bacteria to effectively colonize and cause disease, they must firstly attach to 
host cells.
97
 Most bacteria will only infect hosts that express particular receptors 
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for bacterial adhesion factors on their cell surface. Bacteria use many types of 
appendages for adhering to the host surface including, pili, fimbriae and flagella 
(chapter 1.131). In many cases, the binding structure is a pilus - a long multi-
subunit appendage that often has binding specificity in the terminal subunits.  
Bacterial invasion occurs either by the production of extracellular enzymes 
that damage host tissue, or through the modulation of the host response system 
such as the up-regulation of cytokines. Some virulent bacteria produce proteins 
that either disrupt host cell membranes or stimulate endocytosis into host cells. 
These toxins allow the bacteria to enter host cells and facilitate entry into the body 
across epithelial tissue layers causing tissue damage.
93
 Examples of invasive 
mechanisms include α and γ toxins in S. aureus (chapter 3.122) and the type three 
secretion system and Las B in P. aeruginosa (chapter 4.1222)  
1.334 Bacteria working in a community; Quorum sensing and biofilms 
Inter bacterial communication enables a large number of bacteria to target the host 
simultaneously. The production of several extracellular virulence factors allows 
the bacteria to monitor bacterial cell density, communicate with each other and to 
behave as a population instead of individual cells.
98
 This mechanism, called 
quorum sensing (QS), has been described in many Gram-negative
99
 and Gram-
positive bacteria.
100
 QS is an intercellular signalling process
101
 allowing bacteria 
to migrate to a more inhabitable environment. Molecules known as autoinducers 
constitute the “language” used for this intercellular communication. When 
sufficient bacteria are present, autoinducer concentrations reach a threshold level 
that causes the expression or inactivation of target genes. The effect of QS on the 
host can be harmonious, as in symbiotic bacteria, or detrimental as in pathogenic 
bacteria. 
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 QS can lead to individual colonies linking together to form communities 
that are highly resistant to antimicrobials, known as biofilms. Bacterial biofilms 
are known to contribute to bacterial keratitis by allowing organisms to persist on 
contact lenses and contact lens cases despite vigorous antiseptic regimens (chapter 
1.1211). Biofilms are also known to cause antimicrobial resistance.
102
 
It has also been discovered that there is a universal communication signal 
synthesized by different bacterial species (inter-species communication), as well 
that of signals produced by eukaryotic cells (inter-kingdom communication).
103
 
This may be integral to the formation of multispecies biofilm communities that 
are important in infection and disease.  
 
1.34 Bacteria causing keratitis 
Many bacteria have been implicated in causing keratitis. The Microbiology 
Ophthalmic Group (MOG) collected 772 bacterial isolates from patients with 
keratitis from seven ophthalmic-microbiology centres in the UK (London, 
Birmingham, Bristol, Newcastle, Manchester, Belfast and Liverpool), from 2003 
to 2010. See appendix E for members of MOG. Table 3 shows the variability in 
the proportions of bacteria causing keratitis between the study by the MOG 
(Sueke et al
104
) and three similar studies set in different geographical locations. 
For example, the proportion of Gram-positive isolates (57%) was similar to that in 
the study by Tuft and Matheson
105
 in London (56%), but much lower than that in 
Bourcier et al
2
 in Paris (83%) and Bharathi et al
10
 in South India (74%). S. aureus 
varied between 8% in France, to 33% in the UK (Tuft and Matheson), and 
Coagulase-negative staphylococci (CNS) from 17% in India to 48% in France. 
The most common bacteria isolated by the MOG,
104
 Bharathi
10
 et al and Bourcier 
et al
2
 were. CNS was not included by Tuft and Matheson,
105
 perhaps due to the 
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uncertainty as to whether this species is pathogenic (chapter 1.3412). The 
differences between the studies in table 3 may reflect differences in patient 
population, climate and the prevalence of risk factors such as contact lens use, 
trauma, or coexistent disease. 
 
Table 3. Bacteria isolated from cases of bacterial keratitis  
Study 
Country 
Size of study 
Sueke
104
  
UK 
n=772 
Tuft
105
 
UK 
n=1312 
Bourcier
2
 
France 
n=208 
Bharathi
10
 
India 
n=1109 
Gram-positive bacteria  
total 
 
57% 
 
56% 
 
83% 
 
74% 
Coagulase negative staphylococci  27% N/A 48% 17% 
Staphylococcus aureus  14% 33% 8% N/A 
Streptococcus  12% 19% 9% 38% 
Other Gram-positives* 4% 4% 18% 19% 
Gram-negative bacteria  
total  
 
43% 
 
44% 
 
17% 
 
26% 
Pseudomonas aeruginosa 21% 25% 10% 18% 
Enterobacteriaceae  14% 9% 6% 1% 
Moraxella spp. 3% 6% 1% N/A 
Haemophilus spp. 1% 2% N/A N/A 
Other Gram-negatives** 4% 2% N/A 7% 
*Corynebacterium spp., Bacillus spp., Enterococcus spp., Listeria spp., Nocardia. 
 **Acinetobacter spp., Stenotrophomonas maltophilia, Neisseria spp., Pasturella 
spp., Aeromonas spp., Eikenella spp., Agrobacterium spp., Alcaligines spp., 
Methylbacterium spp. 
N/A = bacterial species not mentioned in study 
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1.341 Gram-positive bacteria 
The most common Gram-positive bacterial to be isolated from patients with 
keratitis are from the genera Streptococci and Staphylococci. 
1.3411 Streptococci 
The genus Streptococcus belongs to the phylum Firmicutes and Family 
Streptococcaceae (table 2). The bacteria grow in chains or pairs, which explains 
the derivation of the genus name; “streptos” meaning twisted chain in Greek. 
Streptococci possess a typical Gram-positive cell wall containing peptidoglycan 
and teichoic acid. Lancefield developed a classification system of Streptococci in 
the 1930s based on isolates containing the same antigenic carbohydrates. The 
Streptococci can produce exotoxins that damage red blood cells (RBCs) and this 
is also used to classify the genus. The extent of the lysis can be quantified by 
examining the discolouration of the agar surrounding colonies. Strains that cause 
partial lysis of RBCs cause a green discolouration of the surrounding agar and are 
called α-haemolytic streptococci. Strains that cause full lysis of RBCs lead to 
clear surrounding agar and these are called β-hemolytic streptococci. When there 
is no change in the agar colour the isolate is called non-haemolytic. α-haemolytic 
streptococci include S. pneumoniae and S. viridans and β-haemolytic streptococci 
include S. pyogenes and S. agalactiae. 
S. pneumoniae is the most commonly isolated streptococci in patients with 
keratitis. Using a Gram stain S. pneumoniae appears as Gram-positive cocci in 
pairs (diplococci) and its cell wall contains an antigen which classifies the isolate 
into Lancefield Group C. The feature of S. pneumoniae that is most clearly 
associated with virulence is the capsular polysaccharide. Laboratory strains that 
have lost the ability to produce a capsule are not pathogenic. S. pneumoniae as 
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with the other Streptococci have complex nutritional requirements. It requires 
agar incorporated with 5% sheep blood and incubation in a CO2 enriched 
atmosphere. 
1.3412 Staphylococci 
Staphylococcus was first identified in 1881 as a cause of wound infection by the 
Scottish surgeon Sir Alexander Ogston.
106
 He named it Staphylococcus describing 
the grape-like clusters (“staphyle” in Greek,) he observed under the microscope. 
He then, in an elegant series of clinical observations and laboratory studies, 
described staphylococcal disease and its role in sepsis and abscess formation.
107
 
More than forty species of staphylococci have now been recognised, most of 
which are not found in humans. Most of those found in humans are harmless, 
residing on the skin and mucous membranes. 
The staphylococci are Gram-positive cocci belonging to the family 
Micrococcaceae, which encompasses two genera: Staphylococcus and 
Micrococcus. Staphylococci are catalase producing and morphologically appear 
as spherical cells occurring singly in pairs or in clusters. They are non-motile and 
non-spore forming. Some species in the genus Staphylococcus produce the 
enzyme coagulase, which is otherwise known as clumping factor. This enzyme is 
used to distinguish between certain isolates in the genus (chapter 2.122). 
Coagulase-positive species include S. aureus, S. delphini, and S. lutrae, of which 
only S. aureus is a common cause of keratitis. 
S. aureus 
In 1884 Anton J. Rosenbach, a German surgeon, isolated two strains of 
staphylococci, which he named for the pigmented appearance of their colonies: 
Staphylococcus aureus, from the Latin aurum for gold, and Staphylococcus albus 
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(now called epidermidis), from the Latin albus for white.
108
 Humans beings are a 
natural reservoir of S. aureus. It is estimated that around 40% of healthy adults are 
colonized, with 10 to 20% persistently colonized.
109
 S. aureus can cause a range 
of illnesses, from minor skin infections, such as impetigo, furuncles, cellulitis, and 
abscesses, to life-threatening diseases such as pneumonia, meningitis, 
osteomyelitis and endocarditis. S. aureus is a common cause of keratitis in most 
studies (table 3). 
S. aureus grows easily on routine laboratory culture media such as 
columbia and blood agar and their optimum growth temperature is 30 °C - 37 °C. 
Since it is a facultative anaerobe, it has the ability to grow in both aerobic and 
anaerobic conditions. After 18-24 hours of incubation colonies measuring 4-8 mm 
are typically seen. Colonies are opaque and may be white, cream or yellow (figure 
7), as the extent of pigmentation is a variable trait. The clinical features and 
virulence factors of S. aureus keratitis are discussed in chapter 3. 
Coagulase-negative staphylococci   
Staphylococci that do not clump when plasma is added are called coagulase-
negative staphylococci (CNS). Over 30 species of CNS have been identified. The 
most clinically relevant species in this group are S. epidermidis and S. 
saprophyticus. The best known member of this family and the most common 
bacterium cultured from the eyelids and conjunctiva is S. epidermidis. CNS are 
considered part of the normal conjunctival flora
110, 111
 and, despite being isolated 
from the corneas of patients with bacterial keratitis, it is often uncertain whether it 
is a pathogen. Although a recent study established that there was a relationship 
between clinical outcome and the MIC of ciprofloxacin and ofloxacin against S. 
aureus, such a relationship was not apparent for CNS.
4
   
 40 
 
 
Figure 7. Agar plate showing small pigmented colonies of S. aureus 
 
1.342 Gram-negative bacteria 
The most commonly isolated Gram-negative bacteria in patients with bacteria 
keratitis are P. aeruginosa and the Enterobacteriaceae. Other Gram-negative 
species have been isolated, for example Moraxella spp., Haemophilus spp. 
Acinetobacter spp., Stenotrophomonas maltophilia, Neisseria spp., Pasturella 
spp., Aeromonas spp., Eikenella spp., Agrobacterium spp., Alcaligines spp., and 
Methylbacterium spp. 
Gram-negative bacteria can be subdivided into two large groups, the 
fermenters and non-fermenters. A bacterium that can metabolize glucose or other 
carbohydrates only in the presence of oxygen is defined as a non-fermenter. The 
non-fermenters account for approximately 15% of all Gram-negative bacilli 
cultured from clinical specimens and include the species P. aeruginosa.
112
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Gram-negatives can also be subdivided into oxidizers; bacteria that can 
oxidize carbohydrates, and non-oxidizers that cannot. Most of the non-fermenters, 
such as P. aeruginosa, are oxidase-positive. Non-fermentative Gram-negative 
bacilli are ubiquitous in the environment. They are particularly prevalent in moist 
environments and hence thrive in contact lens cases.
113
 Non-fermenters can also 
withstand detergents such as clorhexidine and ammonium compounds. They 
rarely live as part of the normal host microbial flora and are considered to be 
opportunistic, causing infections only in individuals who are 
immunocompromised, or whose natural defences are breached. Additional 
features can differentiate this group of non-fermenters: motility, pigmentation and 
the lack of ability to grow on certain media. 
1.3421 Pseudomonas 
The genus Pseudomonas was first described by Migula in 1894.
114
 It is one of the 
most diverse and ubiquitous bacterial genera whose species have been isolated in 
all types of environments for example; plant matter, water, minerals, soil, animals 
and humans. The taxonomy was reclassified in 2000, according to its 16S RNA 
genotype.
115
 
 P. aeruginosa is the most common cause of human infection from the 
genus Pseudomonas (table 2). This species is implicated in various life 
threatening infections and it is a frequent cause of keratitis. P. aeruginosa has 
simple growth requirements and can use a variety of compounds for nutrition. 
This explains the presence of P. aeruginosa infections associated with homemade 
saline solution and soft contact lenses.
116
 P. aeruginosa has a growth temperature 
range of 5-42 °C and can produce at least 6 colonial types after 24 hours of 
aerobic incubation on nutrient agar. The most common type are large, oval, 
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mucoid colonies, which can be surrounded by serrated growth (figure 8). Colonial 
variation from one type to another does not necessarily indicate the presence of 
more than one strain. P. aeruginosa is a strict aerobe and is oxidase and catalase 
positive. The characteristic blue-green appearance of the organism in culture is 
due to the mixture of pyocyanin (blue) and pyoverdine (yellow). Some strains 
produce other pigments, such as pyorubin (red) or pyomelanin (brown). Clinical 
features and virulence factors of P. aeruginosa keratitis are discussed further in 
chapter 3. 
 
1.3422 Enterobacteriaceae 
The Enterobacteriaceae are a large family of Gram-negative bacilli that can be 
differentiated from Pseudomonas as they are oxidase negative. Bergey’s Manual 
of Systemic Bacteriology describes 176 species in the Enterobacteriaceae family. 
Species that have been implicated in keratitis include: Serratia spp, Klebsiella 
spp., Citrobacter spp., Proteus spp., Escherichia coli, Enterobacter spp., 
Morganella morganii spp. and Pantoea spp. Colonial morphology does not 
readily identify the particular Enterobacteriaceae species, except for Klebsiella 
that produce large mucoid colonies. Definitive identification depends on 
biochemical reactions and serological antigenic structures that differ between 
species (chapter 2.123). 
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Figure 8: P. aeruginosa colonies on agar plate. Circular raised mucoid colonies 
stained with pyoverdine green pigment.  
 
1.4 Thesis aims 
The clinical outcome of patients with bacterial keratitis varies considerably. 
Patients with mild disease have a complete resolution of symptoms after a short 
course of topical antimicrobial treatment, with no long term visual sequelae 
whereas a minority of patients may require prolonged treatment and are still left 
with permanent visual loss. There are three main factors, the bacteria, treatment 
and the host, that interplay and determine the outcome of bacterial keratitis. The 
aim of this thesis is to investigate the first two of these factors; firstly the 
characteristics and virulence of the two major species causing keratitis; S. aureus 
and P. aeruginosa and secondly the efficacy and susceptibility of antimicrobials, 
in particular the potentially novel antimicrobial meropenem.  
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CHAPTER 2: GENERAL METHODS 
2.1 Bacteria 
2.11 Collection of samples 
Bacterial isolates used to investigate virulence factors (Chapters 3.3 and 4.3) and 
antimicrobial susceptibility (Chapter 5.3), were collected by the MOG from 
patients presenting with keratitis from seven ophthalmic-microbiology centres in 
the UK.  
Samples were collected by scraping the corneal ulcer using a surgical blade (no. 
11 Baird Parker surgical blade; Swann Morton Ltd., Sheffield, UK), with care 
taken to avoid touching any other part of the eye or its adnexa (figure 9). One 
blade was streaked onto a glass slide. In three centres only one further scrape was 
taken which was placed into BHI broth (Oxoid, UK). In the remaining four 
centres further scrapes were placed directly onto agar plates. 
The plates and broth were incubated for 18-24 hours at 37 °C under both 
aerobic and enriched CO2 (5%) atmospheric conditions in the local laboratory. If 
bacteria were identified, colonies were stored on sterile beads (Protect Beads; 
TSC Ltd., Heywood, Lancashire, UK) and sent to the University of Liverpool 
where they were stored at -80 °C prior to subsequent analysis.  
2.12 Identification of bacteria 
Beads were thawed and streaked onto agar under aseptic conditions and incubated 
in the conditions described in table 4. See appendix A for details of preparation of 
agar. After 18-24 hours of incubation, colonies were observed. The following tests 
were performed where necessary to confirm the identity of the bacteria.   
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Figure 9: Photograph demonstrating (a) the equipment needed for corneal scrape 
and (b) the set up and method of corneal scrape  
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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Table 4: Incubation conditions of bacteria cultured in patients with keratitis.  
Organisms Media  Incubation conditions 
Enterobacteriaceae  
Acinetobacter spp.  
Pseudomonas spp.  
staphylococci  
α-Haemolytic streptococci  
β-Haemolytic streptococci  
Streptococcus pneumoniae  
Haemophilus spp.  
ISA 
ISA 
ISA 
ISA 
ISA+5% horse blood 
ISA+5% horse blood 
ISA+5% horse blood 
ISA+5% horse blood 
35-37 °C in air 
35-37 °C in air 
35-37 °C in air 
35-37 °C in air 
35-37 °C in 4-6% CO2  
35-37 °C in air 
35-37 °C in 4-6 % CO2  
35-37 °C in 4-6 % CO2  
ISA = Iso-Sensitest agar  
 
2.121 Gram stain 
Background: The Gram stain, developed in 1884 by Hans Gram,
117
 can 
differentiate bacteria into two distinct groups based on their cell wall properties. 
The iodine used in a Gram stain is a mordant and is retained by the thick cell wall 
in Gram-positive bacteria resulting in the observed purple/blue colour. Gram-
negative bacteria do not retain the iodine complexes, and a pink/red colour is the 
result of the safranin counterstain. 
Method: Freshly grown colonies were removed from the agar plate and placed 
onto a slide. The slide was briefly heated with a flame to fix the isolate to the 
slide. The slide was flooded with 2% w/v crystal violet and left for 30 seconds. 
1% w/v Lugol’s iodine was applied to the tilted slide to wash away the stain 
followed by a further application of iodine. After 30 seconds the iodine was 
washed off with 100% ethanol until the colour ceased to run out of the isolate. 
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The slide was rinsed with water and 0.1% safranin was poured on. After 2 minutes 
the slide was washed with water and blotted dry. Bacterial cells appearing 
purple/blue on microscopy were considered to be Gram-positive and pink/red 
were considered Gram-negative. Further biochemical tests were performed 
depending on the Gram stain result. 
  
2.122 Gram-positive isolates  
2.1221 Catalase test 
Background: The catalase test was used to differentiate between the two 
commonest Gram-positive cocci, streptococci and staphylococci, which have 
similar colonial appearance. As staphylococci contain the enzyme catalase and 
streptococci do not, the catalase test is a simple method to distinguish these two 
species. Catalase causes hydrogen peroxide to produce oxygen and water, which 
explains the formation of bubbles in catalase positive bacteria. 
Method: 0.2 mL of hydrogen peroxide solution was placed into a tube. The 
colony in question was collected from the agar plate with a sterile loop, which 
was rubbed on the inside wall of the tube above the hydrogen peroxide solution. 
The bottle was tilted to allow the hydrogen peroxide solution to cover the colony. 
The presence of vigorous bubbling within 10 seconds was considered a positive 
result. Positive control S. aureus NCTC 6571 and negative control S. mitis NCTC 
10712 were used. 
2.1222 Coagulase test 
Background: The coagulase test was used to differentiate the Staphylococci into 
two main groups: Coagulase-positive staphylococci and Coagulase-negative 
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staphylococci (CNS). The vast majority of Coagulase-positive staphylococci 
isolated in humans are S. aureus.  Coagulase (or clumping factor) bound to the 
cell wall of Coagulase-positive staphylococci, cause cell agglutination when 
fibrinogen from plasma is added. 
Method: The test strain was emulsified into a homogenous suspension in a drop 
of distilled water on a slide. A 10 µl loop of the rabbit plasma was gently mixed 
with the suspension and the presence of visible clumping within 10 seconds was 
called a positive result. Positive control S. aureus NCTC 6571 and negative 
control S. haemolyticus NCTC 42764 were used. 
 
2.123 Gram-negative isolates 
2.1231 Oxidase test 
Background: P. aeruginosa isolates do not always produce the characteristic 
pigmentation associated with the bacteria and may be mistaken for an 
Enterobacteriaceae. Unlike the Enterobacteriaceae however, P. aeruginosa 
possess the enzyme cytochrome oxidase, which catalyses the transport of 
electrons from donor compounds (NADH) to electron acceptors (usually oxygen). 
The oxidase test utilises the reagent N, N, N’, N’-tetra-methyl-p-
phenylenediamine dihydrochloride, which acts as an artificial electron acceptor 
for the enzyme oxidase. The oxidised reagent forms the coloured compound 
indophenol blue in oxidase positive isolates.  
Method: Freshly grown colonies were taken with a sterile loop and rubbed onto 
an impregnated oxidase test strip (Thermo Scientific, UK). A blue colour within 
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10 seconds indicated bacterial oxidase production and was considered to be a 
positive result.  
 
2.1232 API test for Enterobacteriaceae 
Background: Oxidase negative Gram-negative bacilli were presumed to be from 
the Enterobacteriaceae family. An Analytical Profile Index (API) was used to 
identify the species of Enterobacteriaceae. The API 20E system (bioMérieux, 
UK) was used which consists of a plastic strip of 20 individual, miniaturized tests 
tubes each containing a different reagent used to determine the metabolic 
capabilities and the genus and species (table 5). 
Method: One freshly grown colony was taken from a culture plate and placed 
into 5ml sterile water. Each tube in the API-20E strip (figure 10) was inoculated 
with the bacterial suspension. Some of the tubes were completely filled (tests CIT, 
VP and GEL), whereas others were topped off with mineral oil to maintain 
anaerobic conditions (tests ADH, LDC, ODC, H2S, URE). The strip was 
incubated in air for 18-24 hours at 37 °C and analysed for specific colour changes 
(table 5). Interpretation of the 20 reactions, was converted to a seven-digit code, 
which was entered online to receive a presumed species identification 
(https://apiweb.biomerieux.com/servlet/Authenticate?action=prepareLogin). 
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Table 5: Components of Analytical Profile Index test to determine 
Enterobacteriaceae species 
Test  Substrate  Reaction tested  -ve result  +ve result  
ONPG  ONPG  beta-galactosidase  colourless  yellow  
ADH  arginine  arginine dihydrolase  yellow  red/orange  
LDC  lysine  lysine decarboxylase  yellow  red/orange  
ODC  ornithine  ornithine decarboxylase  yellow  red/orange  
CIT  citrate  citrate utilization  pale green/yellow  green/blue  
H2S  Na thiosulfate  H2S production  colourless/grey  black deposit  
URE  urea  urea hydrolysis  yellow  red/orange  
TDA  tryptophan  deaminase  yellow  brown-red  
IND  tryptophan  indole production  yellow  red  
VP  Na pyruvate  acetoin production  colourless  pink/red  
GEL  charcoal gelatin  gelatinase  no black diffusion  black diffuse  
GLU  glucose  fermentation/oxidation  blue/blue-green  yellow  
MAN  mannitol  fermentation/oxidation  blue/blue-green  yellow  
INO  inositol  fermentation/oxidation  blue/blue-green  yellow  
SOR  sorbitol  fermentation/oxidation  blue/blue-green  yellow  
RHA  rhamnose  fermentation/oxidation  blue/blue-green  yellow  
SAC  sucrose  fermentation/oxidation  blue/blue-green  yellow  
MEL  melibiose  fermentation/oxidation  blue/blue-green  yellow  
AMY  amygdalin  fermentation/oxidation  blue/blue-green  yellow  
ARA  arabinose  fermentation/oxidation  blue/blue-green  yellow  
 
 
 
Figure 10: API20E strip to identify Enterobacteriaceae species 
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2.2 Antimicrobial testing 
2.21 Antimicrobial susceptibility 
Background: The response of a bacterium to an antimicrobial can be quantified 
by determining the lowest antimicrobial concentration required to inhibit 
overnight bacterial growth, known as the minimum inhibitory concentration 
(MIC). The broth dilution method is the traditional method of determining the 
MIC, however, as this method is labour intensive, the E-Test method is preferred. 
E-Tests are inert, non-porous plastic strips measuring 5 x 60 mm, containing an 
exponential gradient of the dried and stabilised antimicrobial (figure 11). One side 
of the strip is calibrated with MIC values in mg/ml and a two-letter code 
designates the identity of the antimicrobial. When an E-Test is applied onto an 
inoculated agar plate, there is an immediate release of the agent from the plastic 
surface into the agar plate. When bacterial growth is visible, following incubation, 
a symmetrical inhibition ellipse centred along the strip is seen. The zone edge 
intersection with the E-Test is the MIC value.  
Method: Antimicrobial susceptibility testing was performed on bacteria collected 
by the MOG using E-Tests, according to British Society of Antimicrobial 
Chemotherapy (BSAC) methods.
118
 Frozen beads were thawed and incubated on 
agar using conditions as described in table 4. Bacterial suspensions were prepared 
by transferring a loop of colonies directly from the plates into tubes containing 
sterile distilled water. The suspension was made to a 0.5 McFarland standard 
using a calibrated spectrophotometer at a wavelength of 500 nm. The bacterial 
suspension was diluted with sterile water; 1 in 10 for S. aureus, 1 in 100 P. 
aeruginosa and suspensions were used within 15 minutes of preparation. A sterile 
cotton-wool swab was dipped into the diluted suspension and the excess liquid 
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removed by turning the swab against the side of the tube. Susceptibility media 
was inoculated by evenly spreading the swab over the entire surface of the plate in 
three directions. E-Tests (AB Biodisk; Solna, Sweden) were placed centrally on 
the inoculated plates. Following incubation in air at 37 °C for 18 to 24 hours, 
MICs were calculated by determining the point of intersection of zone of 
inhibition with E-Test strip (figure 11). Tiny colonies at the edge of the zone were 
ignored and colonies growing within the zone of inhibition were subcultured and 
identified and the test repeated if necessary. Plates with too heavy or too light 
growth were also repeated. Quality control strains S. aureus ATCC 25923, P. 
aeruginosa ATCC 27853, E. coli ATCC 25922, Enterococcus faecalis ATCC 
29212, and S. pneumoniae ATCC 49619 were included.  
 
 
Figure 11: Teicoplanin E-Test on agar plate inoculated with S. aureus. MIC 
calculated at 8 mg/L; point of intersection of zone of inhibition with E-Test strip 
(indicated with arrow).    
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2.22 Identification of meticillin resistance 
To determine whether a staphylococci isolate was resistant to meticillin, a 
bacterial inoculum was prepared and spread onto Iso-Sensitest (ISA) agar as 
described above. A disc containing 10 μg cefoxitin was placed on the surface of 
inoculated agar and plates were incubated in air at 35 °C for 18-20 hours. The 
zone of inhibition surrounding the disc was carefully measured to the nearest 
millimetre with a ruler. Zones of inhibition were considered to be susceptible if 
22 mm diameter and resistant if  21 mm diameter, as per BSAC guidlines.118 
Control strains were used: S. aureus ATCC 25923 (susceptible) and S. aureus 
NCTC 12493 (resistant). 
 
2.3 Molecular techniques 
2.31 Deoxyribonucleic acid extraction 
Two methods of deoxyribonucleic acid (DNA) extraction were used to investigate 
virulence factors. Firstly, the Wizard Genomic DNA purification kit was used in 
P. aeruginosa (chapter 4.3), as suggested by the Clondiag Array Tube 
manufacturer’s instructions. Secondly, the more time efficient QIASymphony 
method was used for S. aureus (chapter 3.3).   
Genomic DNA was extracted from S. aureus isolates using QIASymphony 
SP (Qiagen, UK), following manufacturer’s instructions. 1 ml of overnight culture 
was pelleted and washed in 500 µl phosphate buffered saline (PBS) and 
resuspended in Lysis buffer (20 mM Tris·HCl; 2 mM ethylenediaminetetraacetic 
acid (EDTA) pH 8.0; 1.2% (v/v) Triton) containing 20 µg/ml
 
lysostaphin. Cells 
were incubated at 37 °C for 1 hour before the addition of 20 µl proteinase K and 
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200 µl Buffer AL (Qiagen, UK) followed by incubation at 56 °C for 30 min. The 
lysate was transferred to QIASymphony compatible tubes and DNA was purified 
using the Pathogen Complex 200 protocol. Purity and concentration of isolated 
DNA was determined spectrophotometrically, by measuring the absorbance at 260 
nm and 280 nm (NanoDrop Technologies; Abtech International, UK). 
Preparations which had 260/280 nm and 260/230 nm ratios between 1.8 and 2.0 
were considered to be of sufficient purity. 
Genomic DNA was extracted from P. aeruginosa isolates, using the 
Wizard Genomic DNA purification kit (Promega, UK). Bacterial cultures were 
grown overnight in Luria-Bertani broth (LB) at 37 °C in air (appendix A for LB 
broth methods). Bacterial cells were pelleted by centrifuging 1 ml of culture for 2 
minutes at 16,000×g.  600 μl Nuclei Lysis Solution was added followed by 
incubation for 5 minutes at 80°C. 3 μl of RNase Solution was added, followed by 
incubation at 37 °C for 60 minutes. 200 μl of Protein Precipitation Solution was 
added followed by incubation on ice for 5 minutes. After centrifuging at 16,000 
×g for 3 minutes, the supernatant was transferred to a tube containing 600 μl of 
isopropanol. The mixture was centrifuged and the supernatant removed. 600 μl of 
room temperature 70% ethanol was then added followed by centrifuge for 2 
minutes at 16,000 ×g. Ethanol was removed and the pellet left to air-dry 15 
minutes. The DNA pellet was rehydrated in 100 μl of Rehydration Solution for 1 
hour at 65 °C. Samples were checked for purity and concentration of DNA 
spectrophotometrically, as described above.  
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2.32 Nucleic acid amplification  
2.321 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) amplification was used to determine the 
presence or absence of virulence factor genes in S. aureus and P. aeruginosa from 
extracted DNA. The PCR mastermix comprised BioMix red (Bioline, UK), 
magnesium chloride 3.0 mM, forward and reverse primers (see table 6 for primer 
details) and DNA. Chapters 3 and 4 describe individual PCR conditions.  
2.322 Gel electrophoresis 
Agarose electrophoresis powder (Quiagen, UK) was added to 0.5x tris-borate-
ethylenediaminetetraacetic acid (TBE) to a concentration of 1% w/v.  See 
appendix B for methods of making TBE. The mixture was heated in a microwave 
1-3 minutes until the powder was completely dissolved. The solution was cooled 
down for 5 minutes and ethidium bromide was added, to make a final 
concentration of 0.5 μg/mL. The agarose gel was slowly poured into a gel tray 
with a well comb in place. Air bubbles were pushed away from the well comb 
with a pipette tip. The gel was then let to sit at room temperature until it 
completely solidified (20-30 minutes). The gel was placed into an electrophoresis 
unit was and was bathed in 0.5x TBE. 50 bp DNA ladder (Invitrogen, UK) (see 
appendix B3) was added into the first lane of the gel and samples containing the 
master mix and DNA were loaded into the subsequent wells. Gels were run at 100 
V until the dye line was approximately 75% of the way down the gel (about 1-1.5 
hours). DNA fragments (seen as bands) were then visualised and photographed 
using ultraviolet light. 
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Table 6. Oligonucleotide primers used in PCR for (a) amplification of: 
Staphylococcus genus-specific 16S rRNA, lukSF-PV and mecA, (b) full gene 
sequencing of lukSF-PV and (c) MLST of lukSF-PV +ve S. aureus isolates.  
 Gene Primer  Sequence (5’-3’) 
(a)                         16s rRNA 
 
lukSF-PV 
 
mecA 
Staph756F 
Staph750R 
AACTCTGTTATTAGGGAAGAACA 
CCACCTTCCTCCGGTTTGTCACC 
Luk-PV1   
Luk-PV2 
ATCATTAGGTAAAATGTCTGGACATGATC
CAGCATCAAGTGTATTGGATAGCAAAAGC 
MecA1  
MecA2 
GTAGAAATGACTGAACGTCCGATAA 
CCAATTCCACATTGTTTCGGTCTAA 
(b) 
 
lukSF-PV 
 
PVL1F  
PVL1R 
GGTGATGGCGCTGAGGTAGTCAAA 
CTGTATGATTTTCCCAATCAACTTC 
PVLint2F 
PVLint2R  
CAACTGCAACATCAGATTCCGATAAG 
CAAATTCACTTGTATCTCCTGAGCC 
PVLint3F 
PVLint3R 
GGGACCATATGGCAGAGATAGTTATC 
GTATTGGAAAGGCCACCTCATTGC  
(c)            Carbomate kinase  
 
 Shikimate dehydrogenase 
 
Glycerol kinase  
 
Guanylate kinase  
 
Phosphate acetyltransferase 
 
Triosephosphate isomerise 
 
A acetyltransferase 
arcC-Up  
arcC-Dn 
TTGATTCACCAGCGCGTATTGTC  
AGGTATCTGCTTCAATCAGCG 
aroE-Up   
aroE-Dn 
ATCGGAAATCCTATTTCACATTC 
GGTGTTGTATTAATAACGATATC 
glpF-Up 
glpF-Dn 
CTAGGAACTGCAATCTTAATCC 
TGGTAAAATCGCATGTCCAATTC 
gmk-Up 
gmk-Dn 
ATCGTTTTATCGGGACCATC 
TCATTAACTACAACGTAATCGTA 
pta-Up 
pta-Dn 
GTTAAAATCGTATTACCTGAAGG 
GACCCTTTTGTTGAAAAGCTTAA 
tpi-Up 
tpi-Dn 
TCGTTCATTCTGAACGTCGTGAA 
TTTGCACCTTCTAACAATTGTAC 
yqiL-Up 
yqiL-Dn 
CAGCATACAGGACACCTATTGGC 
CGTTGAGGAATCGATACTGGAAC 
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2.4 Cell culture 
Experiments using cell culture (chapter 5.331) were performed aseptically in a 
Class II biological cabinet. Cultures of Human Keratocytes (HKs) were 
established from the rims of donor corneo-scleral discs that had been used for 
corneal transplantation using cells from passages 5 to 10 as previously 
described.
119
 Human corneal epithelial cells (HCEs), immortalized by the SV40 
virus, were kindly provided by Dr Araki-Sasaki (Kiniki University, Hyogo, 
Japan).
120
 Cryopreserved HKs and HCEs were thawed and grown in a designated 
tissue culture incubator in 5% CO2 at 37 °C. HCEs and HKs were maintained at 
37 °C in 5% CO2 in a mixture of Dulbecco's Modified Eagle Medium (DMEM) 
and Nutrient Mixture F-12 (Sigma, Dorset, UK) supplemented with 10% fetal calf 
serum (FCS) (Biosera, East Sussex, UK), 1% L-glutamine and 1% penicillin & 
streptavidin (Sigma, Dorset, UK). When cells became sub-confluent (70-80% 
confluent) cells were split (passaged) to allow for further cell growth as follows. 
Trypsin was added to the culture-dish to loosen the cells. Media (with FCS) was 
added to the cells to quench trypsin reaction. Cells were then removed and 
centrifuged at 1000 rpm for 5 minutes. The pellet was re-suspended in 10 ml fresh 
media and the cell culture was split into separate dishes or flasks, and topped up 
with fresh media. Media was replaced every other day. 
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CHAPTER 3 STAPHYLOCOCCUS AUREUS 
3.1 Introduction 
S. aureus is frequently implicated in bacterial keratitis (Table 3).
104
 Out of 772 
isolates collected by the MOG from patients with keratitis 14% were S. aureus. 
3.11 Clinical features 
S. aureus associated keratitis is typically insidious in onset.
121
 Symptoms of a red, 
painful eye may have a gradual onset over a few weeks. On examination a 
localised small grey-white ulceration with clear margins is frequently seen. There 
is usually only minimal surrounding epithelial oedema and stromal infiltrate. 
Typically the lesion is in the periphery of the cornea, although it can develop in a 
more central location. A moderate anterior chamber reaction may be present. 
Long standing staphylococcal ulcers penetrate deep into the stroma producing 
intra-stromal abscesses and occasionally perforation. Multiple satellite stromal 
micro-infiltrates may also be seen. 
Blepharitis is a common predisposing feature for S. aureus keratitis. It is 
characterized by thickened eyelid margins with telangiectasia, scaling and 
crusting (figure 12).
122
 Loss of eyelashes and corneal involvement, including 
punctate epithelial erosions, marginal infiltrates, and neovascularization, may 
occur. MGD is characterized by terminal duct obstruction and/or changes in the 
glandular secretion. MGD may result in a poor tear film and ocular surface 
disease. Patients with MGD are frequently noted to have coexisting acne rosacea 
or seborrhoeic dermatitis. Chronic inflammation may be punctuated by acute 
exacerbations that lead to the development of corneal ulceration.
123, 124
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Scarring, CoNV and exudation from previous episodes of keratitis is 
suggestive of possible endogenous sources of bacteria particularly S. aureus from 
the eye lids or nares. 
 
 
Figure 12. Picture of keratitis associated with S. aureus. Features; severe central 
corneal thinning and aggressive corneal neovascularisation. Note blepharitis; 
thickened lid margin (black arrow), blocked and retroplaced meibomian gland 
orifices (yellow arrows), lid margin vascularisation (blue arrows). 
3.12 Virulence factors 
Humans beings are a natural reservoir for S. aureus with 20% persistently 
colonised with the bacteria in their anterior nares and throat.
109,125
 Singer et al 
found 3% of conjunctival swabs taken from healthy eyes grew S. aureus in 
culture.
126
 Whether an infection is contained or spreads is dependent on a complex 
interplay between S. aureus virulence determinants and host defence mechanisms. 
S. aureus has an extraordinary array of virulence factors that allows it to survive 
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extreme conditions within the host. These factors are controlled by a complex 
regulatory network in response to cell density, energy availability and 
environmental signals. Four distinct signal transduction systems have been 
described; agr, sae, srr and arl,
127
 of which agr is the most well known due to its 
regulation of QS.
128
 S. aureus virulence factors (summarised in table 7), will now 
be described. Antimicrobial resistance is described in chapter 5.   
 
Table 7. Summary of S. aureus virulence factors 
Pathogenic function Virulence factor 
Bacterial survival in host 
Neutrophil inhibition  
 
 
Opsonophagocytosis inhibition  
 
 
Evasion of adaptive immunity  
 
Bacterial nutrition 
 
Phenol soluble modulin, chemotaxis inhibitory 
protein, extracellular adherence protein. 
Antioxidants: catalase,  
staphyloxanthin, superoxide dismutase 
Bacterial surface capsule, clumping factor A, protein 
A, multiple complement inhibitors 
Enterotoxins (T-cell inhibition),  
protein A (B-cell inhibition) 
iron acquisition program;  
aureochelin and staphyloferrin;  
Bacterial invasion and host destruction 
Adherence 
 
 
Cytotoxicity  
 
 
Tissue destruction 
 
Staphylococcal protein A, fibronectin & collagen 
binding protein, clumping factor  
α-haemolysin, β-haemolysin, enterotoxin b and c, 
toxic shock syndrome toxin 1, exfoliative toxins, 
epidermolytic toxins A and B, α and γ toxins, 
Panton–Valentine leukocidin 
protease, lipase, and hyaluronidase 
Antimicrobial resistance 
Meticillin resistance 
 
mecA 
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3.121 Bacterial survival within the host 
The success of S. aureus as a pathogen is due in part to its ability to overcome the 
host’s immune system. One of the key host cells in pathogen defence are 
neutrophils (chapter 1.332) and S. aureus has many mechanisms to evade 
destruction by them. S. aureus secretes chemotaxis inhibitory protein and 
extracellular adherence protein which block neutrophil recognition of chemotactic 
factors
129
 and binding to endothelial adhesion molecule ICAM-1.
130
 Reactive 
oxygen species produced by neutrophils are neutralized by the deployment of the 
antioxidant enzymes known as catalases and superoxidase dismutase produced by 
S. aureus.
131
 S. aureus also secretes a specific toxin; phenol soluble modulin 
which induces neutrophil cytolysis.
132
 S. aureus expresses a surface capsule, 
clumping factor A, protein A and at least four complement inhibitors, which 
minimise opsonisation by complement and antibodies.
131
 
A severe bacterial infection normally induces the host to mount an 
adaptive immune response within 7 to 10 days. Studies have shown that S. aureus 
produces enterotoxins that can alter T cell functions,
133
 and protein A that 
suppresses the host B cell response.
134
  
In addition to evasion of host immune defence, the survival of S. aureus 
within the human host is dependent on successful acquisition of nutrients, 
particularly iron. S. aureus secretes the high affinity iron-binding siderophores 
aureochelin and staphyloferrin, to achieve this. The bacteria also initiates 
transcription of an iron acquisition programme upon sensing low iron levels, that 
allows capture and processing of iron within the cell.
135
 Biofilm formation 
(chapter 1.33) is another S. aureus virulence mechanism. This allows the bacteria 
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to persist on foreign material such as contact lenses
136
 and resist host defences and 
antimicrobials.   
3.122 Bacterial adherence and invasion 
Bacterial adhesive proteins are an essential component for S. aureus to cause 
disease. Corneal adhesion of S. aureus is thought to be due to fibronectin-binding 
protein
137
 and collagen-binding adhesin protein.
138
 
The tissue damage resulting from S. aureus infection has been attributed to 
various toxins. α toxin, a cytolytic toxin produced by nearly all S. aureus isolates, 
causes cell death of macrophages and lymphocytes by forming pores in their cell 
membranes.
139
 The toxin also alters platelet morphology, which may contribute to 
increased thrombotic events associated with S. aureus sepsis. α toxin has also 
been found to be an important virulence factor in animal models of keratitis.
140, 141
  
Other toxins that are produced by S. aureus that contribute to virulence 
include γ toxin, S-type protein, F-type protein and Panton-Valentine Leukocidin 
(PVL).
142
 However, the role of these toxins in the pathogenesis of keratitis has yet 
to be fully elucidated.  
3.123 Panton Valentine Leukocidin 
In 1894 van de Velde discovered the leukocidal property of some S. aureus 
isolates.
143
 Doctors Panton and Valentine attributed this to the production of a 
toxin which was named Panton-Valentine Leukocidin (PVL).
144
 PVL is a phage-
encoded bicomponent toxin that consists of the two polypepetides lukS-PV and 
lukF-PV.
145
 The genes encoding PVL, lukS-PV and lukF-PV, have been found to 
reside in the genomes of 6 phages: ΦSa2958, ΦSa2MW, ΦPVL, Φ108PVL, 
ΦSLT, and ΦSa2USA.146 Despite the number of different PVL phages, the genes 
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that encode PVL have been shown to be relatively conserved. Studies have found 
LukS-PV and LukF-PV to bind to neutrophils, monocytes and macrophages but 
not to lymphocytes.
147, 148
 Following the binding of monomers of LukS-PV and 
LukF-PV, further monomers attach to the cell wall forming a heptameric structure 
that forms a pore in the host cell surface.
145, 149
 This pore formation results in 
leukocyte cell death and the release of inflammatory cytokines.
148
 
A review of S. aureus infections reported to the French Reference Centre 
for Staphylococcal Toxaemia identified eight cases of severe community-acquired 
pneumonia caused by S. aureus strains carrying the PVL gene, six of which were 
fatal.
150
 Lina et al
151
 found that in 176 cases of S. aureus infection, PVL genes 
were strongly associated with furunculosis (93%), severe necrotic haemorrhagic 
pneumonia (85%), cellulitis (55%), cutaneous abscess (50%) and osteomyelitis 
(23%).  PVL-encoding genes, however, were not detected in strains responsible 
for other infections, for example, infective endocarditis, mediastinitis, hospital-
acquired pneumonia, urinary tract infection, and enterocolitis, or in those 
associated with toxic-shock syndrome. Table 8 describes the prevalence of the 
lukSF-PV locus in eight studies.
152-157
 Rates range from 2.1% in a Dutch study
154
 
to 51% in an Indian study (table 8).
157
 Differences in prevalence between studies 
may reflect differences in clinical sources of infection or different geographical 
locations. 
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Table 8. Reported rates of lukSF-PV carriage in S. aureus isolates worldwide 
Source of S. aureus isolates n lukSF-PV 
+ve (%)  
Ref 
Thailand Hospital patients range of disease 270 49 
152
 
USA Eurofins Medinet database 1055 36 
153
 
Netherlands  Nasal samples from healthy patients 829 0.6 
154
 
Netherlands  Blood cultures from patients with invasive disease 146 2.1 
154
 
France Range of samples from hospital patients 309 2.1 
155
 
Singapore Range of samples from hospital patients 204 9.8 
156
 
India Patients with various eye infections  33 51.5 
158
 
UK Reference Unit (not all from disease)  515 1.6 
159
 
 
The involvement, however, of PVL in the virulence of S. aureus is equivocal and 
its link with clinical outcome remains uncertain. In vivo studies have produced 
conflicting data. Murine models of S. aureus infection have shown that the 
absence of PVL results in an increase in virulence,
160-163
 whereas studies in rabbits 
indicate that the presence of PVL increases the virulence of S. aureus.
164-166
  
These discrepancies could however be attributed to differences in the immunology 
of the models.
166
 Mouse neutrophils are insensitive to the effects of PVL whereas 
rabbit and human neutrophils both have sensitivity. There is also no consensus on 
the effect of lukSF-PV on clinical outcome in patients with S. aureus infection. 
Some studies suggest that PVL is not associated with clinical outcome or that the 
presence of PVL can reduce virulence,
160, 167-169
 whereas other studies have found 
a correlation between PVL carriage and diseases invasiveness.
170-173
 
In terms of antimicrobial treatment, the most common isolate responsible for 
outbreaks of community acquired meticillin resistant S. aureus (MRSA) infections 
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in the USA, was the PVL+ve strain USA300. The epidemic of the USA300 strain 
has not yet been seen in the UK, where the vast majority of MRSA isolates are 
lukSF-PV-ve.
174
 PVL+ve S. aureus isolates are susceptible to most other 
antimicrobials used to treat staphylococcal infections, including trimethoprim-
sulfamethoxazole, glycopeptides, linezolid and the fluoroquinolones.
174-176
 One 
particular sequence type (ST80), however, has been found to be resistant to 
tetracycline and fusidic acid.
175, 176
  
The potential involvement of PVL as a virulence factor has led to the 
investigation of its relevance in infectious diseases of the eye and its adnexa. 
Rutar et al
177
 described a case series of 9 patients with severe ocular infection 
(including cases of orbital cellulitis and endophthalmitis) caused by the USA300 
S. aureus strain that is known to carry lukSF-PV. More recently, Nadig et al
158
 
reported 33 cases of ophthalmic infections caused by S. aureus taken from two 
centres in India. They found 17 (52%) of the isolates were lukSF-PV+ve, while 5 
of the 9 (56%) keratitis isolates were lukSF-PV+ve. Four of the lukSF-PV+ve 
keratitis isolates were resistant to fluoroquinolones, but outcome data was not 
reported. There are no reported studies, however, that have looked for an 
association between the lukSF-PV genotype and clinical outcome in keratitis 
caused by S. aureus.  
 
3.2 Chapter aims 
This chapter aims to investigate the prevalence and type of lukSF-PV in S. aureus 
isolates taken from patients with keratitis in the UK. An association will be made 
between the presence of lukSF-PV and clinical outcome in patients with keratitis 
associated with S. aureus. 
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3.3 Methods 
3.31 Collection of isolates and determining MICs 
Clinical data and isolates from 95 consecutive cases of keratitis associated with S. 
aureus were collected by the MOG over a 2 year period, as described in chapter 
2.11. Isolates were sent to the microbiology laboratory at the Royal Liverpool 
University Hospital NHS Trust where they were sub-cultured and stored on beads. 
MICs of ciprofloxacin, moxifloxacin, levofloxacin, penicillin, vancomycin, 
teicoplanin, chloramphenicol, gentamicin, meropenem, linezolid and tigecycline 
were determined using E-Tests (as described in chapter 2.21).  
3.32 Detection of mecA and lukSF-PV 
DNA was extracted from the S. aureus isolates collected, using QIASymphony SP 
(chapter 2.21). A multiplex PCR assay was performed using 50-70 ngml
-1
of the 
extracted DNA.  Primers used were as follows: (1) Staph756F and Staph750R; 
amplifying the Staphylococcus genus-specific 16S rRNA gene (positive internal 
control), (2) Luk-PV-1 and Luk-PV-2; amplifying the lukSF-PV gene and (3) 
mecA1 and mecA2; amplifying the mecA gene, a determinant of MRSA. See table 
6a for primer details. The optimized multiplex PCR conditions were as described 
by McLure et al.
178
 Thermocycling conditions were; 94 °C for 10 minutes, 10 
cycles of 94 °C for 45 s, 55 °C for 45 s, 72 °C for 75 s and 25 cycles of 94 °C for 
45 s, 50 °C for 45 s and 72 °C for 75 s. Amplification was assessed by running 
PCR products on 1% agarose gels stained with ethidium bromide. Positive 
controls were USA300 (positive for 16S, mecA and lukSF-PV) and SH1000 
(positive for 16S).  
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3.33 lukSF-PV sequencing 
Isolates that were PCR positive for lukSF-PV underwent further genetic analysis. 
PCR amplification of an internal fragment (+108 to +1807) of the lukSF-PV 
operon was performed. The 25 µl PCR mixture contained 50-70 ngml
-1
of bacterial 
DNA, 1.25 units Accuzyme, 12.5 µl Biomix red (Bioline), 2.5 mM magnesium 
chloride and 100 pmol primers; PVL1F, PVL1R, PVLint2F, PVLint2R, PVLint3F 
and PVLint3R (table 6b for primer details). PCR cycle conditions were as 
follows: 5 minutes at 95 
o
C, followed by 30 cycles of 1 minute at 94 
o
C, 1 minute 
at 50 
o
C and 2 minutes at 72 
o
C. PCR products were then sequenced (GATC 
Biotech, Germany) and single nucleotide sequences were built for each isolate 
utilising a multiple sequence alignment tool from Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/).
179
 
3.34 Multi Locus Sequence Typing 
Background: Multilocus sequence typing (MLST) is a method of characterising 
bacterial isolates on the basis of the sequences of seven housekeeping genes: 
arcC, aroE, glpF, gmk, pta, tpi and yqiL.
180
 For each gene fragment the sequences 
are assigned as distinct alleles, and each isolate is defined by these alleles known 
as a sequence type (ST). Isolates with the same allelic profile can be assigned as 
members of the same clone allowing comparisons with other studies. Appendix C 
lists the full amino acid sequence for each gene.    
Methods: MLST was performed with DNA extracted from isolates from the 
MOG collection. PCR amplicons of the 7 S. aureus housekeeping genes were 
sequenced (primer details table 6c) and the loci of each gene was constructed 
from reads using the Clustal Omega tool described in section 3.33. STs were 
determined using the database provided by http://www.MLST.net.  
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3.35 Clinical outcome data collection 
Clinical outcome data was collected in a similar manner to a previously validated 
method by Kaye et al.
181
 Parameters collected were; ulcer size (mm
2
) at 
presentation, scar size (mm
2
) at final examination, healing time (days) defined as 
interval to epithelialisation, treatment time (days), risk factors for infection, 
surgical interventions (amniotic membrane grafts, penetrating keratoplasty or 
evisceration/enucleation), and the ratios of ulcer size to healing time and ulcer 
size to treatment time. For each parameter, patients were assigned a positive or 
negative clinical outcome score according to the deviation of the parameter in 
standard deviations (SD) from the mean. For example, if the ulcer size was within 
1 SD of mean it was scored 0, between 1 and 2 SD they scored 1, and >2 SD they 
scored 2. Similarly, negative scores were given for negative SD values. Surgical 
events were assigned a score of 3 and loss of the eye a score of 5. Aggregate 
clinical scores were then calculated for all parameters.  
3.36 Statistical Analysis 
Logarithms were taken for all clinical and MIC data, except for discrete events 
such as surgical intervention or loss of the eye. The Kruskal-Wallis test (SPSS 
version 20) was used to determine differences between groups. 
 
3.4 Results 
3.41 LukSF-PV presence and type 
Each individual PCR yielded fragments of the expected sizes, i.e., 756, 433, and 
310 bp for the 16S rRNA, lukS/F-PV, and mecA genes, respectively. Of the 95 S. 
aureus keratitis isolates; 9 (9.5%) were lukSF-PV+ve, 9 (9.5%) were mecA+ve 
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and 1 isolate was positive for both (1.1%) (figure 13). The lukSF-PV gene was 
highly conserved in 8 isolates. One amplification was unsuccessful despite 
numerous attempts. There was, however, nucleotide variation in seven of the 
isolates compared to the USA300 reference strain (figure 14). In total there were 5 
nucleotide substitutions causing 4 amino acid changes. Two major sequence 
variants of lukSF-PV, the R and H variants, were identified, based on a 
substitution of adenine for guanine at nucleotide 528 that resulted in a histidine 
(H) to arginine (R) amino acid change. MLST typing showed that lukSF-PV+ve 
isolates could be classified into two diverse STs: 3 of the 9 were classified as 
ST30 and the others were STs 12, 49, 1, 121 and 8. A summary of the gene 
sequencing and MLST results is included in table 9. 
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Figure 13. PCR of S. aureus isolates positive for pvl and mecA. Positive controls 
USA 300 (positive for lukSF-PV and mecA), SH1000 and Newman (positive for 
16s).  
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   lukSF-PV sequence 
USA300  516G 528G   665T        1397A 1730G  
39073   528A         665G              1397G       1730A  
39165   528A         665G              1397G       1730A  
39200  516C                   
39348                  1397G   
48016                  1397G      1730A  
48135          1730A  
106030   528A          665G                     1730A  
106035 
       
       
 
Figure 14: Schematic representation of sequence variance between the 8 lukSF-
PV+ve S. aureus isolates sequenced. Strain identity numbers are indicated on the 
left with the USA300 used as a comparator reference strain at the top. The 
position of amino acid substitutions in relation to the USA300 strain are indicated 
for each strain followed by the alternative base. For example, for strain 39200; at 
position 516 amino acid G in USA300 was replaced with C. A = Adenine, T = 
Thymine, C = Cytosine, G = Guanine 
 
 
 
 
Start: 108 end: 1807 
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Table 9. Gene sequencing and Multi Locus Sequence Typing (MLST) of lukSF-
PV+ve S. aureus isolates  
Isolate No. Location mecA Genotype variant MLST type 
39073 London -ve R 30 
39076 London -ve  N/A 12 
39165 London -ve H 49 
39200 Manchester -ve H 1 
39348 Birmingham -ve H 121 
48016 London -ve H 30 
48135 London -ve H 30 
106030 London -ve R 1 
106035 London +ve H 8 
 
3.42 Antimicrobial sensitivity patterns 
The MICs of the 95 isolates to 11 antimicrobials tested are shown in table 10. 
There was no significant difference in the mean MIC between the lukSF-
PV/mecA-ve and lukSF-PV+ve groups, apart for tigecycline which had a 
significantly lower mean MIC for the lukSF-PV+ve compared to both the 
mecA+ve and lukSF-PV/mecA-ve isolates. There was greater variation in the 
MICs of the lukSF-PV +ve isolates than that of the lukSF-PV/mecA-ve isolates to 
the fluoroquinolones and penicillin as evident in the higher MIC90 (antimicrobial 
concentration required to inhibit the growth of 90% of organisms). In contrast, the 
mecA+ve isolates had significantly higher mean MICs (p<0.05) with higher MIC90 
and MIC50 to meropenem and the fluoroquinolones. 
3.43 Clinical outcome 
Ninety of the patients had received a fluoroquinolone (ofloxacin or ciprofloxacin) 
as initial treatment. Five of the patients with isolates negative for both lukSF-PV 
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and mecA had received chloramphenicol as initial treatment. There were no 
significant differences in age, gender distribution or position of the ulcer (distance 
from the limbus) between the groups that were positive or negative for lukSF-PV 
or mecA (p= 0.40). The healing and treatment times, ulcer and scar size and 
overall clinical score tended to be greater in the lukSF-PV+ve group (Table 11). 
The proportion of patients that required surgery as management for their keratitis 
was significantly greater in the lukSF-PV+ve group (3 of 9 cases required surgery) 
compared to the lukSF-PV-ve group (3 of 81 cases required surgery) or the 
mecA+ve group (1 of 9 required surgery) (p=0.016).  In comparison to patients 
with lukSF-PV-ve isolates, the odds ratio for patients with lukSF-PV+ve isolates 
requiring surgery was 7.8 (95% CI 1-42, p=0.018) whilst those with mecA isolates 
was 2.6 (95% CI 0.3-27, p=0.42). 
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Table 10. Antimicrobial susceptibility data for patients with S. aureus keratitis 
who were lukSF-PV+ve (n=9), mecA+ve (n=9) or negative for both (lukSF-
PV/mecA -ve (n=77). Mean MIC and the antimicrobial concentration at which 
90% and 50% of bacteria are inhibited (MIC90 and MIC90 respectively). 
Antimicrobials tested were ciprofloxacin (Cip), moxifloxacin (Mox), levofloxacin 
(Lev), penicillin (Pen), teicoplanin (Tei), chloramphenicol (Chl), gentamicin 
(Gen), meropenem (Mer), linezolid (Lnz) and tigecycline (Tig).  
  Cip Mox Lev Pen Tei Chl Gen Mer Lnz Tig 
lukSF-PV-ve 
mecA-ve 
Mean MIC 0.5 0.03 0.1 0.4 0.9 3.6 0.4 0.03 0.4 0.1 
MIC50 0.4 0.03 0.1 0.8 1.0 3.0 0.4 0.02 0.5 0.1 
MIC90 1.5 0.05 0.2 1.5 1.5 8.0 1.0 0.05 0.8 0.1 
lukSF-PV+ve Mean MIC 0.8 0.1 0.2 0.3 0.6 2.4 0.4 0.03 0.4 0.04* 
MIC50 0.4 0.1 0.1 0.5 0.8 2.0 0.4 0.03 0.5 0.1 
MIC90 32 1.6 25.7 7.2 1.0 4.2 0.6 0.1 0.6 0.1 
mecA+ve Mean MIC 20* 2* 12* 12* 0.4* 6.2 0.3 0.7* 0.4 0.1 
MIC50 32 1.0 8.0 32.0 0.3 3.5 0.4 0.9 0.4 0.1 
MIC90 32 4.0 38.0 32.0 1.6 131 0.5 2.3 0.6 0.1 
*significant difference between the mean MIC of the three S. aureus groups.  The 
mean MIC for teicoplanin was significantly lower in the lukSF-PV+ve group of 
isolates. 
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Table 11. Clinical outcome (mean and SD) for patients with S. aureus keratitis; 
lukSF-PV+ve (n=6), mecA+ve (n=8) or negative for both (lukSF-PV/mecA -ve 
(n=70). Parameters analysed: Treatment time (TT), healing time (HT), ulcer area 
(UA), scar area (SA), ulcer to scar area (UA/SA), healing time to ulcer area 
(HT/UA) and clinical outcome score (CS) according to the deviation of the 
parameter in standard deviations (SD) from the mean and % of patients requiring 
surgery (Sur).   
  
TT 
(days) 
HT 
(days) 
UA 
(mm
2
) 
SA 
(mm
2
) 
UA/ 
SA 
HT/    
UA 
CS 
 
Sur 
(%)  
lukSF-PV-ve 
and mecA –ve 
Mean 20.2 9.7 3.1 1.6 0.8 3.4 2.1 3.7 
SD 26.3 12.6 11.8 7.6 1.1 5.6 2.8  
lukSF-PV +ve 
Mean 20.6 13.6 5.3 3.4 0.7 2.4 3.6 33 
SD 31.7 27.0 5.9 4.3 0.4 2.8 3.7  
mecA +ve 
Mean 15.5 6.2 2.2 1.0 0.7 3.4 1.3 11 
SD 20.3 3.4 3.7 4.2 0.3 5.3 1.9  
 
3.5 Discussion 
Interest in PVL toxin as a S. aureus virulence factor intensified after it was 
associated with fatal cases of community acquired pneumonia in previously 
healthy children.
151
 Yoong et al
160
 identified that PVL induces pro-inflammatory 
cytokines and a moderate TNF-α response in pulmonary infections in a murine 
model, indicating a possible immunomodulatory role. The same group had 
previously found that mutant PVL strains with isogenic lukS and lukF deletions 
were more virulent in a murine skin abscess model compared to wild type.
161
 
Further studies using murine models of sepsis, abscess, skin infection and 
pneumonia showed similar results.
162, 163
 As previously mentioned there has been 
much discussion about the suitability of using mice to study PVL toxicity, due to 
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the differences in mouse and human immunology, in particular, the insensitivity 
of mouse neutrophils to the effects of the leukocidin.
166
 There is a growing 
consensus that a rabbit model might yield more meaningful results. In vivo studies 
in rabbits indicate that the presence of PVL increases the virulence of S. aureus 
strains.
164, 165
 Diep et al
165
 identified a role for PVL in the virulence of S. aureus 
USA300 and USA400 strains during the early, acute stages of bacteraemia in 
rabbits, when lysis of PMNs might allow colonisation to be established. These 
findings were supported by Lipinska et al,
166
 who noted that during the early 
course of skin infection in a rabbit model a PVL+ve USA300 isolate of S. aureus 
produced larger lesions and more skin necrosis, compared to PVL knockout 
strains. There is also debate on the role of PVL in S. aureus infection in patients. 
There are several studies which suggest that there is no difference in clinical 
outcome with PVL+ve MRSA infections or that the presence of PVL can reduce 
virulence.
160, 167-169
 The presence, however, of PVL in the virulent CA-MRSA 
clone USA300
182
 lends epidemiological support that the toxin influences the 
virulence of S. aureus. Indeed a correlation between PVL carriage and 
invasiveness of disease, as well as virulence, has been found not only in USA300, 
but also in other community-acquired strains.
170-172
 Although these hyper-virulent 
lineages are known to be MRSA, attention must also be paid to PVL+ve 
meticillin-sensitive S. aureus (MSSA), which represents the vast majority of UK 
PVL-containing clones.
174
 
In this study of 95 patients with S. aureus keratitis, 9.5% of isolates were 
lukSF-PV+ve and these cases tended to have larger ulcers and worse outcomes, in 
particular a significantly higher incidence of cases requiring surgical intervention. 
These findings reflect those of Muttaiyah et al
173
 who found a statistically 
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significant correlation between PVL+ve MSSA and the need for surgical 
intervention, amongst 411 isolates taken from patients with a variety of S. aureus 
infections. The data does not suggest a link between a particular allele of lukSF-
PV and keratitis, as 6 different lukSF-PV alleles were identified, including both H 
and R variants. The predominant subgroup was the H variant, which is consistent 
with the findings of Wolter et al
183
 who identified the H variant as the most 
common form in S. aureus isolates from Europe. 
It is noteworthy, that 8 of the 9 lukSF-PV+ve isolates in this study were    
mecA-ve. The MRSA status of a S. aureus isolate is determined by the mecA gene 
that lies in the SCCmec cassette (chapter 5). It has been proposed that the presence 
of mecA may impose a fitness cost on isolates in environments such as the 
community with limited antimicrobial use. This may result in evolutionary 
pressure for some CA-MRSA strains to lose the SCCmec cassette while retaining 
key virulence or fitness factors such as lukSF-PV.
184
 Alternatively, the MSSA 
strains may have never acquired the SCCmec cassette. The small number of 
lukSF-PV+ve isolates in this study makes it difficult to speculate why only 1 of 9 
lukSF-PV+ve was mecA+ve.  
The diversity in the sequence types observed in this study is in agreement 
with the clonal diversity observed in MSSA isolated from skin and soft tissue 
infections in the USA.
184
 The presence of multiple PVL alleles within the same 
genetic lineage, for example the presence of both H variants and R variants as 
well as 3 different single nuclear polymorphisms (SNPs) among the ST30 isolates, 
could indicate horizontal gene transfer of the PVL phage between different clonal 
complexes. 
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 Multiplex PCR as described by McClure et al
178
 is a relatively quick and 
inexpensive way to screen for both lukSF-PV and mecA using the 16S rRNA gene 
locus as a positive control. The higher MICs seen to the fluoroquinolones for 
mecA isolates reflects that reported in previous studies on patients with 
keratitis.
104, 185
 In contrast, the mean MICs for lukSF-PV and lukSFPV-ve groups 
were similar for the antimicrobials tested. Of note however, was the lower mean 
MIC of lukSF-PV to tigecycline compared to both the lukSF-PV-ve and mecA+ve 
S. aureus isolates.   
 
3.6 Conclusion 
The study found that patients with lukSF-PV+ve S. aureus were associated with a 
trend to worse clinical outcome and more surgical interventions, with an effect 
unrelated to MICs. This suggests that lukSF-PV may be an important virulence 
factor in S. aureus associated keratitis. A larger study would be needed to verify 
this, especially in light of differing effects on clinical outcome that PVL has been 
shown to have, in previous studies.
167, 168, 173, 186
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CHAPTER 4 PSEUDOMONAS AERUGINOSA 
4.1 Introduction 
P. aeruginosa is an important Gram-negative human pathogen. It is a frequent 
cause of hospital acquired infections such as pneumonia, urinary tract infections 
and bacteraemia. P. aeruginosa is an opportunistic pathogen, only rarely causing 
disease in healthy people. In most cases of infection, the integrity of a physical 
barrier to infection (e.g. cornea, skin) is lost, or an underlying immune 
deficiency
187
 (e.g. neutropenia, immunosuppression) is present. Patients with 
cystic fibrosis are at an increased of infection due to P. aeruginosa colonisation in 
excess secretions.
188
 Adding to its pathogenicity, this bacterium has minimal 
nutritional requirements and can tolerate a wide variety of physical conditions. P. 
aeruginosa is one of the most frequent causative bacteria implicated in keratitis in 
most studies (table 3). It constituted 20.9 % of isolates collected from patients 
with keratitis in the UK by the MOG.  
 
4.11 Clinical features 
Contact lens use significantly increases the susceptibility of the cornea to P. 
aeruginosa
19,136
 (chapter 1.1311). A detailed contact lens history, including type 
of lens, extent of wear and lens hygiene, should therefore be taken from all 
patients presenting with keratitis (see chapter 1.121). 
P. aeruginosa associated keratitis is typically rapid in onset.
121
 Early signs 
of infection include a grey epithelial and stromal microinfiltration with oedema. 
The stromal infiltration may extend horizontally and vertically involving the 
whole width and depth of the cornea and a yellow-green mucopurulent discharge 
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is typically seen. A severe anterior chamber reaction is often seen, sometimes with 
the development of a hypopyon. During the next 2-3 days, if untreated, a ring 
infiltration may develop, with scleral and corneal melting. If the ulcer progresses, 
descemetocele formation may occur with subsequent corneal perforation.
189
 
Figure 1 shows an example of keratitis caused by P. aeruginosa.  
4.12 Virulence factors 
The large array of bacterial surface factors and active cellular processes that 
contribute to the virulence of P. aeruginosa will now be described (summarised in 
table 12). 
 
Table 12.  Summary of virulence factors associated with P. aeruginosa 
Pathogenic function Virulence factor 
Defence against bactericidal reaction 
Complement inhibition 
 
Proteases, alkaline protease, protease IV, alginate   
Pseudomonas aeruginosa small protease,  
large exoprotease 
Host invasion/cytotoxicity 
Adhesion 
Invasion 
 
 
 
 
 
 
 
Inter-bacterial communication 
 
Motility/chemotaxis 
  
Type IV pili, lectins 
Glycocalix, biofilms, elastases (Las B and Las A), 
Alkaline protease, haemolysins  
(phospholipases and rhamnolipid),  
cytotoxin (leukocidin) pyocyanin pigment, 
siderophores and siderophore uptake systems, 
endotoxin, LecA and LecB lectins 
Type III secretion system: PcrV, PopB, and PopD  
and exoS, exoT, exoU, exoY 
Quorum sensing: las and rhl systems  
Pseudomonas quinolone system 
Flagella, retractile pili 
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4.121 Bacterial survival  
P. aeruginosa has developed a number of strategies to combat the vast repertoire 
of host defences in humans.
190
  
P. aeruginosa can evade detection by the host by directly destroying host 
immune molecules that are involved in pathogen detection. For example, an 
important component of host defence is the deposition of a complement 
component C3b on the bacterial surface, leading to pathogen destruction. P. 
aeruginosa is able to counter complement activation by producing alginate to 
limit accessibility of complement, and proteases (including alkaline protease and 
elastase) that degrade C3b.
191
  
P. aeruginosa can also down-regulate their own expression of PAMPs 
(chapter 1.332) in order to “hide” from the host immune system. The flagellum, a 
virulence determinant required for motility and attachment, is also a PAMP that is 
detected by the host. It has been shown that upon growth on purulent mucus, P. 
aeruginosa down-regulates flagellin synthesis, thereby dampening the host 
immune response.
192
  
Reactive oxygen species produced by neutrophils are neutralized by the 
deployment of the antioxidant enzymes known as catalases. P. aeruginosa  
produces a catalase that is not dependent on the presence of iron, known as 
nonhaem catalase KatN (chapter 4.133).
193
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4.122 Bacterial adhesion and invasion 
4.1221 Twitching motility 
P. aeruginosa spread rapidly across surfaces by twitching motility as a result of 
the repeated extension, tethering, and retraction of long surface filamentous 
appendages, called type IV pili.
194
 Twitching has been implicated in the virulence 
of P. aeruginosa associated disease including pneumonia and keratitis.
195
 
Zolfaghar et al
196
 found twitching motility mutants of P. aeruginosa had reduced 
virulence in a murine keratitis model, compared to twitching motility-competent 
wild-type bacteria. It is postulated that type IV pili have a role in epithelial 
adherence and traversal,
87
 as well being one of the many factors in biofilm 
formation (chapter 1.33).  
4.1222 Type III secretion system 
Of the many bacterial factors that contribute to the pathogenesis of P. aeruginosa, 
the type III secretion system (TTSS) is important for bacterial persistence in the 
presence of host defence mechanisms and has been associated with poor clinical 
outcomes.
197
 The TTSS consists of 43 genes that encode the secretion apparatus, a 
translocon and factors that regulate secretion.
198
 The secretion apparatus exports 
toxins from across the bacterial cell envelope, and the translocon assembled by 
the proteins PcrV, PopB, and PopD, is responsible for injecting these toxins into 
the host cell.
199
 Four secreted toxins, or exotoxins, have been identified to date: 
exoU, exoS, exoT, and exoY. The first two have been closely linked to virulence in 
keratitis and will be discussed here.  
The contribution of exoU to virulence is attributable to its phospholipase 
A2 activity.
200-202
 Upon injection into host cells, exoU is activated and targeted to 
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the plasma membrane, where it cleaves membrane phospholipids, resulting in 
rapid and complete cell lysis. ExoS has invasive properties and encodes both 
GTPase-activating protein and ADP-ribosyltransferase activities.
203
 It induces 
rapid lysis of macrophages, epithelial cells and fibroblasts. 
Most P. aeruginosa strains contain either exoS or exoU. Strains containing 
both genes, however, are uncommon.
204
 Isolates from keratitis have been found to 
be disproportionately carriers of exoU (rather than exoS) in comparison with the 
wider P. aeruginosa population.
205
 exoU-positive strains are associated with 
greater morbidity in P. aeruginosa keratitis.
206, 207
 
208
  
 
4.1223 Proteases 
Proteases are enzymes that hydrolyse peptide bonds in proteins and contribute to 
the corneal melting that occurs in severe cases of keratitis. P. aeruginosa is 
capable of secreting at least seven different proteases
142
; elastase A (Las A), 
elastase B (Las B), modified elastase, alkaline protease, protease IV, 
Pseudomonas aeruginosa small protease, and the large exoprotease. Las A, Las B, 
modified elastase, and AP are metalloproteinases and may be produced by only 
some strains.   
4.1224 Quorum sensing-regulated factors 
QS-regulated factors (see chapter 1.33) have an essential role in P. aeruginosa 
virulence. They regulate around 350 genes (6% of the P. aeruginosa genome), 
playing critical roles in biofilm formation
101, 209
 and production of numerous 
toxins.
210
 The commonest QS molecules in P. aeruginosa, (as well as most Gram-
negative bacteria) are acyl homoserine lactones (AHLs). When the concentration 
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of AHLs in the intracellular environment increases (due to increasing numbers of 
bacteria) transcriptional regulators are induced. Three QS systems have been 
extensively studied in P. aeruginosa; las, rhl and Pseudomonas Quinolone Signal 
(PQS).
211
 The las system consists of LasR, the regulator protein and LasI synthase 
protein, which is essential for the production of the AHL signal molecule N-(3-
oxododecanoyl)-L-homoserine lactone (3O-C12-HSL). The rhl system consists of 
RhlI and RhlR proteins. The RhlI synthase produces the AHL N-butyryl-L-
homoserine lactone (C4-HSL), and RhlR is the transcriptional regulator. PQS has 
only recently been identified in P. aeruginosa. Häussler
212
 postulated that PQS is 
an essential mediator of formation of the population structure of Pseudomonas 
and its survival in hostile environmental conditions. On the one hand it acts as a 
pro-oxidant and sensitizes the bacteria towards oxidative and other stresses and, 
on the other, it induces a protective anti-oxidative stress response. This dual 
function may be beneficial to Pseudomonas populations in promoting survival of 
the fittest, and in contributing to bacterial multi-cellular behaviour. McKnight et 
al
213
 suggest that PQS acts as a link between the las and rhl QS systems and that 
this signal is not involved in sensing cell density.   
4.123 Invasive and cytotoxic P. aeruginosa 
Two important virulence determinants in P. aeruginosa are invasiveness and 
cytotoxicity which are due in part to the possession of two mutually exclusive 
effector exotoxins of the type III secretion system; exoU or exoS (chapter 
4.1222).
207
 Invasive P. aeruginosa strains encode exoS and can sequester 
themselves intracellularly, replicating and stimulating membrane bleb formation 
within host cells. Cytotoxic strains lack exoS and instead encode the cytotoxin 
exoU, which can quickly kill cells without being sequestered inside the host cell. 
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Borkar et al
214
 showed that bacterial keratitis caused by invasive (exoS+ve) strains 
was associated at presentation with significantly better visual acuity than 
cytotoxic (exoU+ve) strains, but had less improvement in visual acuity at 3 
months. They also revealed that adjunctive treatment with topical steroids had a 
different effect on cytotoxic and invasive strains. This illustrates the concept that 
not all infections caused by pathogens of a single species present or respond to 
treatment similarly.  
4.124 P. aeruginosa reference strains  
PAO1 and PA14 are two frequently used reference strains used in P. aeruginosa 
studies. The PAO1 strain (originally called P. aeruginosa strain 1) was first 
isolated from a patient’s wound over 50 years ago in Australia.215 It became the 
first reference strain for Pseudomonas genetics and analyses of the physiology and 
metabolism of this bacterium. With the advent of pulsed-field gel electrophoresis 
(PFGE), a physical map of the PAO1 genome was constructed and later merged 
with the genetic map information.
216
 By 2000 the PAO1 strain had been 
completely sequenced.
217
 PAO1 is known to encode exoS and is therefore 
classified as an invasive P. aeruginosa strain.
206
 PAO1 is used as the reference 
strain in in Array Tube genotyping (chapter 4.131).  
PA14 (originally called UCBPP-PA14) is a clinical isolate taken from a 
human burn patient. The genome of PA14 was published in 2004 and revealed a 
high degree of conservation compared to PAO1.
218
 PA14 has been shown to be 
much more virulent than PAO1 in a number of diverse models of infection, 
leading to the hypothesis that PA14 is a multihost pathogen capable of infecting 
invertebrate and vertebrate animal species and plant species.
219
 The virulence of 
PA14 has been attributed to two pathogenicity islands; PAPI-1 and PAPI-2, that 
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are absent in PAO1.
220
 PAPI-1 encodes a number of likely virulence factors, 
including type IVB pili
221
 and PvrR, a regulator involved in biofilm synthesis.
222
 
PAPI-2 encodes the cytotoxin exoU of the TTSS and is therefore classified as a 
cytotoxic strain.
223,224
 
4.13 Genotypic features of P. aeruginosa clones  
A range of genotyping methods have been used to study P. aeruginosa isolates, 
including pulse field gel electrophoresis,
225
 Random Amplification of 
Polymorphic DNA,
226
 MLST,
225, 227
 and more recently the Clondiag Array Tube 
(AT).
228
  
4.131 Array Tube genotyping 
The AT was developed in 2007 and consists of 77 oligonucleotides immobilised 
into a microchip and embedded into the base of a tube.
229
 The layout is divided 
into four sections, as shown in Figure 15. The chip has 29 markers for a range of 
genomic islands and islets, (boxed in red), 15 markers for variable genes, (boxed 
in blue), a LES PS21 marker, (boxed in black) and 16 markers relating to single 
nuclear polymorphism (SNP) loci, (boxed in green). The markers for genomic 
islands, variable genes and the LES PS21 marker are represented by two spots and 
the SNPs by four spots. There are six control spots (four in the first column and 
two in the last) that indicate the efficiency of hybridisation, conjugation and 
precipitation. 
Interpretation of the AT chip 
A genetic profile can be determined by analysis of thirteen SNP patterns at seven 
conserved loci ampC, citS, alkB2, fliCa, oprI, oprL and oriC and the presence or 
absence of 3 variable genes encoding the type III secretion virulence proteins 
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(exoU and exoS) and the flagellin protein FliC. These patterns for each locus are 
compared to a predetermined table (Figure 16). The genomic islands (red) and 
variable genes (blue) are represented by two oligonucleotides and the presence of 
the spots indicates whether the target is present or absent. If the gene is present the 
strain is assigned a ‘1’ for that locus and ‘0’ if the gene is absent. In contrast each 
SNP is represented by four oligonucleotides, two on the left that have sequences 
that match with PAO1, and two on the right, with sequences that don’t match 
PAO1 (considered a “mutant strain”). If the hybridisation spots are stronger on the 
left (the PAO1 sequence) the strain is assigned a ‘0’ for that locus and a ‘1’ if the 
hybridisation is stronger for the spots on the right.  
The resulting hexadecimal code can then be shortened to a 4 digit code as 
shown in Figure 17 and an individual genetic fingerprint is produced. This code 
can be compared to a large, previously described database
229
 and the strain can be 
assigned a clone type.  
The AT system has been used to successfully genotype P. aeruginosa 
isolates from a range of chronic and acute clinical conditions, including chronic 
obstructive pulmonary disease
230
 and more recently by Stewart et al
231
 on a 
selection of keratitis associated strains. 
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Figure 15. Sequence positions on Array Tube. Genomic islands and islets, (boxed 
in red), variable genes, (boxed in blue), LES PS21 marker, (boxed in black) and 
16 markers relating to single nuclear polymorphism (SNPs) loci, (boxed in green). 
Markers for genomic islands, variable genes and the LES PS21 marker are 
represented by two spots and the SNPs by four spots. Six biotin control spots 
(boxed in yellow). SNPs and variable markers were used for strain identification.  
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Figure 16.  Method of generating hexadecimal code from Array Tube image. (a) 
predetermined table for comparison of precipitation patterns for the seven 
conserved loci, (b) example of Array Tube image generated from P. aeruginosa 
isolate. In this example oriC SNP (boxed in red) compared to oriC on table (boxed 
in green). As oriC pattern in the isolate is comparable to the PAO1 strain it is 
annotated as “0” in the hexadecimal code. In this way the entire hexadecimal code 
is generated. 
 
 
 
 
O 
(a) 
(b) 
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(a)
 
 
(b) 
 
Figure 17. Conversion of Array Tube hexadecimal code into four digit code. (a) 
hexadecimal code generated from Array Tube image from Figure 16. (b) 
hexadecimal code separated it into four parts. Four corresponding code digits are 
found by comparing to a predetermined table. Originally described by Wiehlmann 
et al.
229
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4.132 Population genotyping 
Population genotyping is the method of displaying the genetic relationships 
between isolates of a bacterial population. The BURST algorithm (which stands 
for; Based Upon Related Sequence Types) is a web-implemented clustering 
algorithm designed for use on genotype data sets from bacteria. BURST was 
devised and developed by Ed Feil from the University of Bath.
232
 An enhanced 
version of BURST (eBURST version 1) was developed and integrated into the 
website www.mlst.net.
233
 The latest version; eBURST version 3, has been 
developed with funding from the Wellcome Trust by and contains several new 
features improving on previous versions.  
eBURST uses a simple model of bacterial evolution based on a founding 
or ancestral genotype that increases within a population and, in doing so, begins to 
diversify to produce a cluster of closely related genotypes. It then predicts the 
descent from the founder genotype and displays the output as a radial diagram 
(Figure 18).  Although the eBURST method has been applied mostly to MLST 
data, it can also be used to display relationships between strains using other data, 
such as the AT genotyping data. 
The first step of the process is to divide the input data into groups of STs 
that have some level of similarity in their allelic profiles. Within a group, all the 
STs must be a single locus variant (SLV) of at least one other ST in the group. 
The primary founder of the group is defined as the ST that differs from the largest 
number of other STs at only a single locus. If two STs have the same number of 
associated SLVs, the one with the largest number of double-locus variants (DLVs) 
is selected as the founding ST. A clonal complex is a set of STs that are believed 
to be descended from the same founding genotype. More than one cluster of 
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linked STs (clonal complex) may be displayed in the eBURST diagram, along 
with a number of unlinked individual STs or ‘outliers’. 
The eBURST diagram displays the patterns of descent within each group 
from the predicted founder ST in a radial fashion, with lines showing the links 
from the founder to each of its SLVs. The circle representing the predicted 
founder is coloured blue.  In a large eBURST group there may be several STs that 
have a number of SLVs of their own. A ST that has diversified to produce 
multiple SLVs is called a subgroup founder and these are depicted by a yellow 
circle. The size of the circle for each ST represents its abundance within the 
population. 
 
 
Figure 18. Example eBURST diagram depicting the relationship between closely 
related bacterial isolates based on MLST. Sequence types (STs) are represented 
by dots, the larger the dot - the more it is represented in the population. Black 
dots; STs, blue dots; primary founders, yellow dots; subgroup founders.  
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4.133 Genotyping and population mapping of keratitis isolates 
Stewart et al
231
 studied 63 P. aeruginosa isolates collected between 2003 and 
2004 from patients with keratitis to investigate whether specific P. aeruginosa 
clones are associated with the disease. Isolates taken from patients with P. 
aeruginosa associated keratitis were genotyped using the AT methodology as 
previously described. eBURST population analysis, comparing keratitis isolates to 
a wider collection of P. aeruginosa from various non-ocular sources, identified 
various markers in a subpopulation of P. aeruginosa associated with keratitis that 
were in strong disequilibrium with the wider P. aeruginosa population. There was 
a significantly higher proportion of isolates with the oriC1 allele within the 
keratitis group compared to the isolates taken from non-keratitis sources. These 
oriC1 isolates were much more likely to be exoU+ve and exoS-ve in the keratitis 
group compared to the non-keratitis group. The keratitis isolates were also shown 
to be more frequently associated with exoU, glycosylated but unmodified flagellin 
and the absence of the nonhaem catalase KatN (chapter 4.121). One isolate 
(39016) was selected for further genome sequencing. This was because it 
represented the commonest clone (clone D) and serotype (O11). Strain 39016 was 
shown to have a novel type 4 pili gene cluster pilA gene. Type 4 pili are 
associated with adhesion and twitching motility (chapter 4.1221), which is 
thought to be important in keratitis.
194, 196
 The majority of clone D isolates and 
some other O11 isolates carried this novel pilA gene. Winstanley et al
205
 reported 
that 90% of 63 keratitis isolates exhibited better twitching motility than strain 
PA14. 
Stewart et al
231
 concluded that the similar genetic characteristics of the 
keratitis isolates suggests that a subpopulation of P. aeruginosa may be adapted to 
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causing corneal infections. It is unclear however, if these features are consistent 
temporally or represent a feature of the particular time period chosen for 
sampling. 
 
4.2: Chapter aim 
This chapter aims to investigate whether the genetic features of the isolates 
investigated by Stewart et al
231
 are consistent temporally with P. aeruginosa 
isolates associated with keratitis. A population genotype of P. aeruginosa keratitis 
isolates from a later time period; 2009-2010 will be compared to the isolates 
described by Stewart et al.
231
  
4.3 Methods 
4.31 Genotyping and population mapping of P. aeruginosa  
P. aeruginosa isolates were taken from patients presenting with bacterial keratitis 
between 2009 and 2010 (chapter 2.11). DNA was extracted from the isolates 
using the Promega wizard kit (chapter 2.31). Genotyping was conducted using the 
AT genotyping system (Alere Technologies, Jena, Germany).
229, 231
 Components 
of the AT system are described in appendix B2. Analysis of 13 SNPs based on the 
conserved genome, and three variable markers (flagellin types a or b and the 
mutually exclusive type III secretion exotoxin genes exoU or exoS) was 
performed as follows:  
1) Linear amplification and biotin labelling  
A PCR master mix was prepared with: 4.9 μL of B1 (2x Labelling Buffer), 0.1 μL 
of B2 (DNA Polymerase) and 0.5‐2 μg of the extracted DNA suspended in 5 μL 
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of water. PCR conditions: 300 sec at 96 °C, 50 cycles of 20 sec at 62 °C, 40 sec at 
72 °C and 60 sec at 96 °C. 90 μL of buffer C1 was added. 
2) Array Tube hybridisation  
General precautions with Array Tubes: Plastic Pasteur pipettes were used with 
flexible tips and care was taken not to touch the Array Tube surface. 
Pre‐washing of the Array Tubes: 500 μL of ultrapure water was added to each 
tube. Tubes were incubated in the thermomixer at 60 °C, 550 rpm for 2 minutes. 
Water was then removed from the tubes. 200 μL buffer C1 added to each tube. 
Tubes were incubated in the thermomixer at 60 °C, 550 rpm for 2 minutes. Buffer 
C1 was removed and discarded.  
Hybridisation: Amplified DNA from step 1 was transferred to a prepared 
Array Tube which was then incubated for one hour at 60 °C and 550 rpm.  
Washing steps: The hybridisation mixture was removed and 500 μL of buffer C2 
was added and discarded from the tubes. A further 500 μL of buffer C2 was added 
and the tubes were incubated for 5 minutes at 30 °C, 550 rpm followed by 
removal of the washing solution. This step was repeated once.  
Addition of HRP conjugate: 100 µL C3/4 (containing Streptavidin‐Horseradish 
Peroxidase (HRP) was added to each tube followed by incubation for 10 minutes 
at 30 °C and 550 rpm. C3/C4 was then removed and 500 μL of buffer C5 was 
added and removed. This step was repeated.  
Staining of bound HRP‐conjugate: 100 μL of reagent D1 (containing a 
substrate for Horseradish Peroxidase) was added to each tube which was then 
incubated at room temperature without agitation for 10 minutes.  
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3) Data Acquisition 
The final washing solution was removed from the ATs and 100 μL of 3,3’5,5’,-
tetramethylbenzidine staining solution was added. Data was acquired from the 
chip by inserting the AT containing the hybridised and stained products into an 
AT Reader. Images were acquired using the IconoClust-AT software 
(CLONDIAG Chip Technologies GmbH). Acquired images were composed of a 
series of dots (see figure 16b for example), which was converted into a 4 digit 
code, as described in chapter 4.131.  
Isolates with 4 digit codes found more than once in the study were 
designated a clone ‘type’ depicted by a capital letter (e.g. A) or a letter followed 
by a number (e.g. A3). Isolates with 4 digit codes that were found only once in the 
study were recorded as ‘single’ and those not previously identified as ‘novel’. The 
genotypic relationship between our isolates and P. aeruginosa isolates from other 
sources was assessed using the 4 digit code using the eBURST (v3) algorithm 
(Imperial College London, UK).
232,233
 4 digit codes were entered to the eBURST 
website (http://eburst.mlst.net/v3/enter_data/comparative/mlst/default.asp) and a 
comparison was made to 322 P. aeruginosa isolates taken from environmental 
and other non-ocular sources. 
231,229, 234,235,236
 
 
4.32 Distribution of regions of difference 
Background: In the previous study of the 2003-4 isolates, Stewart et al
231
 
selected isolate 39016 for further genome sequencing. This was because it 
represented the most abundant clone in their study (clone D) and the most 
common serotype (O11), it occupied a central location within the major cluster of 
isolates, and it was associated with a severe keratitis. In addition, AT data suggest 
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that it lacks many of the accessory genome genes represented on the microarray. 
Hence, they hypothesized that its accessory genome carries novel genomic islands 
shared with other keratitis isolates. From this they identified accessory genome 
regions which differed from the laboratory PAO1 strain and designed assays to 
screen for regions of differences (ROD).  
Methods: Indicative PCR assays designed by Stewart et al
231
 were used to 
determine the distribution of the RODs showing a frequency > 15% amongst the 
63 isolates of the 2003-2004 study (ROD 1, 15, 16, 17, 18 and the novel pilA 
gene) amongst the 60 isolates from the current study. PCRs for each of these 
RODs were multiplexed with an assay for the oprL gene as an internal control. 
Table 13 lists individual primer details. P. aeruginosa isolate strain number 
039016 was used as a positive control. All reactions were conducted with initial 
denaturation at 94 °C (5 minutes), followed by 25 cycles of denaturation (92 °C, 3 
mins), annealing (58 °C, 1 minute) and elongation (72 °C, 2 mins), with final 
elongation at 72 °C (10 mins).  
Statistical analyses: Independent data comparing genetic features of keratitis 
isolates in a temporal manner or comparing features of keratitis isolates with non-
keratitis isolates were assessed by chi square double classification with one degree 
of freedom. 
 
4.4 Results 
Distribution of clone types amongst 2003–2004 and 2009–2010 collections 
60 keratitis-associated P. aeruginosa isolates were collected by the MOG (2009 to 
2010). DNA was extracted and successful AT image acquisition was performed in 
all of them. Appendix D describes the clone type attributed to each isolate in the 
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study. 36 (60%) of the isolates analysed in this study were assigned to an existing 
clone type in the database of 322 strains. This compares with 33 of 63 (52%) 
isolates from the 2003 to 2004 collection.
231
 Clone types that did not yield a 
match in the published database were assigned as ‘novel’ clone types. Nearly 23 
novel clone types (representing 25 of 60 isolates) were identified in this study 
compared to 19 novel clone types (representing 30 of 63 isolates) in the previous 
study from 2003 to 2004. The combined prevalence for the six most common 
clone types (clones A, B, C, D, I and V) was similar in the two collections [27 of 
60 (45%) in 2009–2010 compared to 24 of 63 (38%) in 2003–2004]. Among 
keratitis isolates, one novel clone type (C429) was identified at both time points. 
 
Keratitis isolates within the wider P. aeruginosa population structure 
When keratitis isolates were examined within the wider P. aeruginosa population 
structure, it was possible to identify two major clusters of P. aeruginosa; cluster 1 
and cluster 2 (figure 19). 86 of 123 (71%) keratitis-associated isolates were 
present within cluster 1, representing 39% (86 of 222) of all isolates in this 
cluster. Forty-seven of 63 (75%) isolates from 2003 to 2004 and 39 of 60 (65%) 
of the 2009–2010 isolates were found in this cluster. In comparison, 135 of 322 
(42%) of the non-keratitis isolates were within cluster 1, which is significantly 
reduced (p = 0.001) compared to the percentage of keratitis isolates within the 
cluster. 
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Table 13. List of oligonucleotide primers used to detect regions of differences 
(RODs)   
Primer 
 
Sequence 
 
Size  
(bp) 
Target gene 
/ROD
a
 
Ref 
PAL1 ATGGAAATGCTGAAATTCGGC 504 oprL 
237
 
PAL2 CTTCTTCAGCTCGA  oprL  
ORF5228F GTCATGCCCACAAACTGATG 325 ROD16 
231
 
ORF5228R ACCTTGGTGGACCGCTTAC  ROD16  
ORF6116F TCGAATGTGAAGTGCCTCAG 218 ROD18 
231
 
ORF6116R GTAACGGATTTCGGTGTTGC  ROD18  
ORF4339F AACTCGCAATCCACCGTATC 150 ROD15 
231
 
ORF4339R GATCCGTCCTCCTGTTTCAA  ROD15  
ORF5388F TGTTCATGGACATGGAGGAA 326 ROD17 
231
 
ORF5388R CAGCTCGTTCTGGTCTTCG  ROD17  
ORF265F GTGGGTTTGCAAAAGCGTAT 234 ROD1 
231
 
ORF265R CACCTCTTCAGGTGTGCTGA  ROD1  
novPilAF CGGGTTCCAGTTTGTTGACT 184 pilA 
231
 
novPilAR CAGCCACCATTAACATCACG  pilA  
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Figure 19. Keratitis isolates within a wider P. aeruginosa population structure. 
The diagram shows an eBURST representation of 123 keratitis-associated P. 
aeruginosa isolates (red spots) among a total of 445 strains. The number of 
isolates for each clone type that was recovered is indicated in brackets. Where no 
number is given, only one isolate of that type was identified. Two clonal 
complexes are seen indicated as cluster 1 and cluster 2. 71% of keratitis isolates 
fall within cluster 1. 
 
 
 
 
 
Cluster 1 
Cluster 2 
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Comparison of prevalence of genomic islands and variable genes between the 
2003-2004 and 2009-2010 isolate collections 
All 60 of the 2009–2010 keratitis isolates carried the PAGI-1 genomic island, a 
common genomic island found in 85% of clinical isolates.
238
 On the AT chip, 
PAGI-2- and PAGI-3-like genomic islands were represented by 10 hybridisation 
signals.
229, 234
 Analysing both 2003-4 and 2009-10 groups together showed a 
similar prevalence of the genomic island compared to non-keratitis isolates; 65 of 
123 (53%) keratitis isolates lacked PAGI-2/3-like genomic islands compared with 
159 of 322 (49%) non-keratitis P. aeruginosa.  PAPI-1, PAPI-2 and pKLC102 
represent a family of genomic islands that carry virulence genes absent in the 
commonly used laboratory strain P. aeruginosa PAO1. AT markers pKL-1 and 
pKL-3 represent conserved domains of this family of genomic islands.
229, 234
 
Sixty-seven of 123 (55%) keratitis isolates did not show hybridisation for either 
marker pKL-1 or pKL3 compared to 122 of 322 (38%) non-keratitis isolates (P = 
0.05). P. aeruginosa-type flagellins vary because of the presence of a 
glycosylation island
239
 that can be present as either a longer insert encompassing 
14 open reading frames (ORFs), or as a shorter version with a 5.4-kb deletion.
240
 
Twenty of 123 (16%) keratitis isolates carried the full length glycosylation island 
(12 of 63 isolates in 2003–2004 and 8 of 60 isolates in 2009–2010) and 61 of 123 
(50%) carried the truncated version. This compares with 28% and 35% of non-
keratitis isolates carrying the full length and truncated glycosylation island, 
respectively.
231
 Carriage of the variable gene PA2185 encoding the nonhaem 
catalase KatN was higher (25 of 60; 42%) in the second isolate collection 
compared with the first isolate collection (18 of 63; 29%), but this increase was 
not significant (v2 = 2.318). Carriage of PA2185 is significantly lower (P = 0.001) 
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among keratitis isolates (43 of 123; 35%) than amongst the non-keratitis 
collection (188 of 322; 58%). Carriage of the exoU island A
224
 is associated with 
the non-PAO-1 type oriC1 allele in keratitis isolates.
231
 exoU-positive strains 
continued to show significant (P = 0.001) association with the presence of oriC1 
in the 2009–2010 isolate cohort, whereas exoS-positive strains do not show 
association with either oriC allele. When we included all 120 keratitis isolates 
(three isolates were negative for exoS and exoU) from both studies, the association 
between exoU and oriC1 allele continued to be significant (P = 0.001).  
 
Distribution of ROD associated with P. aeruginosa keratitis strains 2003-04  
In the previous study of the 2003–2004 isolates,231 isolate 039016 was selected for 
genome sequencing and PCR assays were developed to analyse the distribution of 
10 ROD among the 63 keratitis isolates. Table 14 shows that among the 60 
keratitis isolates from 2009 to 2010, the prevalence of four of the ROD and the 
novel pilA showed significant reduction compared to the 2003–2004 collection (P 
= 0.05). The only exception was ROD16 (26.7%). To establish whether ROD16 
might be a specific feature of keratitis-associated P. aeruginosa, contemporary 
blood culture isolates of P. aeruginosa were analysed. The prevalence for ROD16 
amongst the blood culture isolates was 22.2%, suggesting that carriage of this 
region was not something particular to isolates associated with keratitis. 
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Table 14. Prevalence of ROD of interest among keratitis strains isolated between 
2003–2004 (Stewart et al., 2011) and 2009–2010 (this study) 
  2003-04 study (n = 63) 2009-10 study (n = 60) 
Region size(kb) +ve  % +ve  % 
ROD16 39.7 19  30.2 16 26.7 
ROD18 > 13.5  19  30.2  8  13.3* 
ROD15 > 45 14  22.2  1  1.7* 
ROD17 37.2  12  19.1 3 5.0* 
ROD1 34.7  11  17.5  1  1.7* 
Novel  17 27.0  2  3.3* 
+ve = number of isolates positive for ROD. % = prevalence of ROD in group of 
isolates. *Statistically significant (P= 0.05; chi-squared test) deviations from 
previously determined prevalence of ROD of interest. 
 
4.5 Discussion 
Various approaches have been used to define the population structure of P. 
aeruginosa and to identify an association between strain types and environmental 
origin or particular types of infection. Using a combined analysis of amplified 
fragment length polymorphism (AFLP), serotype, pyoverdine type and 
antibiograms, Pirnay et al
241
 concluded that population diversity in river water 
reflected the wider population diversity of P. aeruginosa and that environmental 
and clinical isolates are indistinguishable. A combination of phenotypic and 
genotypic characteristics used in a larger survey reached similar conclusions.
242
 In 
contrast, a study using MLST indicated that oceanic isolates were divergent from 
the general P. aeruginosa population.
243
 AT genotyping has been applied to 
collections of isolates of clinical relevance, particularly in chronic infections 
associated with cystic fibrosis
244
 and chronic obstructive pulmonary disorder.
230
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Although dominant clones are a feature in these populations, evidence for an 
association between a subgroup of P. aeruginosa clones and a specific type of 
infection has only been reported in the previous study AT genotyping of keratitis 
isolates by Stewart et al.
231
  
To determine whether this association of a clonal subgroup with disease 
was a unique occurrence among UK keratitis isolates collected between 2003 and 
2004, rather than an inherent feature of isolates associated with this disease, the 
study was replicated on a further set of 60 isolates obtained 5 years later from the 
same contributing hospitals. Our results show that there was a similar cluster to 
that observed previously, revealing that a subgroup of keratitis-associated P. 
aeruginosa strains was a feature of both collections when analysed separately or 
when combined (n = 123). There were some minor variations between the two 
time points. Differences were observed in the dominant clone types (type A in 
2009–2010 vs. type D in 2003–2004). There was also a reduction in the 
proportion of keratitis isolates falling within the core keratitis cluster (cluster 1) 
between the time points (40% in 2009–2010 vs. 48% in 2003–2004). However, 
overall 71% of keratitis isolates belonged to a core keratitis cluster (cluster 1; 
figure 19). Although the carriage of the exoU/S was not included in the eBURST 
analysis, all of the exoU positive keratitis isolates (66 of 123) belonged to cluster 
1. This cluster also includes 19 isolates carrying the exoS gene. However, 35 of 
the 36 keratitis isolates not within cluster 1 carry the exoS gene.  
In the previous study by Stewart et al,
231
 RODs were identified between 
keratitis isolate 039016 (AT clone type D; serotype O11; poor clinical outcome) 
and strain PAO1. The carriage of these regions as indicated by PCR assay was 
lower in the more recent collection of isolates. It is likely that this is because of a 
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lower number of Clone D isolates in the more recent collection and that these 
RODs were largely associated with Clone D specifically, rather than a general 
features of the cluster. The exception was ROD16. However, the similar 
prevalence of this ROD amongst blood culture isolates of P. aeruginosa suggests 
that ROD16 is not a particular feature of keratitis associated isolates. Previously 
identified characteristics associated with the core keratitis cluster described by 
Stewart et al
231
 were confirmed in the current study. The keratitis-specific 
subpopulation strains carry the oriC1 allele, exoU, and a truncated version of the 
flagellin glycosylation island, but are less likely to carry the gene encoding the 
nonhaem catalase KatN (. As previously noted, carriage of the exoU gene was 
significantly associated with the oriC1 allele.  
The AT genotyping scheme has also been used to analyse strains from 
diverse backgrounds, indicating the presence of dominant clones that are widely 
distributed.
229, 234
 A recent study using AT typing reported the presence of several 
extended clonal complexes (ecc) that were nonuniformly distributed in freshwater 
sources of varying water quality, suggesting that the population dynamics of P. 
aeruginosa may be shaped by environmental rather than clinical factors.
245
 
Isolates of the divergent eccB were the most frequently sampled from various 
environmental water sources, prompting the suggestion that this clonal complex 
represents a ‘water ecotype’ better adapted to environmental water than other P. 
aeruginosa. Interestingly, an exoU+/exoS- genotype is a feature within this eccB 
group. In this study, the core keratitis cluster was found to include clone types 
(such as A, B, D and I) that are eccB clone types.
245
 The eccB group also includes 
serotypes O11, O10 and O8 which feature prominently amongst the core keratitis 
cluster. For 78 isolates, we had clinical data regarding the use of contact lenses. 
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Although the differences were not statistically significant, a greater proportion of 
core keratitis cluster isolates were associated with contact lens use (72%, 56 of 
78) than for isolates not within the core cluster (28%, 22 of 78). A larger sample 
size would be needed to test whether this association is significant. 
Full gene sequencing is being increasingly performed in P. aeruginosa 
genetic studies. 
246, 247
 Gene sequencing of the keratitis isolates used in this study 
could provide a more complete understanding of the P. aeruginosa genome and 
its involvement in keratitis.  
4.6 Conclusion 
It appears from this study, and the study by Stewart et al,
231
 that there is a sub-set 
of P. aeruginosa isolates that are associated with bacterial keratitis in the UK. 
These isolates have been found to be related to the eccB clonal complex 
associated with adaptation to survival in environmental water,
245
 which is 
consistent with the notion that aquatic environments are integral to the 
transmission dynamics of P. aeruginosa, in the context of bacterial keratitis. 
However, the link between specific genotypes and clinical outcome or risk factors 
is not clear. Further analysis of clinical data and studies involving additional sets 
of patients for verification of this hypothesis will provide a clearer picture, 
helping to link genetic features with evidence-led clinical management of P. 
aeruginosa keratitis. 
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CHAPTER 5: ANTIMICROBIALS IN KERATITIS 
5.1 Introduction  
5.11 How do antimicrobials work?  
Antimicrobials are a class of drug that kills or prevents the growth of 
microorganisms. The efficacy of an antimicrobial is dependent on its 
pharmacodynamics and pharmacokinetics. Pharmacodynamics is the study of the 
effects of drugs on the body, or on microorganisms within the body. It also 
includes the mechanisms of drug action and the relationship between drug 
concentration and effect. Pharmacokinetics is concerned with the fate of 
substances administered externally to a living organism. It can be subdivided into 
the following four processes; absorption, distribution, metabolism, and excretion,  
5.112 Pharmacodynamics 
Antimicrobial pharmacodynamics is measured by determining its MIC, which is 
defined as the lowest antimicrobial concentration that will inhibit overnight 
growth of bacteria (chapter 2). The MIC90 is a descriptive statistic estimating the 
antimicrobial concentration which will inhibit the growth of 90% of isolates and 
the MIC50 is the concentration which inhibits 50% of isolates. 
 There is good evidence demonstrating the relationship between the MIC 
of topically applied antimicrobials and clinical outcome in bacterial keratitis for 
certain bacteria. Kaye et al
181
 described the relationship between clinical outcome 
of patients with bacterial keratitis (defined by the ratio of healing time to ulcer 
size) and the MIC of a particular antimicrobial agent. General linear multivariate 
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modelling showed a significant association between the MIC of the antimicrobial 
prescribed and clinical outcome for Pseudomonas spp., S. aureus and 
Enterobacteriaceae. A significant association was not seen for CNS, suggesting 
that CNS may not necessarily be pathogenic in bacterial keratitis. 
The MIC is used to determine the susceptibility or resistance of an antimicrobial, 
by comparing it to a set of standard MICs based on the safe achievable 
concentrations of antimicrobial in the serum (chapter 5.15). It is important to note 
that systemic interpretive MIC breakpoints are likely to be inappropriate for the 
topical ophthalmic use of antimicrobials. The clinical outcome of a corneal 
infection to a given topically applied antimicrobial, is not only dependent on the 
MIC of the infecting bacteria, but is also critically dependent on the achieved 
corneal antimicrobial concentration and bioavailability (i.e. its pharmacokinetics, 
see next section). This is recognised by BSAC,
118
 who state the following in their 
antimicrobial testing guidelines; “MIC breakpoints specific for topical antibiotics 
are not given because there are no pharmacological, pharmacodynamic or 
clinical response data on which to base recommendations. Relevant data would 
be gratefully received.” 
5.113 Pharmacokinetics 
When evaluating pharmacokinetics one must consider the body spaces between 
which drugs pass and within which drugs are distributed. Ocular 
pharmacokinetics is concerned with (a) the tear film and conjunctival fornices, (b) 
the anterior chamber, (c) the vitreous cavity and (d) the retro-orbital space. Most 
topical ophthalmic drugs exhibit first order kinetics; where the absorption rate and 
elimination rate of the drugs vary directly with the drug concentration.
248
 The 
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drug half-life in first order kinetics is therefore constant regardless of the amount 
of drug that is present. 
Upon administration of topically applied drops to the ocular surface, 
precorneal factors and anatomical barriers negatively affect the bioavailability of 
topical formulations.
249
 Precorneal factors include solution drainage, blinking, tear 
film and lacrimation. The tear volume is estimated to be 7 μl, and the cul-de-sac 
can transiently contain around 30 μl of the administered eye drop. The tear film, 
however, displays a rapid restoration time of 2–3 minutes, and most of the 
topically administered solutions are washed away within just 15–30 seconds after 
instillation. 
Topically applied drug may penetrate into the eye via the cornea, the 
conjunctiva or the sclera. In practice, however, the vast majority of topical drugs 
penetrate via the cornea.
249
 The cornea is composed of several layers with 
different physiological and anatomical functions (chapter 1.2). The corneal 
epithelium is the most important layer when considering the penetration of 
topically applied drugs into the eye.
250
 During the maturation of the corneal 
epithelium, the cells become flatter and form tight junctions in the intercellular 
space. These tight junctions, known as zonula occludens, are located only in the 
most apical surface cell layers, providing the diffusional barrier for drug 
absorption from the tear film to the anterior chamber. The corneal epithelium 
poses a significant resistance for permeation of topically administered hydrophilic 
drugs.
251
 The presence of zonula occludens restricts paracellular drug permeation 
from the tear film into the cornea. The highly hydrated structure of the corneal 
stroma poses a significant barrier to permeation of lipophilic drugs. The 
endothelium possesses leaky junctions that facilitate the passage of 
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macromolecules between the aqueous humour and stroma. This layer is therefore 
not as important as the epithelium and stroma as a barrier for drug penetration.
249
 
In bacterial keratitis there is usually an ulcer present so that neither the epithelium 
or its basement membrane are present. This would allow greater penetration of 
antimicrobials directly into the stroma. 
Trans-corneal penetration of topically applied drug can be through passive 
diffusion or active transport mechanisms. Passive diffusion is driven by the 
physico-chemical parameters that determine the partitioning and diffusion of the 
drug in the cell membrane. Lipophilicity is thought to be the critical feature of a 
drug that determines its passive diffusion through the cornea.
250, 252
 Compounds 
that are more lipophilic, as a general rule, penetrate the cornea more readily. The 
optimal lipophilicity for corneal permeation has been estimated between 2–3 logD 
values.
253
 Molecular weight, pH and stability in solution all may play a part in the 
passive permeation of a drug. Active transport of drug through the cornea requires 
the expression of transporters in the epithelium.
250
 Corneal transporters that have 
the highest impact on drug permeation are located in the most apical surface of the 
corneal epithelium.
254
 Transporter expression in other locations in the cornea such 
as wing cells and basal cells of the epithelium, keratocytes and corneal 
endothelium are important in physiology, but are thought to be less relevant in 
pharmacokinetics. Transporters that have been described in the human corneal 
epithelium include the SLC6 neurotransmitter transporter family
255
 and the SLC7 
cationic amino acid transporter y+ system.
256
 Since corneal permeability is the 
sum of passive diffusion and active transport, the relative impact of active 
transport depends on the background level of passive diffusion. Active transport 
mechanisms may have a higher impact on the permeation of hydrophilic 
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compounds than that of the lipophilic drugs, due to the low passive diffusion of 
hydrophilic drugs.  
5.12 Drugs used to treat keratitis 
5.121 History of antimicrobial use in keratitis  
In the 1940s, the vast majority of Gram-positive and Gram-negative bacteria were 
found to be susceptible to the early antimicrobials penicillin, streptomycin, and 
tetracycline.
257
 For this reason these antimicrobials were popular choices for 
topical treatment of bacterial keratitis. The overuse of penicillin, however, led to 
the selection of resistant strains. By the end of the 1950s, S. aureus had acquired 
resistance to virtually all available systemic antimicrobials, including 
erythromycin and the tetracyclines.
258
 In 1960 meticillin was introduced, a β-
lactam antimicrobial that is not inactivated by the enzyme β-lactamase.259 A host 
of other β-lactam antimicrobials with similar properties, including oxacillin, 
nafcillin, and cefazolin, soon followed.
260
 
At the end of the 1960s, gentamicin was developed from the old 
aminoglycoside streptomycin, because of the upsurge in P. aeruginosa infections 
(susceptible to gentamicin but resistant to streptomycin). Over the next decade, 
other aminoglycosides, tobramycin and amikacin, were introduced and 
commercial drops of tobramycin and gentamicin became available, which become 
popular for the treatment of bacterial keratitis.
257
 In the 1970s and 1980s there was 
extensive development of new β-lactams to overcome the problems of resistant 
Gram-negative bacterial infections and of aminoglycoside toxicity. The 
cephamycins (cefoxitin and cefotetan), the “third-generation” cephalosporins 
(ceftriaxone, ceftazidime, cefotaxime and others), and the carbapenems 
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(imipenem) were all used for systemic treatment.
261
 The development of an old 
class of antimicrobials, the quinolones, in the 1990s, provided for the first time a 
class of drugs with broad Gram-positive and Gram-negative activity and little 
corneal toxicity.
257
 The second generation fluoroquinolones, ciprofloxacin and 
ofloxacin have been found to be as effective for bacterial keratitis as fortified 
drops of older agents and are freer of the problems of corneal toxicity and short 
shelf-life. Third generation (levofloxacin) and fourth generation fluoroquinolones 
(moxifloxacin and gatifloxacin) are now FDA approved for the treatment of 
bacterial keratitis.
262
 
5.122 Fluoroquinolones 
Fluoroquinolones work by inhibiting DNA gyrase (also known as topoisomerase 
II) and topoisomerase IV, enzymes necessary in bacterial DNA synthesis. Second 
generation fluoroquinolones, ciprofloxacin and ofloxacin, are widely used in 
treating bacterial keratitis. They offer a great potency against Gram-negative 
bacilli (including P. aeruginosa), moderate activity against S. aureus and little 
activity against Streptococci and the pneumococci. Despite the success of the 
first- and second-generation fluoroquinolones, there has been a trend (based on 
systemic breakpoints) towards an in increase in resistance of both S. aureus
263
 and 
P. aeruginosa.
264
 Further molecular modifications of the fluoroquinolones in 
2000s lead to the development of the third-generation levofloxacin, and the fourth 
generation moxifloxacin and gatifloxacin. These agents have greater potency 
against Gram-positive bacteria, in particular the Streptococci. The later generation 
fluoroquinolones unfortunately have not been a treatment panacea because of the 
emergence of resistance (albeit based on systemic breakpoint data).
265, 266
 Park et 
al.
267
 showed a rate of 2% resistance (based again on systemic breakpoint data) to 
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moxifloxacin and 5% to gatifloxacin in isolates of normal bacterial ocular flora. 
Sueke et al
104
 showed a rate of 2% resistance using systemic breakpoint data to 
moxifloxacin and 16% to ciprofloxacin in S. aureus isolates from patients with 
bacterial keratitis. A number of pharmacokinetic studies have shown moxifloxacin 
to have superior corneal penetration compared to the other fluoroquinolones.
268-270
 
For example, in a rabbit endophthalmitis model
270
 aqueous levels of levofloxacin 
were 9 mg/L, and moxifloxacin was 43 mg/L after topical administration. The 
greater lipophilicity of moxifloxacin compared to the other fluoroquinolones may 
explain this phenomenon. Besifloxacin is a novel fluoroquinolone for topical 
ophthalmic use recently approved by the US Food and Drug Administration 
(FDA) for the treatment of bacterial conjunctivitis.
271
 Besifloxacin appears to 
have a broad spectrum of activity against aerobic and anaerobic bacteria, possibly 
due to its cyclopropyl group and chloride substituent at C-8 improving its activity 
against DNA gyrase and topoisomerase IV enzymes. Besifloxacin has been shown 
to be active against both Gram-positive (S. aureus, S. pneumoniae, 
Corynebacterium and Propionibacterium acnes) and Gram-negative organisms 
(H. influenzae, Moraxella, E. coli, Neisseria gonorrhoeae and P. aeruginosa). 
Recent studies have found besifloxacin to have good pharmacokinetic parameters 
in vitro
272
 as well as excellent efficacy in animal models of keratitis, compared to 
fourth generation fluoroquinolones.
273, 274
 
5.123 Aminoglycosides  
Aminoglycosides such as gentamicin and tobramicin, are often used to treat 
bacterial keratitis. They have a broad range of bactericidal activity against many 
bacterial species, particularly Gram-negative rods. They have an affinity to 
bacterial 30S and 50S ribosomal subunits producing a non-functional 70S 
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initiation complex resulting in an inhibition of protein synthesis. They are 
sometimes given in combination with predominantly Gram-positive 
antimicrobials. Their use is limited by their associated corneal toxicity.
275
  
Sueke et al
104
 showed 4% of isolates to be resistant to gentamicin against S. 
aureus and P. aeruginosa, using systemic breakpoints. 4% of P. aeruginosa 
isolates and 0% of S. aureus isolates were resistant to amikacin. Gentamicin has, 
however, been shown to have poor corneal penetration which may be due to the 
hydrophilic nature of the compound. Baum et al
276
 showed that the concentration 
of gentamicin in the aqueous at 1 hour is only 1 mg/L, which is lower than the 
suggested MIC using systemic breakpoints. 
5.124 Cephalosporins 
Cephalosporins have a broad spectrum of activity, including effective action 
against Haemophilus species. They contain a β-lactam ring similar to penicillins 
but have the advantage of being resistant to the penicillinases. They inhibit 
bacterial cell wall synthesis and are well tolerated topically. The 1
st
 generation 
cephalosporins include cephazolin, 2
nd
 generation cefuroxime and 3
rd
 generation 
ceftazidime. Cefuroxime is often used in combination with an aminoglycoside for 
the empirical treatment of suspected bacterial keratitis. Sueke et al
104
 showed 
cefuroxime and ceftazidime had high MICs against S. aureus and P. aeruginosa 
suggesting a significant degree of antimicrobial resistance, however, systemic 
breakpoints were not available to formally assess this. The poor corneal 
penetration of cefuroxime maybe due to due to it being hydrophilic in nature.
277
 
5.125 Meropenem 
Meropenem is a broad-spectrum carbapenem that is currently FDA approved to 
treat skin infections, intraabdominal infections and bacterial meningitis.
278
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Meropenem is a β-lactam antimicrobial, working through bacterial cell wall 
inhibition. The antimicrobial, however, differs from other β-lactam antimicrobials, 
as it is chemically stable to hydrolysis by the most common β-lactamases (chapter 
5.131).
279
 It has activity against Gram-positive and Gram-negative pathogens, 
including extended-spectrum lactamases (ESBL) and AmpC-producing 
Enterobacteriaceae. Sueke et al
104
 showed meropenem to have wide coverage 
against both Gram-positive and Gram-negative microorganisms, where only one 
of the 772 isolates tested (P. aeruginosa) was resistant using systemic 
breakpoints. Corneal pharmacokinetics of meropenem are not yet known, 
however intravitreal meropenem in a rabbit model of endophthalmitis
280
 did not 
show any evidence of toxicity. Similarly intravenous meropenem prior to cataract 
surgery showed penetration of the drug into the anterior chamber with no notable 
side effects.
281
  
5.126 Combination therapy in bacterial keratitis 
As opposed to single therapy, an antimicrobial combination offers a broader 
spectrum of activity and may reduce selective pressures. This may be of particular 
importance for the fluoroquinolones, as increasing resistance has been reported in 
S. aureus and P. aeruginosa isolates from cases of bacterial keratitis.
111, 263-266
 An 
often overlooked reason for combination therapy, however, is not for providing a 
broader spectrum but for an increased antimicrobial effect. In particular, 
combination therapy may result in synergy as occurs, for example, with the 
combination of penicillin and gentamicin when used in the treatment of 
enterococcal endocarditis.
282, 283
 This synergistic effect can be explained by the 
increased ease of gentamicin passage into the bacterial cell, due to cell wall 
disruption caused by the action of penicillin. Conversely, combinations of 
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antimicrobials may be antagonistic, as occurs with the combination of 
chloramphenicol and penicillin in the treatment of pneumococcal meningitis.
284
 
The presumed reason for this antagonism is; bacterial growth is reduced by 
chloramphenicol, this prevents penicillin, which requires a dividing and growing 
organism, from having its full effect on cell wall synthesis inhibition. It is 
important therefore not to use combination therapy which may have inhibitory or 
antagonistic effects.  
Antimicrobial combinations can be assessed in vitro by checkerboard, 
time-kill and E-Test methods. All methods involve determining the ratio of the 
MIC of each antimicrobial when tested alone, compared to when the 
antimicrobials are combined (chapter 5.42), which determines if the combination 
is additive, synergistic, indifferent or antagonistic. Suzuki et al
285
 investigated 
various antimicrobial combinations against isolates taken from patients with 
keratitis. They showed that the combinations of levofloxacin/cefmenoxime, and 
gatifloxacin/cefmenoxime were additive in over 70% of isolates tested. No 
consistent synergistic or antagonistic effect was observed with the combinations 
used.  
 
5.13 Antimicrobial resistance 
Antimicrobial resistance is the development of resistance in a microorganism, to 
an antimicrobial to which it was previously sensitive. A wide range of 
biochemical and physiological mechanisms may be responsible for resistance. 
Antimicrobial resistance is a consequence of the overuse of antimicrobials and 
develops when a microorganism mutates or acquires resistance genes. Increasing 
resistance could compromise the utility of a valuable class of antimicrobial agents, 
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which emphasises the importance of the careful use of antimicrobials, in 
appropriate patients, at the correct dose. 
To determine whether an isolate is resistant or susceptible to an 
antimicrobial, the MIC (chapter 5.112) is compared to a set of standard MICs 
based on the safe achievable concentrations of antimicrobial in the serum. These 
standards are set by the Clinical and Laboratory Standards Institute (CLSI) in the 
USA and BSAC in the UK (table 15). As mentioned in chapter 5.112, interpreting 
resistance and susceptibility needs to be done with caution, as currently there are 
no standards for topical ocular therapy that relate to the concentrations of 
antimicrobial in ocular tissue. For example, Sueke et al
104
 found the range of 
MICs for ciprofloxacin against 140 P. aeruginosa isolates to be 0.016 to 6.0 
mg/L. Using the breakpoint figure of 1.0 mg/L from BSAC, which was calculated 
from systemic data, 98% of isolates were susceptible to ciprofloxacin. 
The antimicrobial resistance mechanisms of S. aureus and P. aeruginosa 
will now be discussed. 
5.131 S. aureus resistance 
S. aureus is well known for its resistance to the β-lactam group of antimicrobials 
including penicillins, cephalosporins, carbapenems, and monobactams.
257
 S. 
aureus resistance to penicillin is attributed to the production of penicillinase (a 
class A β-lactamase), an extracellular enzyme that hydrolyses the amide bond of 
the β-lactam ring of penicillin, yielding an inactive compound. Novick et al286  
demonstrated in 1971, that the genes responsible for the synthesis of penicillinase 
and its regulation were extrachromosomal and carried by a plasmid.  
Meticillin was the first antimicrobial specifically tailored to counteract a 
bacterial resistance mechanism, initially being invulnerable to the attack of 
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penicillinase. Occasional strains of MRSA were first detected in 1961 very soon 
after its introduction but these were only resistant to β-lactam antimicrobials. 
MRSA strains in Australia in the late 1970s, however, were found to be resistant 
to other antimicrobial classes. The resistance of S. aureus to meticillin constitutes 
a significant healthcare problem worldwide. MRSA is now thought to be 
responsible for 40% to 70% of S. aureus infections in intensive care units.
287
 In 
the past decade new strains of MRSA have emerged in the community, causing 
infections in young, otherwise healthy people.
288
 Meticillin resistance is 
determined by the mecA gene that lies on a novel genetic element in the genome 
of S. aureus known as the SCCmec cassette.
289
 The gene product of mecA is a 
penicillin-binding protein (PBP2a) which renders S. aureus refractory to the 
action of all available β-lactam antimicrobials.290 Because meticillin is rarely used 
today, the term “MRSA” is used now to describe strains of S. aureus resistant to 
all β-lactam antibiotics. Colonization with MRSA is more likely to result in 
infection than colonization with MSSA.
291, 292
  MRSA has been isolated with 
increasing frequency from patients with bacterial keratitis.
293
 It is a severe form of 
S. aureus keratitis and is being increasingly seen following keratorefractive 
surgery.
294
 Community acquired meticillin S. aureus (CA-MRSA), in particular 
those associated with lukSF-PV, is present in epidemic proportions in the USA.
295
 
In the 2000s, the USA300 S. aureus strain was identified as the most common 
isolate responsible for outbreaks of CA-MRSA infections in the USA.
296
 
Although USA300 isolates were initially resistant only to β-lactam antimicrobials 
(mediated by mecA), they have broadened their resistance profiles considerably 
over the last 5 years. This includes resistance to clindamycin, tetracycline, 
vancomycin, gentamicin and the fluoroquinolones.  
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S. aureus resistance to fluoroquinolones emerged soon after their 
introduction in 1991. This was especially noted in MRSA strains.
297
 Goldstein et 
al
263
 examined the resistance of S. aureus isolates taken from patients with 
keratitis. They found that resistance significantly increased annually for 
ciprofloxacin from 6% in 1993 to 35% in 1997 and for ofloxacin from 5% to 35% 
over the same period. The fourth-generation fluoroquinolones have also not been 
a treatment panacea because of the emergence of resistance. Moshirfar et al
265
 
recently reported two cases of S. aureus associated keratitis after refractive 
corneal surgery that were resistant to the fourth generation moxifloxacin and 
gatifloxacin. S. aureus resistance to the fluoroquinolones is attributed to mutations 
that cause amino acid changes in one or both enzymes critical for bacterial DNA 
replication; DNA gyrase and Topoisomerase IV. This subsequently leads to 
reduced drug binding and efficacy.
298
 Resistance is conferred by point mutations 
occurring in the subunits of grlA of topoisomerase IV and gyrB of DNA gyrase.
299
 
In some strains, overexpression of an efflux pump, termed NorA, contributes to 
the resistance phenotype.
300
 Multiple mutations and combination of resistance 
mechanisms also confer cross-resistance to newer fluoroquinolones.
298
  
5.132 P. aeruginosa resistance 
P. aeruginosa is an extremely adaptable bacteria and is more than capable of 
developing resistance, in particular when antimicrobials are used extensively. 
Chaudhary et al
301
 (Florida, USA) reported that the rate of ciprofloxacin resistance 
of P. aeruginosa taken from patients with keratitis rose significantly from 0.4% in 
1991–1994 to 4% in 1995–1998. Garg et al264 noted that 22 out of 141 cases of 
keratitis associated with P. aeruginosa were identified as resistant, using systemic 
breakpoints.  
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The three basic mechanisms of P. aeruginosa resistance; restricted uptake 
through its cell wall, drug efflux and drug inactivation will be discussed. 
Antimicrobial resistance through bacterial adherence to biofilm formation in 
contact lens patients has been mentioned previously (chapter 1.334).  
P. aeruginosa has innate antimicrobial resistance due to the low 
permeability of antimicrobials through its cell wall. The outer membrane of P. 
aeruginosa presents a significant barrier to antimicrobials, restricting the rate of 
penetration of small hydrophilic molecules and excluding larger molecules. Small 
hydrophilic molecules such as β-lactams and fluoroquinolones must pass through 
aqueous channels provided by porin proteins.
302
 The aminoglycosides do not pass 
through porin channels but bind to lipopolysacharide on the outer surface of the 
membrane, followed by active transportation into the cell.  
Many classes of drugs are susceptible to multidrug efflux systems in P. 
aeruginosa.
303
 The efflux system is composed of three protein components, an 
energy dependent pump, an outer membrane porin and a linker protein. Three 
main antimicrobial efflux systems have been described in P. aeruginosa: mexAB-
oprM, responsible for the extrusion of β-lactams and fluoroquinolones; mexXY-
oprM, responsible for the extrusion of the aminoglycosides, and mexCD-oprJ 
responsible for the extrusion of carbapenems and quinolones.
304
    
P. aeruginosa are able to cause resistance by drug inactivation. Over-
expression of the gene ampC, for example, leads to the production of β lactamase. 
This poses a threat to cephalosporins and other β lactam antimicrobials.302 
Aminoglycosides can be inactivated by the production of enzymes which transfer 
acetyl, phosphate or adnylyl groups on the antimicrobials.  
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Finally, P. aeruginosa can cause mutational changes in target enzymes, 
which result in maintaining their role in cell metabolism whilst causing resistance 
to certain antimicrobials. This mechanisms is most commonly seen with the 
fluoroquinolones through mutation in gyrA, a gene encoding the A subunit of the 
target enzyme DNA gyrase.
305
  
 
5.2: Chapter aims 
This chapter aims to compare the MICs of existing, recently introduced and 
potentially novel antimicrobials against bacterial isolates taken from patients with 
keratitis over two time periods. The in vitro interaction of clinically relevant 
antimicrobial combinations will also be described against a selection of isolates.  
 Pharmacokinetic properties of meropenem as a potential novel 
antimicrobial for the treatment of bacterial keratitis, will be investigated. Firstly 
the toxicity profile of meropenem will be examined using corneal cells in culture 
and secondly the corneal penetration of meropenem will be observed across donor 
human corneas mounted on artificial anterior chambers. 
 
5.3 Methods 
5.31 Minimum Inhibitory Concentration  
Isolates were collected from patients with bacterial keratitis by the MOG in two 
time periods 2003-2005 and 2010-2011. Isolates were identified using methods 
described in chapter 2.12. MICs were calculated by E-Tests (chapter 2.21) for 
meropenem, moxifloxacin, gentamicin and ciprofloxacin against P. aeruginosa, 
and Enterobacteriaceae; and moxifloxacin, linezolid, ciprofloxacin, penicillin, 
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meropenem and teicoplanin against S. aureus. Mean MIC and MIC90 were 
calculated for each time period. An isolate was characterized as resistant if the 
MIC was greater than the systemic breakpoint MIC defined by BSAC (table 
15).
118
 It should be noted that breakpoints for the topical use of antimicrobials to 
treat bacterial keratitis are not available and may differ significantly from the 
systemic breakpoints. 
 
Table 15: Antimicrobial resistance levels determined by the British Society of 
Antimicrobial Chemotherapy for S. aureus, P. aeruginosa and S. pneumoniae. 
Values determined from systemic data.  
Antimicrobial Systemic breakpoint by BSAC (mg/L) 
S. aureus P. aeruginosa S. pneumoniae 
Penicillin >0.12 N/A >2 
Cefuroxime N/A N/A >1 
Chloramphenicol >8 N/A N/A 
Gentamicin >1 >4 >128 
Vancomycin >2 N/A >2 
Teicoplanin >2 N/A >2 
Ciprofloxacin  >1 >1 >2 
Moxifloxacin >1 N/A >0.5 
Meropenem N/A >8 2 
N/A: resistance values not available 
 
5.32 Antimicrobial combinations  
10 S. aureus and 10 P. aeruginosa isolates collected by the MOG from patients 
with bacterial keratitis were selected to investigate combinations of 
antimicrobials. Bacterial suspensions were prepared from colonies grown 
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overnight on agar plates, (chapter 2.2) 10 µL of which was evenly spread onto 
fresh agar plates. E-Test strips of two antimicrobials were placed on the plate 
forming a cross with a 90 degree angle. The intersection point of the cross was 
made to coincide with the MIC for each antimicrobial, calculated from previous 
experiments (figure 20). The plates were incubated at 35-37 °C in air for 18 hours, 
and the MIC of each antimicrobial in the combination was read. Each bacterial 
isolate was tested three times for each antimicrobial combination. The 
antimicrobial combinations tested for S. aureus were: teicoplanin and 
moxifloxacin, teicoplanin and ciprofloxacin, teicoplanin and meropenem, 
meropenem and linezolid, moxifloxacin and linezolid, meropenem and 
ciprofloxacin, and moxifloxacin and meropenem. The antimicrobial combinations 
tested for P. aeruginosa were: meropenem and ciprofloxacin, gentamicin and 
moxifloxacin, moxifloxacin and meropenem, meropenem and levofloxacin and 
gentamicin and ciprofloxacin.  
Using the results of MICs determined with the antimicrobial alone and in 
combination, the fractional inhibitory concentration (FIC) was calculated, as per 
the following formula:- 
FIC of drug A = MIC drug A when tested in combination with drug B  
          MIC of drug A alone 
 
FIC of drug B = MIC drug B when tested in combination with drug A  
           MIC of drug B alone 
 
FIC = FIC drug A + FIC drug B 
 
The mean FIC of triplicate experiments for each antimicrobial 
combination for a particular isolate was then calculated. The mean FIC allowed 
the combination to be classified into one of 4 groups as defined by Pillai et al
306; ≤ 
0.5 = synergy, 0.5-1 = additivity, 1-4 = indifference and >4 = antagonism. For 
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example, Figure 21a shows synergy i.e. MICs of A and B are 1 mg/L and 0.5 
mg/L, and decrease to 0.125 mg/L and 0.063 mg/L when measured in 
combination  25.0
5.0
063.0
1
125.0
FIC   
Figure 21b shows additivity i.e. MICs of A and B are 1 mg/L and 0.5 mg/L, and 
decrease to 0.5 mg/L and 0.125 mg/L when measured in combination 
62.0
5.0
125.0
1
5.0
FIC . It is apparent that a synergistic or additive effect can 
only occur for the combination if both FIC drug A and FIC drug B are each less 
than 1. Figure 21c shows indifference i.e. MICs of A and B are 1 mg/L and 0.5 
mg/L with no change when measured in combination 2
5.0
5.0
1
1
FIC . Figure 
21d demonstrates antagonism i.e. MICs of A and B are 1 mg/L and 0.5 mg/L, and 
increase to 8 mg/L and 4 mg/L after combination 16
5.0
4
1
8
FIC .  
The mean, standard deviation (SD), minimum, maximum and coefficient of 
variance of the FIC was calculated for each antimicrobial combination against S. 
aureus and P. aeruginosa isolates. 
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Figure 20. Illustration demonstrating the set up for E-Test combination testing of 
antimicrobial A and B (indicated at top of each E-Test) on an agar plate 
inoculated with bacteria. The two E-Tests are crossed at 90 degrees at the point of 
their individual minimum inhibitory concentrations i.e. MIC of A = 1 mg/L and B 
= 0.5mg/L.  
 
 
 
 
 
 
 
 
 
 
Point of MIC 
intersection 
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(a) Synergy (b) Additivity 
  
(c) Indifference   (d) Antagonsim 
  
Figure 21. Illustrations demonstrating the appearance of E-Test combination 
experiments of antimicrobial A and B which result in (a) synergy, (b) additivity, 
(c) indifference and (d) antagonism. 
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5.33 Pharmacokinetics of meropenem  
5.331 Toxicity assays 
Meropenem was applied to HKs HCEs in culture, to investigate its cellular 
toxicity. Cell culture conditions were as described in chapter 2.4 
5.3311 Methyl thiazolyl tetrazolium assay  
Background: The methyl thiazolyl tetrazolium (MTT) assay, described by 
Mosman,
307
 is a measure of mitochondrial cell function and hence is an indirect 
indicator of cell viability. It consists of the addition of the tetrazolium salt MTT 
which is reduced to a formazan product when added to growing cells. The 
resulting yellow to purple colour change is quantifiable on a 96 well plate reader. 
Methods: The Cell Titer 96® Cell Proliferation Assay Kit (Promega, 
Southampton, United Kingdom) was used. HCEs and HKs were seeded at 5,000 
cells per well in 96-well plates. Once confluence was achieved, cells were kept 
overnight in DMEM/F12 media without any supplements. Cells were treated with 
5 mg/ml and 2.5 mg/ml of meropenem or moxifloxacin for 1 hour. 15 µl MTT dye 
solution was then added followed by incubation at 37 °C for 4 hours and 100 µl 
Stop Solution. The plates were then kept at 4 °C overnight in a moistened 
chamber. Each experiment was done in triplicate and blank controls (culture 
medium only), positive controls (cells plus medium) and negative controls (cells 
treated with the cytotoxin dimethyl sulfoxide (DMSO)) were included. 
Absorbance was read at 570 nm using an automated microplate reader (Bio-Rad, 
Hemel Hempstead, United Kingdom) and cell viability was expressed as 
percentages in relation to untreated controls. Values were expressed as the mean 
percentages of control values ± standard deviation (SD) from three independent 
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experiments. The Mann-Whitney U test (SPSS version 21) was used to compare 
cell viability between the drugs tested. A P-value <0.05 was considered to be 
statistically significant. Figure 22 shows the set-up of the 96 well-plates. 
 
     
        Blanks           Positive control   Negative control   
  
 
         
  
 Moxi 2.5mg/ml  
 
  Moxi 5mg/ml    
  
  
 
         
  
 Mero 2.5mg/ml  
 
Mero 5mg/ml  
  
  
 
         
           
Figure 22: Illustration showing set-up of 96 well-plate for MTT assay of 
meropenem and moxifloxacin 2.5 mg/ml and 5 mg/ml, including positive and 
negative controls. Mero = meropenem and Moxi=moxifloxacin. 
 
5.3312 Live dead assay  
Background: Live Dead assay distinguishes live cells by the presence of 
intracellular esterase activity. This is determined by the enzymatic conversion of 
the non-fluorescent calcein acetomethoxy (AM) to the intensely fluorescent 
calcein. Calcein is well retained within live cells, producing an intense uniform 
green fluorescence (exitation/emmission 495 nm/515 nm). Conversely, ethidium 
enters cells with damaged cell membranes and undergoes a 40-fold enhancement 
of fluorescence upon binding to nucleic acids, thereby producing a bright red 
fluorescence in dead cells. 
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Methods: 24 well plates were seeded with 50,000 HKs or HCETs per well. Once 
confluence was achieved the cells were incubated overnight in DMEM/F12 media 
without any supplements. Each experiment included cells treated with meropenem 
10 mg/ml for 1 hour, positive controls (cells plus medium) and negative controls 
(cells treated with DMSO). Three wells were used for each parameter and the 
experiment was repeated on three separate plates. 100 μl of a Live Dead assay 
(Invitrogen, Paisley, UK) containing 2 μM calcein AM and 4 μM ethidium 
homodimer-1 was added to each well and incubated at 37 
o
C in CO2 for 1 hour. 
Cells were examined with an Axiovert 200 fluorescent microscope (Carl Zeiss). 
Green and red filters were used to photograph live and dead cells respectively. 
The number of cells was determined using an in house automated programme 
written in Matlab R14 (The Mathworks Inc., Natick, MA). In brief, the original 
image was pre-processed by an adaptive thresholding technique to improve the 
contrast and uneven illumination. A selective enhancement filter, initially 
described by Li et al,
308
 was used to enhance the cells in the pre-processed image. 
Regions of interest (ROIs) were detected by thresholding the enhanced image and 
further refined by removing smaller objects. The number of cells was determined 
by labelling the remaining ROIs in the image.  
 
5.332 Corneal and aqueous model  
Human cadaver corneo-scleral discs stored in organ culture medium and not 
suitable for transplantation due to low endothelial cell density (ECD) <2200 cell / 
mm
2
, were provided by the Manchester eye bank. Due to the reduced ECD and 
often absent or disrupted epithelium, and in order to make the corneas as similar 
as possible, the epithelial and endothelial layers were removed under the 
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dissecting microscope using cellulose eye spears (Beaver-Visitec, Oxfordshire, 
UK). Following trephination of a 9 mm central corneal disc, each cornea was 
washed in phosphate buffered saline (PBS) and mounted onto a flow type Franz 
Cell (PermeGear, Hellertown, USA) containing 5 ml PBS, at room temperature 
(figure 23). 50 µl of 10 mg/ml (500 µg) solution of meropenem was placed into 
the receptacle above the cornea. Prior to sampling, to ensure even mixing of 
meropenem in the artificial anterior chamber, fluid was repeatedly aspirated and 
injected via the sampling port, using a needle attached to a 20 ml syringe. 20 µl 
samples were collected from the artificial anterior chamber at 45 minutes, 1.5 
hours, 4 hours and 24 hours and stored the corneas at -20 °C prior to processing. 
After 24 hours the corneas were washed and homogenised in 2 ml of PBS, 
centrifuged at 10,000 g for 5 minutes, and the supernatant transferred into a 
microtube. To ensure that the intra-stromal meropenem had been recovered from 
the corneas, three pellets were sequentially re-homogenised after reconstitutions 
in 2 ml PBS. Concentrations of meropenem were determined from the aqueous 
and corneal homogenates using a bioassay and high performance liquid 
chromatography (HPLC). 
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Figure 23. Franz Cell (PermeGear, US) used in meropenem penetration 
experiments. Flow in/flow out ports not used in this study.  
 
5.3321 Bioassay 
A disc diffusion bioassay was performed to estimate the concentration of 
meropenem in corneal homogenate and the anterior chamber samples. A standard 
curve was constructed using known concentrations of meropenem as follows. E. 
coli (ATCC 25922) was seeded on agar plates supplemented with horse blood and 
incubated overnight at 37 °C in air. Bacterial colonies were removed from the 
plates and added to sterile water to a 0.5 McFarland turbidity standard. The 
suspension was diluted 1 in 100 in sterile water, 10 µl of which was spread evenly 
onto fresh agar plates. Blank antimicrobial sensitivity discs were inoculated with 
10 µl of meropenem and the plates incubated overnight in air at 37 °C. The zone 
of inhibition (ZOI) was calculated by measuring to the nearest millimetre the 
Cornea clamped 
into place 
Artificial 
anterior 
chamber filled 
with PBS 
Sampling port 
Drug application  
flow in           
 
                       
                        
flow out  
 
heater/circulator 
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diameter of the circle surrounding the disk devoid of bacterial growth (figure 24). 
Experiments were performed in triplicate for each of the 16 concentrations of 
meropenem from 0.01 to 313 µg/ml. A standard curve was constructed using a 
logarithm transformation of the data. To estimate the meropenem concentration in 
the anterior chamber fluid and corneal homogenate; 10 µl of the sample in 
question was placed onto blank discs on agar plates inoculated with E. coli. Plates 
were incubated overnight and ZOI were measured, as described above. Positive 
and negative controls were run in parallel with the test specimen. 
 
 
 
Figure 24. Example of meropenem bioassay. Discs containing various 
concentrations of meropenem placed onto agar plate inoculated with E. coli. Zone 
of inhibition (ZOI) surrounding disc after 24 hours incubation is measured to the 
nearest mm. For example ZOI top left = 32 mm. 
 133 
 
5.3322 HPLC 
Quantitation of meropenem in experimental samples was carried out using an 
isocratic reverse-phase high performance liquid chromatography (RP-HPLC) 
based on a method by Mendez et al.
309
 Samples were centrifuged at 10,000 g for 5 
minutes and 20 µL applied to a Phenomenex Luna 3u C18 100 Å RP-HPLC 
column (150 x 2.00 mm) equilibrated in 30 mM sodium phosphate, 12% 
acetonitrile, pH 3.0. Meropenem was eluted isocratically in the same buffer and 
typically emerged with a 5-6 minute residence time. Two HPLC systems were 
used for the analyses: a Beckman System Gold HPLC system with elution 
monitored at 300 nm or an ESA HPLC system fitted with an auto sampler and 
electrochemical detector with the electrode set at 600 mV. A standard curve of 0 – 
50 µg/L meropenem in Hanks BSS was used for calibration in both cases.  For the 
analysis of meropenem metabolites generated during the experiments, a gradient 
RP-HPLC separation was used. Samples were applied to the same column as 
above but which was equilibrated in 0.1% trifluoroacetic acid (TFA). Separation 
was carried out using a 30 minute gradient of 0 – 60 % [v/v] acetonitrile in 0.1% 
TFA, using a flow rate of 0.2 ml/min. Elution was monitored at 220 nm.  
 
5.4 Results 
5.41 MICs of antimicrobials against keratitis isolates 
Table 16 shows the MICs and percentage of isolates resistant to the antimicrobials 
tested. Figure 25 shows histograms of MIC90 against across the 2 time periods. 
Using systemic breakpoints, 1% and 2% of P. aeruginosa isolates were resistant 
to ciprofloxacin in the 2003-05 and 2010-2011 time periods. 4% of isolates were 
resistant to Enterobacteriaceae in 2003-05, although this was not observed in the 
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later time period. High levels of ciprofloxacin resistance (18% and 8%) were seen 
in S. aureus isolates. Lower resistance was seen with moxifloxacin in S. aureus, 
2% in 2003-2005 and 0% in 2010-2011. Similar low resistance to moxifloxacin 
was seen with P. aeruginosa. High gentamicin MICs and resistance were seen in 
2010-2011 against Enterobacteriaceae. The sample size was low, however, in this 
cohort; n=16. The novel antimicrobial meropenem had low MICs in all isolates in 
both time periods with only 1 resistant isolate throughout (P. aeruginosa). 
Linezolid had low MICs with no resistance when tested against S. aureus. 
 
Table 16: Minimum inhibitory concentrations (MICs) and resistance (using 
systemic breakpoints of antimicrobials) against (a) P. aeruginosa (b) 
Enterobacteriaceae and (c) S. aureus across two time periods: 2003-2005 and 
2010-2011. Number of isolates tested (n), mean MIC (mean), MIC90 and % of 
isolates resistant using systemic breakpoints (resistance). Systemic breakpoint 
from BSAC indicated where available.  
16a: MICs against P. aeruginosa (mg/ml) 
 
Year 
n 
 
mean 
 
MIC90 
 
resistance 
 
systemic 
breakpoint 
Ciprofloxacin 2003-2005 140 0.2 0.5 1% 
>1 
 
2010-2011 51 1.4 0.2 2% 
Moxifloxacin 2003-2005 140 0.8 1.0 N/A 
N/A 
 
2010-2011 51 0.7 1.0 N/A 
Gentamicin 2003-2005 140 3.4 2.0 4% 
>4 
 
2010-2011 51 1.3 2.0 0% 
Meropenem 2003-2005 140 0.4 0.3 0% 
>8 
 
2010-2011 51 0.2 0.4 1.9% 
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16b. MICS against Enterobacteriaceae (mg/ml)  
  
n 
 
mean 
 
MIC90 
 
resistance 
 
systemic 
breakpoint 
Ciprofloxacin 2003-2005 84 0.1 0.1 4% 
>1 
 
2010-2011 16 0.1 0.2 0% 
Moxifloxacin 2003-2005 84 0.1 0.3 0% 
>1 
 
2010-2011 16 0.3 0.9 0% 
Gentamicin 2003-2005 84 1.1 1.0 1% 
>4 
 
2010-2011 16 1.6 4.0 13% 
Meropenem 2003-2005 84 0.1 0.1 0% 
>8 
 
2010-2011 16 0.03 0.05 0% 
 
16c. MICS against S. aureus (mg/ml) 
  
n 
 
mean 
 
MIC90 
 
resistance 
 
systemic 
breakpoint 
ciprofloxacin 2003-2005 94 5.0 32.0 18% 
>1 
 
2010-2011 39 2.6 0.6 8% 
moxifloxacin 2003-2005 94 0.2 0.25 2% 
>1 
 
2010-2011 39 0.1 0.1 0% 
Teicoplanin 2003-2005 94 1.5 0.9 0% 
>2 
 
2010-2011 39 0.1 0.1 0% 
Penicillin 2003-2005 94 1.5 3.2 78% 
>0.12 
 
2010-2011 38 0.4 0.8 66% 
Linezolid 2003-2005 94 0.8 0.5 0% 
>4 
 
2010-2011 40 0.7 1.0 0% 
Meropenem 2003-2005 94 0.08 0.12 N/A 
N/A 
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Figure 25: Histograms showing MIC90 of antimicrobials against (a) P. 
aeruginosa, (b) Enterobacteriaceae and (c) S. aureus across 2 time periods; 2003-
05 and 2010-11.   
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5.42 in vitro combination of antimicrobials 
The results for each antimicrobial combination against S. aureus and P. 
aeruginosa are shown in tables 17a and 17b. The coefficient of variance for the 
antimicrobial combinations was 11% against S. aureus and 22% against P. 
aeruginosa. The antimicrobial combinations with the greatest additive effect 
against S. aureus were meropenem and teicoplanin, meropenem and 
ciprofloxacin, and moxifloxacin and teicoplanin. Synergy was demonstrated in 
20% of isolates with the combination of meropenem and teicoplanin and in 10% 
of isolates with meropenem and ciprofloxacin. Synergy or additivity was seen in 
80% in each of those two combinations. The remaining combinations including 
ciprofloxacin and teicoplanin, linezolid and moxifloxacin, moxifloxacin and 
meropenem and linezolid and meropenem demonstrated a predominantly 
indifferent interaction. No antagonism was seen in any of the experiments. Of the 
combinations against P. aeruginosa isolates (table 17b), meropenem and 
ciprofloxacin demonstrated the lowest mean FIC (0.7) with synergy observed in 
10% and additivity seen in 80%. The interaction between gentamicin with 
moxifloxacin, meropenem and moxifloxacin, meropenem and levofloxacin and 
gentamicin and ciprofloxacin were predominantly indifferent. No antagonistic 
effect was seen, although one isolate demonstrated a mean FIC of the three tests 
of 3.7 (3.5, 3.5 and 4.1) with the combination of meropenem and moxifloxacin. 
 
 
 
 
 
 138 
 
Table 17. in vitro activity of antimicrobials individually and in combination 
against (a) 10 S. aureus isolates and (b) 10 P. aeruginosa isolates, determined by 
E-Test method. Mean minimum inhibitory concentrations (MICs) calculated for 
each antimicrobial alone and in combination with another antimicrobial (mean 
values indicated). Fractional inhibitory concentration (FIC) determined for each 
combination, mean FIC (SD) and FIC range indicated. FIC interpretation of 
combinations (% of isolates) synergistic (Syn) FIC≤ 0.5, additive (Add) FIC= 0.5-
1, indifferent (Ind) FIC= 1-4, or antagonistic (Ant) FIC>4.  
(a): MICs and FICs for antimicrobials against S. aureus isolates 
 mean MIC (mg/l) FIC FIC interpretation 
alone     in 
combination 
range 
 
mean 
(SD) 
Ant 
(%) 
Ind 
(%) 
Add 
(%) 
Syn 
(%) 
meropenem & 
teicoplanin 
0.4 
1.0 
0.1 
0.3 
0.3 - 1.3 
0.8  
(0.2) 
0 20 60 20 
meropenem &  
ciprofloxacin 
0.4 
16.5 
0.2 
9.8 
0.3 - 2.0 
0.9  
(0.3) 
0 20 70 10 
meropenem &  
moxifloxacin 
0.4 
0.8 
0.1 
0.6 
0.6 - 2.0 
1.2  
(0.2) 
0 60 40 0 
meropenem &  
linezolid 
0.4 
0.5 
0.4 
0.5 
1.6 - 2.0 
1.9  
(0.1) 
0 100 0 0 
moxifloxacin &  
linezolid 
0.8 
0.5 
0.8 
0.5 
1.8 - 2.0 
2.0  
(0.0) 
0 100 0 0 
moxifloxacin &  
teicoplanin 
0.8 
1.0 
0.6 
0.3 
0.5 - 1.3 
0.9 
(0.1) 
0 40 60 0 
ciprofloxacin &  
teicoplanin 
16.5 
1.0 
13 
0.2 
0.3 - 2.0 
1.0  
(0.1) 
0 40 50 10 
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 (b): MICs and FICs for antimicrobials against P. aeruginosa isolates 
 
5.43 In vitro toxicity of meropenem and moxifloxacin 
MTT assays of HCEs and HKs showed meropenem had significantly higher cell 
viability at both 5 mg/ml and 2.5 mg/ml compared to moxifloxacin (p=0.029 and 
p=0.018 respectively) (figure 26). Live dead assay of HCEs showed the viability 
of cells treated with meropenem was 96%, compared to cell 95% in the untreated 
control cells (p=0.52). The high cell viability in meropenem treated cells in both 
assays, suggests low cell toxicity.    
 
 
mean MIC (mg/l) FIC FIC interpretation 
alone in 
combination 
range mean 
(SD) 
Ant 
(%) 
Ind 
(%) 
Add 
(%) 
Syn 
(%) 
meropenem &  
ciprofloxacin 
2.0  
0.1 
0.5 
0.03 
0.3-1.7 
0.7 
(0.2) 
0 10 80 10 
meropenem &  
moxifloxacin 
2.0 
2.5 
0.7 
0.5 
0.4-3.7 
1.3 
(0.2) 
0 50 30 20 
meropenem & 
levofloxacin 
2.0 
0.7 
0.7 
0.4 
0.5-2.0 
1.8 
(0.5) 
10 80 10 0 
gentamicin &  
ciprofloxacin 
1.0 
0.1 
0.8 
0.1 
0.8-3.1 
1.9 
(0.4) 
10 13 6 0 
gentamicin &  
moxifloxacin 
1.0 
2.5 
0.6 
0.6 
0.3-2.0 
1.3 
(0.2) 
0 80 0 20 
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Figure 26. MTT cell viability assay of cultured (a) HKs and (b) HCEs incubated 
for 1hr with meropenem (MP) and moxifloxacin (MX) 5 and 2 mg/ml. Values are 
expressed as percentage of control (viability in absence of drug). Results are 
shown as the mean ± SD (n =6, p < 0.01).  
5.44 Concentration of meropenem in chamber and corneal tissue  
The standard curve for the meropenem bioassay gave a coefficient of 
determination of R
2
=0.99, p<0.01). Anterior chamber concentrations of 
meropenem taken at 45 minutes, were lower than the MIC90 of E. coli (0.094 
µg/ml) in 33% (7/18) of corneas in the bioassay group and 17% (3/18) of corneas 
in the HPLC group. In all subsequent sampling points, however, anterior chamber 
meropenem concentrations exceeded the MIC90 of E. coli, using both HPLC and 
0%
50%
100%
150%
MP 5 MX 5 MP 2 MX 2
%
 c
e
ll
 v
ia
b
il
it
y
  
Drug concentration mg/ml  
HK cell viability 
0%
50%
100%
150%
MP 5 MX 5 MP 2 MX 2
%
 c
e
ll
 v
ia
b
il
it
y
  
Drug concentration mg/ml  
HCE cell viability (b) 
(a) 
 141 
 
bioassay. Variability was seen between the corneas in the aqueous meropenem 
concentration calculated by both bioassay and HPLC (figure 27).  
The mean meropenem concentration in the anterior chamber at 45 minutes 
was 1.3 (±1.5) µg/ml and 0.9 (±0.9) µg/ml using the bioassay and HPLC, 
respectively (table 18). Aqueous concentrations increased steadily with time and 
at 24 hours, mean values were 43.7 (±27.2) µg/ml (bioassay), and 13.5 (±14.8) 
µg/ml (HPLC). At the 24 hour time point, meropenem concentration measured by 
bioassay exceeded the measurements made by HPLC in 12 out of the 18 corneas.  
Figure 28 demonstrates HPLC meropenem metabolite analysis. The presence of a 
single peak of meropenem can be seen in Figure 28a in a sample containing 
freshly made meropenem. The presences of other peaks are observed samples are 
analysed from later time points. The compartmentalisation of meropenem in the 
cornea and aqueous at 24 hours, is shown in Figure 29. 
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Figure 27. Aqueous concentration of meropenem determined after the application 
of meropenem 10 mg/ml on a donor human cornea across the artificial anterior 
chamber in 18 corneas (C1 to C18). Measurements made using bioassay and 
HPLC at (a) 45 minutes, (b) 1.5 hours, (c) 3.5 hours and (d) 24 hours. 
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Table 18.  Mean concentration of meropenem (µg/ml) collected in Franz Cell 
artificial anterior chamber after application of 500 µg meropenem onto human 
corneas, n=18 
 Bioassay (µg/ml) HPLC (µg/ml) 
Sample time Mean SD Mean SD 
45 min 1.3 1.5 0.9 0.9 
1.5 hr 6.9 7.1 4.1 5.3 
3.5 hr 14.3 12.4 6.5 7.6 
24 hr 43.7 27.2 13.5 14.8 
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Figure 28. Detection of the presence of meropenem metabolites during 
penetration experiments, using RP-HPLC. Aqueous samples were analysed using 
a gradient RP-HPLC separation with elution monitored at 220 nm. (a) fresh 
meropenem sample (10 mg/ml), (b) cornea 5 aqueous sample at 3.5 hours and (c) 
cornea 5 aqueous sample at 24 hours. 
(a) 
(b) 
(c) 
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Figure 29. Compartmentalisation of meropenem (mp) at 24 hours in the cornea 
and aqueous, following the application of 500 µg meropenem, (n=18) onto human 
corneas set up in the in Franz Cell. Mean values of meropenem (µg), from 
bioassay and HPLC used. SD = standard deviation, UCI = upper confidence 
intervals, LCI = lower confidence intervals.   
 
5.5 Discussion 
5.51 Selecting an antimicrobial for further study based on in vitro study 
Prompt and effective treatment of bacterial keratitis is critical in reducing the 
impact of this sight-threatening disease. There are several considerations when 
choosing the most appropriate antimicrobial therapy for bacterial keratitis. First, 
because an increase in bacterial resistance to the standard antimicrobials used to 
treat bacterial keratitis has been reported,
263, 264, 266, 310
 it is essential to establish 
contemporaneous data on the spectrum of causative microorganisms and their 
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expected resistance profile.
104
 Temporal changes in the spectrum of pathogens and 
resistance have also been noted worldwide (table 3) and monitoring the 
susceptibility of bacterial isolates to current antimicrobials and evaluation of 
novel therapies is therefore important. Second, the absence of established 
breakpoint concentrations for antimicrobials when they are used topically makes 
the interpretation of MIC data difficult. The susceptibility criteria used to select an 
antimicrobial for treatment are based on the anticipated response of the bacteria 
against concentrations of the antimicrobial that can be achieved in serum.
118, 311
 
Topical application of an antimicrobial to the cornea may achieve a very different 
concentration and bioavailability in the tissue than the serum levels.
312
 Although 
the appropriate disc susceptibility breakpoint for each antimicrobial and bacterial 
isolate combination has not yet been determined, there is good evidence
4, 313
 
demonstrating the relationship between the MIC of topically applied 
antimicrobials and clinical outcome in bacterial keratitis. This relationship is 
particularly well established for pathogenic bacteria such as P. aeruginosa and S. 
aureus.
4
 The MIC is therefore an important measure for evaluating the potential 
effectiveness of topically applied antimicrobials in the treatment of bacterial 
keratitis. In this study, systemic breakpoint standards from the BSAC were used 
for reference, although these may not be relevant for interpreting the sensitivity of 
ocular isolates. 
Based on systemic breakpoints, this study found resistance in several 
commonly used antimicrobials across two time periods; 2003-05 and 2010-11. 
Particularly worrying was the high level of resistance in the commonly used 
ciprofloxacin against S. aureus. All the Gram-positive isolates tested were 
susceptible, however, to teicoplanin and the novel antimicrobials, meropenem, 
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and linezolid. Lower resistance was seen against the Gram-negatives tested. 
Overall, the in vitro data suggest that, of the antimicrobials currently in use, 
moxifloxacin offers the best coverage against both Gram-positive and Gram-
negative isolates. Moxifloxacin has also been shown in other studies to have both 
good patient tolerability
314
 and pharmacokinetics.
268
 Of the newer antimicrobials 
potentially suitable for ophthalmic use, meropenem appears to be a good choice 
for empiric monotherapy in bacterial keratitis, offering broad-spectrum cover 
against both Gram-positive and Gram-negative microorganisms, with only one of 
the 772 isolates tested (P. aeruginosa) found to be resistant. Linezolid was active 
against all S. aureus isolates including a small number of MRSA isolates. 
Linezolid may therefore be useful for dual therapy when used in combination with 
an antimicrobial with good cover against Gram-negative bacteria. 
 
5.52 Combination testing in vitro 
As opposed to single therapy, an antimicrobial combination offers a broader 
spectrum of activity and may reduce selective pressures. In addition, combination 
therapy may also result in synergy (chapter 5.126).  If a combination of 
antimicrobials demonstrates a synergistic or additive effect as determined by MIC 
this combination may prove more effective than monotherapy with the individual 
agents. It should be noted that the definitions of synergy through to antagonism
282, 
315
 are definitions that relate to interaction in vitro and it is unknown whether they 
translate into an improved outcome for topical combination therapy. If the 
extrapolation to an in vivo effect is valid, a synergistic or additive antimicrobial 
combination does offer a broader spectrum of activity
62
 that may reduce selective 
pressures and the emergence of resistance. The traditional approaches to assess 
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antimicrobial combinations in vitro are by checkerboard and time kill methods.
316
 
These methods are however, time and material expensive and for that reason they 
are not used routine in routine clinical practice. The method used in this study 
with pairs of E-Test strips is relatively new and has the advantage that it is easy 
and cheap to perform.
317
 The degree of agreement between FIC results calculated 
by the checkerboard and the E-Test method varies in the literature depending on 
the type bacteria tested. For example 55% agreement was found between the two 
tests when used with Brucella melitensis isolates,
315
 63% with Acinetobacter
318
 
and 90% with P. aeruginosa.
319
 A limitation of the E-Test method is that it does 
not provide information about the bactericidal activity of the combination.  
The current study showed that the E-Test method has a reasonably low 
coefficient of variance and is particularly useful to screen a large number of 
isolates against several combinations of antimicrobials. The combination of 
meropenem and teicoplanin gave the lowest mean FIC for S. aureus, with synergy 
or antagonism seen in 80%. For P. aeruginosa the combination with the lowest 
mean FIC was meropenem and ciprofloxacin with synergy or antagonism seen in 
90%. Against S. aureus the combinations of teicoplanin with meropenem, 
ciprofloxacin or moxifloxacin also gave a low mean FIC with more than 50% 
demonstrating either an additive effect or synergy. Other combinations tested 
were predominantly indifferent. No combinations were found, of antimicrobials 
that were consistently antagonistic, when used against S. aureus or P. aeruginosa. 
5.53 Pharmacokinetics of meropenem 
Any conclusions about antimicrobial treatment of bacterial keratitis based on in 
vitro studies of drugs have inherent limitations. As previously discussed (chapter 
5.112), the breakpoints for the antimicrobials are determined from expected serum 
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concentrations after systemic administration and breakpoints after topical 
administration have yet to be standardised. More information about the 
bioavailability of antimicrobials delivered topically to the cornea is needed to 
interpret the MIC levels. This is especially relevant to the novel antimicrobials 
tested. The antimicrobial meropenem was selected to undergo pharmacokinetic 
testing based on the in vitro results from these studies.  
Topically applied drops are rapidly lost from the ocular surface and 
therefore bioavailability of topically applied drugs is very low, typically less than 
5%.
252
 In order to reach adequate tissue concentrations in the cornea, high drug 
concentrations coupled with frequent application are required. An assessment of 
corneal cellular toxicity is therefore an important aspect of analysing a drug that is 
to be applied to the eye. In this study we used the MTT assay
16
 to assess the 
toxicity of meropenem. The MTT assay is a measure of mitochondrial cell 
function and hence is an indirect indicator of cell viability. Saarinen-Savolainen et 
al
320
 have shown the MTT assay in immortalised corneal cell lines to be an 
accurate and reliable method to assess for the toxicity of topically applied drugs to 
the cornea. We found the cellular toxicity of meropenem on HKs and HCEs was 
significantly lower than moxifloxacin. The low cell viability we found in corneal 
cells treated with moxifloxacin was similar to previous studies.
321
 The Live Dead 
assay distinguishes live cells by the presence of intracellular esterase activity, 
determined by the enzymatic conversion of the nonfluorescent calcein AM to the 
intensely fluorescent calcein. The Live Dead assay in this study showed similar 
high levels of cell viability in both meropenem treated and untreated (control) 
cells. The low level of toxicity, seen in both MTT and Live Dead assay, parallels 
the good systemic safety profile of meropenem.
322,
 
278, 323
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The study of antimicrobial corneal pharmacokinetics is commonly 
performed in animals such as rabbits.
324, 325
 There are several structural, 
physiological and biochemical differences between the human and the rabbit 
eye.
326
 Rabbits have a nictitating membrane, a larger corneal surface area and a 
thinner cornea, all of which could alter corneal pharmacokinetics. Studying 
corneal pharmacokinetics in vivo in human subjects is ideal but this is a long, 
costly process. The method used in this study of testing corneal penetration with 
ex-vivo human corneas on artificial anterior chambers, allows testing of human 
tissue without the constraints of testing on live patients.  
Two methods of analysing meropenem concentration were used in this 
study; HPLC and bioassay. Chemical assays are sensitive but may not reflect the 
activity of the compound particularly in the tissue which may be affected for 
example, by pH and protein binding.
327, 328
 A further important difference in 
considering the data between both methods relates to their ability to measure 
active metabolites. HPLC detects compounds with predefined chemical structures 
and (not necessarily) different chemical species that result from metabolic 
reactions. The extra peaks on the HPLC traces, seen in the older aqueous samples 
(figure 28), may therefore represent metabolites of meropenem. A bioassay will 
detect any active substances against the test bacteria, irrespective of their chemical 
characteristics.
329
 The higher concentrations using the bioassay, therefore, may 
suggest the metabolites of meropenem are biologically active, which could 
explain the higher meropenem concentration calculated in bioassay, compared to 
HPLC. Further studies to investigate the metabolic products of meropenem would 
be indicated. 
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An important factor that determines the efficacy of an antimicrobial is its 
ability to penetrate to the target ocular tissues at concentrations greater than the 
MIC. Sueke et al
104
 calculated the MIC90 of meropenem to be 0.08 µg/ml to S. 
aureus; 0.25 µg/ml to P. aeruginosa; and 0.054 µg/ml to Streptococci against 
isolates from patients with keratitis. The mean concentration of meropenem in the 
aqueous of the artificial chamber detected by both HPLC and bioassay methods 
superseded the MIC90, at even the earliest (45 minute) sampling point. To achieve 
standardisation of the corneas, the remaining epithelium and endothelium was 
removed. An ulcer is usually present in most patients with bacterial keratitis and 
would support this in vitro model. It is unclear however, whether the presence of 
an intact functioning endothelium would affect the pharmacokinetics of 
meropenem across the cornea into the anterior chamber, and therefore further 
work using in vivo studies would be appropriate. Whether the same concentrations 
would be achieved in vivo is unclear but these results would support the 
consideration of meropenem in the treatment of bacterial keratitis. 
 
5.6 Conclusion 
The antimicrobial meropenem was found to have excellent pharmacodynamic 
properties, with low MICs against a wide range of isolates from patients with 
bacterial keratitis, both singly and in combination with other antimicrobials. 
Further pharmacokinetic studies, showed excellent penetration of meropenem in 
an artificial anterior chamber model and low cellular toxicity. Prior to initiating 
meropenem as a treatment in bacterial keratitis further pharmacokinetic and safety 
data should be obtained from live human subjects.   
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CHAPTER 6: SUMMARY AND FURTHER WORK 
6.1 Summary of S. aureus study (chapter 3) 
The prevalence, genetic diversity and clinical relevance of the lukSF-PV gene, 
encoding the bacterial toxin PVL, were investigated in S. aureus, isolated from 
cases of bacterial keratitis in the UK. Multiplex PCR investigating carriage of 
lukSF-PV and mecA were performed on 95 S. aureus isolates taken from patients 
with keratitis. The lukSF-PV operon was sequenced to investigate its diversity and 
MLST to test for a clonal relationship between lukSF-PV isolates. Antimicrobial 
MICs and clinical outcome data were compared for isolates characterized as 
lukSF-PV+ve, mecA+ve, and lukSF-PV/mecA-ve.  
Out of 95 isolates, 9 (9.5%) were lukSF-PV+ve, 9 (9.5%) mecA+ve and 1 
was positive for both. Five SNPs were found in lukSF-PV genes of 7 strains. 
There was no significant difference between the MICs of lukSF-PV/mecA-ve and 
lukSF-PV+ve isolates to the antimicrobials tested, except for tigecycline (p<0.05). 
The mecA+ve isolates had significantly higher mean MICs to meropenem and 
fluoroquinolones (p<0.05). There were non-significant trends for healing and 
treatment times, ulcer and scar size and overall clinical score to be greater in the 
lukSF-PV+ve group. The proportion of patients, however, that required surgery 
was significantly greater amongst patients with lukSF-PV+ve isolates with an 
odds ratio of 7.8 (95% CI 1-42, p=0.018) for patients requiring surgery. 
In conclusion; patients with lukSF-PV+ve S. aureus were associated with a 
trend to worse clinical outcome and more surgical interventions, with an effect 
unrelated to MICs. This suggests that lukSF-PV may be an important virulence 
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factor in S. aureus associated keratitis. To further ascertain the relevance of 
lukSF-PV in S. aureus keratitis, a larger study would be needed. This is especially 
the case in light of previous epidemiological studies that suggest that the presence 
of PVL is not associated with a worse clinical outcome in S. aureus infection in 
other organs.  
6.2 Summary of P. aeruginosa study (Chapter 4) 
To examine temporal dynamics of keratitis-associated P. aeruginosa, the genetic 
characteristics of isolates collected during 2003-04 published by Stewart et al
231
 
and 2009-10 were compared using an AT genotyping system.  
60 P. aeruginosa isolates were collected by the MOG from patients with 
keratitis from 2009 to 2010. Results from AT genotyping were compared to 
similar isolates collected by the MOG between 2003 and 2004. The distribution of 
keratitis-associated isolates from the two time periods (n=123) among a database 
of P. aeruginosa strains of non-ocular origin (n=322) indicated that 71% of UK 
keratitis-associated P. aeruginosa isolates clustered together. There was no 
evidence for major variations in the distribution of clone types between the two 
collections. The “core keratitis cluster” is related to the P. aeruginosa eccB clonal 
complex, which is associated with adaptation to survival in environmental water.  
This suggests that adaptation to environmental water is a key factor in the ability 
of P. aeruginosa to cause eye infections which is consistent with the notion that 
aquatic environments are integral to the transmission dynamics of P. aeruginosa, 
in the context of bacterial keratitis. However, the link between specific genotypes 
and clinical outcome or risk factors is not clear.  
Further analysis of clinical data and studies involving additional sets of 
patients for verification of this hypothesis will provide a clearer picture, helping to 
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link genetic features with evidence-led clinical management of P. aeruginosa 
keratitis. 
6.3 Summary of antimicrobial study (chapter 5) 
6.31 Pharmacodynamics of single and combinations of antimicrobials 
Pharmacodynamic properties of commonly used and potentially novel 
antimicrobials were determined by calculating MICs against isolates from patients 
with keratitis in 2003-2005 and 2010-2011. MICs were calculated by E-Tests for 
meropenem, moxifloxacin, gentamicin and ciprofloxacin against P. aeruginosa, 
and Enterobacteriaceae and moxifloxacin, linezolid, ciprofloxacin, penicillin, 
meropenem and teicoplanin against S. aureus. Based on systemic breakpoints this 
study found resistance in several commonly used antimicrobials across two time 
periods. Particularly worrying was the high level of resistance in the commonly 
used ciprofloxacin against S. aureus. All the Gram-positive isolates tested were 
susceptible, however, to teicoplanin and the novel antimicrobials meropenem and 
linezolid. Lower resistance was seen against the Gram-negatives tested. Overall, 
this data suggest that of the antimicrobials currently in use, moxifloxacin offers 
the best coverage against both Gram-positive and -negative isolates. Of the newer 
antimicrobials potentially suitable for ophthalmic use, meropenem appears to be a 
good choice for empiric monotherapy in bacterial keratitis, offering broad-
spectrum cover against both Gram-positive and -negative microorganisms, with 
only one of the 772 isolates tested (P. aeruginosa) found to be resistant. Linezolid 
was active against all S. aureus isolates including a small number of MRSA 
isolates. Linezolid may therefore be useful for dual therapy when used in 
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combination with an antimicrobial with good cover against Gram-negative 
bacteria. 
Antimicrobial combinations were investigated for synergy or antagonism 
against isolates of S. aureus and P. aeruginosa. Isolates were collected from cases 
of microbial keratitis from six centres in the UK. E-Test strips were used to test 
selected antimicrobials in combination against a representative set of 10 S. aureus 
and 10 P. aeruginosa isolates. Antimicrobial combinations were classified as 
synergistic, additive, indifferent, or antagonistic, according to their fractional 
inhibitory concentration (FIC). The combinations meropenem and ciprofloxacin, 
meropenem and teicoplanin, moxifloxacin and teicoplanin and ciprofloxacin and 
teicoplanin, gave the lowest mean FICs for S. aureus, with synergy or additivity 
being seen in 60% to 80% of isolates. The meropenem/ciprofloxacin combination 
gave the lowest mean FIC for P. aeruginosa isolates, with 90% showing an 
additive or synergistic effect. The other combinations elicited a predominantly 
indifferent response. No consistent antagonistic effect was observed with the 
combinations used. In conclusion, the combination of meropenem and 
ciprofloxacin was predominantly additive or synergistic for both S. aureus and P. 
aeruginosa. Teicoplanin combined with meropenem, ciprofloxacin, or 
moxifloxacin was also predominantly additive or synergistic against S. aureus.  
Following the above two studies, the antimicrobial meropenem was 
selected for further corneal pharmacokinetic investigation.  
6.32 Pharmacokinetics of meropenem 
To investigate the toxicity of topically applied meropenem, corneal cell toxicity 
assays were undertaken using cultures of HKs and HCEs. MTT and Live Dead 
assays evaluated cell viability of cells treated with meropenem and moxifloxacin. 
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Corneal penetration of meropenem was assessed in human cadaver corneo-scleral 
discs mounted onto artificial anterior chambers. Meropenem 10 mg/ml was 
applied and samples collected at 45 mins, 1.5 hrs, 3.5 hrs and 24 hrs. 
Concentrations of meropenem were estimated using (1) a bioassay with E. coli 
and (2) HPLC. MTT assay showed meropenem had significantly higher cell 
viability at both 5 mg/ml and 2.5 mg/ml compared to moxifloxacin (p<0.05). Live 
dead assay showed no statistical difference in cell viability between cells treated 
with meropenem and untreated controls. The concentration of meropenem in the 
aqueous exceeded the MIC90 at 45 mins; 1.3 µg/ml (±1.5) bioassay and 0.9 µg/ml 
(±0.9) HPLC and steadily increased over 24 hours to; 43.7 µg/ml (±27.2) bioassay 
and 13.5 µg/ml (±4.8) HPLC. At the 24 hour time point, the meropenem 
concentration measured by bioassay exceeded measurements made by HPLC in 
12 out of the 18 corneas. This may be due to metabolites of meropenem that are 
active in the bioassay but not quantifiable by HPLC.  
In conclusion meropenem was shown to have low cellular toxicity on HKs 
and HCEs. It had good tissue penetration, achieving concentrations well above the 
MIC90 by 45 minutes. 
 
6.4 Bacterial keratitis: the future 
A small proportion of patients with keratitis continue to have a poor outcome 
when managed with conventional topical antimicrobial therapy. Difficulties in 
bacteriological diagnosis, increasing antimicrobial resistance, and poor 
pharmacokinetics are all drawbacks to standard techniques in managing the 
disease. Potential areas of further research will be now be discussed; firstly, novel 
strategies in diagnosing keratitis and secondly novel strategies in treating keratitis.   
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6.41 Novel strategies in diagnosis 
In order to determine the causative bacteria in a patient with keratitis, samples 
from the corneal ulcer need to be collected. This is conventionally undertaken 
using a blade or a needle to scrape the edges of the ulcer which are then 
inoculated directly onto agar plates (figure 9). Kaye et al 
61
 reported that 
collecting two corneal scrapes, one for a smear and the other placed in BHI broth, 
resulted in detection
 
rates similar to those of direct plating with no significant loss 
of organisms (chapter 1.131). Culture yield from corneal ulcers using corneal 
scraping, however, are low varying between 30 to 60%.
61
 This may explain the 
reluctance of some ophthalmologists to perform a corneal scrape to reach a 
microbiological diagnosis. For example, McDonnell et al 
330
 found
 
that 49% of 
ophthalmologists treated corneal ulcers empirically
 
without attempting to identify 
the causative organism. It is evident that improvements are required in the 
detection and diagnosis of the causative bacteria in cases of suspected bacterial 
keratitis. 
6.411 Impression cytology  
The application of circular pieces of cellulose filter paper onto the ocular surface, 
known as impression cytology (IC), has been shown to reliably remove surface 
cells from the eye in viral,
331, 332
 fungal,
333
 and acanthamoeba
334
 corneal 
infections. It has also been investigated in the diagnosis of a variety of other 
ocular surface conditions such as ocular surface neoplasia,
335
 keratoconjunctivitis 
sicca,
336
 vitamin A deficiency,
337
 and atopic conjunctitivits.
338
 This technique is 
simple to perform and less traumatic than the conventional scraping method. 
Furthermore it is potentially less invasive for the patient and is easier to apply 
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than using a blade to scrape the ulcer. IC may therefore, be suitable for use by 
non-ophthalmologists or where less sophisticated biomicroscopes are available, 
such as in less developed countries. In addition IC allows collection of fluid 
overlying the ulcer, which can then be analysed for bacterial secreted factors 
including QS molecules. Lastly, an additional but overlooked issue is the ability to 
determine or measure the bacterial response to treatment. By sampling the corneal 
ulcer during the time course of infection with IC it will be possible to study 
bacterial adaptations to treatment. This will provide a clear picture of bacterial 
mechanisms during in vivo infection and help to identify appropriate novel 
treatment strategies. 
A randomised control study comparing the application of IC filter paper to 
the standard corneal scrape method is currently in progress. This will ascertain the 
value of IC in diagnosing bacterial keratitis. 
6.412 Molecular biology techniques 
Recently attempts have focused on the diagnostic yield from bacterial DNA using 
PCR to amplify bacterial DNA from patients with keratitis.
63, 339
 This involves 
either amplifying a conserved region of DNA from the gene encoding the 
bacterial ribosomal RNA and then sequencing the product to identify the type of 
bacteria, or using a set of primers specific to known bacterial pathogens. Subrayan 
et al
339
 evaluated the role of real-time PCR in the detection of P. aeruginosa in 10 
patients with keratitis. They found PCR was at least as good as conventional 
cultures in detecting P. aeruginosa. Larger, randomised control trials, however, 
would be necessary to fully ascertain the role of PCR in diagnosing keratitis. 
Matrix Assisted Laser Desorption/ Ionisation - Time Of Flight (MALDI-
TOF) is also being used in increasing frequency to identify bacteria in other 
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infectious diseases.
340, 341
 MALDI-TOF uses the application of a matrix to break 
open the bacterial cell wall which immediately crystallizes proteins. A laser 
generates a cloud of ions which are accelerated up a tube in the analyser. The 
detector estimates the molecular weight of the ions by calculating the time of 
flight it takes for the ions to reach the detector. A protein profile is thus produced, 
which can be compared to a database to identify the bacteria. 
Utilising molecular techniques detecting DNA such as PCR and/or 
MALDI-TOF, may improve the diagnostic yield in patients with keratitis and also 
has the advantage of being a quicker and more sensitive technique than traditional 
culture methods. The interpretation of these DNA detecting techniques, however, 
may be difficult, because the presence of bacterial DNA does not distinguish 
between an active or inactive infection. To determine the degree of bacterial 
activity, and importantly the expression of virulence factors, the detection and 
measurement of bacterial mRNA would complement the use of DNA methods 
and this may be the future direction in diagnosing the disease.  
Molecular biological methods also provides the opportunity to identify 
particular sub-sets of bacteria associated with keratitis (chapter 3 and 4). Early 
detection of virulence factors such as lukSF-PV, could provide information to 
enable treatment of bacterial keratitis to be modified if necessary. Knowledge of 
particular virulence factors may enable a clinician to predict if a patient is at 
higher risk of experiencing a poorer prognosis. This will help target such patients 
for more intensive treatment including hospital admission, frequent antimicrobial 
therapy and earlier surgical intervention. 
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  6.42 Novel management strategies 
As discussed in chapter 5.13, increasing resistance to commonly prescribed 
antimicrobials treating keratitis has been noted. In order to combat this, various 
strategies have been proposed; (1) to develop existing antimicrobials that have not 
yet been used in the eye, (2) to develop more effective ways of drug delivery and 
(3) to tailor drugs against specific virulence factors in selected patients. 
6.42 Novel strategies in management  
6.421 Development of existing antimicrobials 
Sueke et al
104
 investigated a number of antimicrobials that had previously been 
used to treat systemic infections, but had not been used (other than an occasional 
case report for some
342
) as a topical application to treat microbial keratitis or other 
ocular infections. Meropenem has been discussed in detail in chapter 5. Linezolid 
and tigecylcline were also suggested by Sueke et al
104
 as potential novel 
antimicrobials for bacterial keratitis. 
Linezolid,
343
 the first of a new class the oxazolidinones, is a synthetic 
compound with activity against all the major Gram-positive groups of bacteria, 
but no activity against Gram-negative bacteria. Linezolid works by inhibiting 
bacterial ribosomal protein synthesis by binding to a site on the 50S ribosomal 
subunit thus preventing the formation of a 70S initiation complex. The 
investigation of MICs in chapter 5.41
104
 showed linezolid to have low MICs 
against Gram-positive isolates including MRSA. Pharmacokinetic studies using 
animal models of keratitis have showed good corneal penetration and no recorded 
toxicity with linezolid.
344, 345
 
Tigecycline
346
 is a glycylcycline with activity against most aerobic and 
anaerobic Gram-positive and Gram-negative bacteria, but with limited activity 
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against P. aeruginosa. Glycylclines are bacteriostatic agents that inhibit protein 
synthesis in bacteria by reversibly binding to the 30S ribosomal subunit. Sueke et. 
al.
104
 showed Gram-positive isolates to have no resistance to tigecycline using 
systemic breakpoints, but P. aeruginosa had 100% resistance. Corneal 
pharmacokinetics of tigecycline have not yet been determined. 
 
6.423 Drug delivery systems  
The majority of ophthalmic drugs used to treat keratitis are administered to the 
eye topically in the form of drops, solutions, emulsions or suspensions. It is well 
known, however, that this delivery method is inefficient and the majority of drug 
delivered topically never reach the aqueous humour. This may in part account for 
the poor outcome from bacterial keratitis.
251
 Zhang et al
347
 suggests that less than 
5% of lipophilic molecules reach the aqueous humour and less than 0.5% of 
hydrophilic molecules. Reasons for this low efficiency include clearance by tear 
drainage and the presence of the corneal barrier. Patient compliance also affects 
the success of topical administration. 
Many studies have investigated means of increasing drug absorption when 
the agent is delivered topically. This area has recently been reviewed by Shirasaki 
et al.
348
 One method is to make the drug more lipophilic so it will pass more easily 
through the cornea. Increasing the solubility of the drug can also increase 
penetration. Methods of modifying the physicochemical properties of drugs to 
increase ocular penetration may include the addition of particulates such as nano-
particles and other penetration enhancers, as well as using the prodrug and 
mucoadhesive dosage forms. Iontophoresis is a novel method improving ocular 
penetration of topically applied drugs.
349
 It is a non-invasive technique where a 
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small electric current is applied to enhance ionized drug penetration into tissue. 
The drug is applied with an electrode carrying the same charge as the drug, and 
the ground electrode, which is of the opposite charge, is placed elsewhere to 
complete the circuit. The drug serves as a conductor of the current through the 
tissue. Eljarrat-Binstock and Domb
349
 have reviewed the use of iontophoresis in 
ocular drug delivery.  
Some researchers have looked at alternative drug delivery devices to 
enhance antimicrobial delivery (summarised in table 19).
251, 350
 They broadly fall 
into two groups: matrix and reservoir based devices. In matrix-based implants, 
such as Bioadhesive Ophthalmic Drug Inserts,
351
 the drug is distributed 
throughout a polymer matrix. The polymer is usually degradable, with common 
components being polylactic acid, polyglycolic acid and polylactic-co-glycolic 
acid. Once the matrix is introduced to the eye, the degradation of the polymer 
leads to the release of the drug, so tailoring of the degradation rate controls the 
rate of drug release.  
In a reservoir implant, the drug is stored within a reservoir and is generally 
released over a time period of months or years. Non-degradable reservoir 
implants, such as Ocufit SR®,
251
 are often manufactured from a combination of 
polyvinyl alcohol (PVA) and ethylene vinyl acetate (EVA). In a standard reservoir 
design, the drug is formed into a pellet with PVA and the pellet is coated with 
EVA. In a reservoir implant the drug is stored within a reservoir made of a non-
degradable substance such as a collagen shield.  
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Table19. Summary of some of the drug delivery devices that have been trialled 
clinically. M: Matrix implant; NI: Nonimplantable; PLGA: Polylactic-co-glycolic 
acid; PVA: Polyvinyl alcohol; R: Reservoir-based implant. 
Delivery system Insertion Type and location duration 
Soluble Ophthalmic 
Drug Insert (SODI™)  
Upper/lower 
conjunctiva 
NI, M 
film of acrylamide,    
N-vinylpyrrolidone, 
ethyl acrylate  
Hours 
Lacrisert
®
 Lower conjunctiva NI, M 
Hydoxypropyl cellulose 
1 day 
Bioadhesive 
Ophthalmic Drug 
Inserts (BODI
®
)  
Lower conjunctiva NI, M 
Combination of 4 
polymers 
Days 
Ocufit SR
®
 Lower conjunctiva NI, R 
Silicone elastomer tube 
weeks 
Scleral plugs Sclera I, M 
biodegradable 
polymers, PLGA 
1 month 
 
6.424 Anti-virulence therapy 
Traditional approaches to antimicrobial therapy are based on targeting bacterial 
cellular processes crucial for survival (chapter 5.12). Reducing bacterial survival, 
however, has two major drawbacks; (1) the encouragement of antimicrobial 
resistance (chapter 5.13) and (2) the non-intended eradication of useful host 
symbiotic bacteria.
352
 
Targeting bacterial virulence is an alternative approach in treating 
infectious disease, which may offer a reduced selection pressure for drug-resistant 
mutations. This strategy aims at disarming pathogens of their harmful properties, 
without threatening their existence.
353
 Anti-virulence drugs could be designed to 
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target specific pathogens and the virulence factors that are unique to their 
pathogenic cascades. As discussed in chapter 1.33, bacteria use an array of 
virulence factors to cause disease including adhesins, toxins, specialized secretion 
systems and QS. These are all potential therapeutic targets.  
Many Gram-positive and Gram-negative bacteria use a pilus to adhere to 
the host cell (chapter 1.33). Pilicides are mimics of the normal pilin subunits that, 
when incorporated into the growing pilus, prevent elongation and the formation of 
a functional pilus. Treatment with pilicides has been shown to decrease the 
efficiency of colonization of E. coli.
354
  
Inhibitors to bacterial toxins has been extensively investigated in vitro and 
in vivo. For example, an inhibitor of Las B (a metalloproteinase secreted by P. 
aeruginosa chapter 4.122) has been shown to inhibit targets that are instrumental 
in biofilm formation and immunomodulation in vitro.
355
 McCormick et al
356
 
demonstrated that inhibition of α toxin associated with S. aureus (chapter 3.122) 
resulted in significantly less corneal damage in a rabbit model of keratitis.  
The importance of the TTSS in the virulence of P. aeruginosa has been 
discussed in chapter 4.122. Numerous small-molecule inhibitors of this system 
have been identified using high-throughput screening (HTS) of small-molecule 
libraries.
357
 
Several strategies have been developed to inhibit the QS system. For 
example; the marine macroalgae Delisea pulchra has been shown to inhibit the 
AHL-based QS system of Pseudomonas.
358
 The inhibition of auto-inducing 
peptide that regulates the Agr QS in S. aureus (chapter 3.12) has also been 
suggested.
359
 Although these molecules show promising in vitro results in 
preventing pathogenesis, in vivo activity remains to be assessed. 
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Safety is always a concern when introducing new therapies. As anti-
virulence treatments are targeted to pathways or factors that exist exclusively in 
pathogens, it is likely that there will be less host toxicity compared to therapies 
that affect targets which are also expressed by the host. It is unclear, however, 
what effects these types of therapies will have on the commensal bacterial 
population and whether they will produce metabolites harmful to the host. Broad-
scale clinical trials would shed light on this question.  
6.5 Conclusion: patient stratification and personalised treatment 
New approaches are necessary in managing patients with the sight-threatening 
disease bacterial keratitis. 
This study has identified virulence factors and genetic characteristics have 
been identified in S. aureus and P. aeruginosa associated with keratitis. Future 
strategies in the disease may involve the identification of particular virulence 
factors that may enable the (1) the stratification of patients into poor and good 
outcomes and (2) the use of specific anti-virulence therapy in selected patients 
causing less side effects and resistance. 
Using a pharmacodynamic / pharmacokinetic approach, this study has 
identified meropenem as an ideal candidate for the treatment of keratitis. The 
antimicrobial was shown to have; low MICs, good synergistic properties in 
combination with other antimicrobials, adequate corneal penetration and low 
cellular toxicity. Further studies on live human subjects would be necessary prior 
to initiating it as a therapy in disease. 
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APPENDIX 
(A) LB broth 
Components 
Tryptone  10 g 
Yeast Extract     5 g 
NaCl                  10 g  
All components were dissolved in 1L of sterile distilled water and mixed to 
dissolve, sterilised by autoclaving at 121 °C for 15 mins, cooled and stored at 
room temperature.  
(B) Molecular techniques 
1) Array Tube Solutions and Buffers 
Wash buffer 1 (2xSSC/0.01% Triton X100) 
NaCl     175.3 g 
Sodium citrate  88.2 g 
Nacl and sodium citrate were dissolved in 800 ml of sterile distilled water 
(SDW). The pH was adjusted to 7.0 and the volume made up to 1L with 
SDW. The solution was then diluted 1:10 in H20 and Triton X100 was 
added to a final concentration of 0.01% v/v. 
Wash buffer 2 (0.2 x SSC) 
Wash buffer 1 was diluted 1:100  
Hybridisation buffer 
Formamide 60-100%  125 ml 
HRP Conjugation solution 
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Luminol (3-aminopthalhydrazide)  125 ml 
 
2) TBE Buffer  
Tris    162 g  
EDTA    11.16 g 
Boric Acid   83.5 g 
All components were added to 2.5 litres of distilled water. This was then 
mixed on a stirring plate until completely dissolved. The volume was then 
made up to 3 litres.  
 
3) DNA ladders/Markers 
 1 kb plus DNA ladder (Invitrogen) 
The 1 kb plus DNA ladder is composed of 20 double-
stranded DNA bands ranging from 100 bp to 12,000 
bp. This ladder has 12 evenly spaced bands ranging 
from 1 kb to 12 kb, a quick orientation band at 1,650 
bp that forms a distinct doublet with the 2 kb band, and 
seven bands of round sizes below 1 kb. The ladder 
contains: 1 Kb Plus DNA Ladder™ (1 µg/µl) in 10 
mM Tris-HCl (pH 7.5), 50 mM NaCl, and 1 mM 
EDTA. For loading 1 part 1 Kb plus ladder was added 
to 5 parts 6x loading buffer. 
(C) MLST gene sequences  
1) arcc  
TTATTAATCCAACAAGCTAAATCGAACAGTGACACAACGCCGGCAATG
CCATTGGATACTTGTGGTGCAATGTCACAGGGTATGATAGGCTATTGG
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TTGGAAACTGAAATCAATCGCATTTTAACTGAAATGAATAGTGATAGA
ACTGTAGGCACAATCGTTACACGTGTGGAAGTAGATAAAGATGATCCA
CGATTCAATAACCCAACCAAACCAATTGGTCCTTTTTATACGAAAGAA
GAAGTTGAAGAATTACAAAAAGAACAGCCAGACTCAGTCTTTAAAGA
AGATGCAGGACGTGGTTATAGAAAAGTAGTTGCGTCACCACTACCTCA
ATCTATACTAGAACACCAGTTAATTCGAACTTTAGCAGACGGTAAAAA
TATTGTCATTGCATGCGGTGGTGGCGGTATTCCAGTTATAAAAAAAGA
AAATACCTATGAAGGTGTTGAAGCG 
2) aroe 
AATTTTAATTCTTTAGGATTAGATGATACTTATGAAGCTTTAAATATTC
CAATTGAAGATTTTCATTTAATTAAAGAAATTATTTCGAAAAAAGAAT
TAGATGGCTTTAATATCACAATTCCTCATAAAGAACGTATCATACCGT
ATTTAGATCATGTTGATGAACAAGCGATTAATGCAGGTGCAGTTAACA
CTGTTTTGATAAAAGATGACAAGTGGATAGGGTATAATACAGATGGTA
TTGGTTATGTTAAAGGATTGCACAGCGTTTATCCAGATTTAGAAAATG
CATACATTTTAATTTTGGGCGCAGGTGGTGCAAGTAAAGGTATTGCTT
ATGAATTAGCAAAATTTGTAAAGCCCAAATTAACTGTTGCGAATAGAA
CGATGGCTCGTTTTGAATCTTGGAATTTAAATATAAACCAAATTTCATT
AGCAGATGCTGAAAAGTATTTA 
3) glpf 
GGTGCTGATTGGATTGTCATCACAGCTGGATGGGGATTAGCGGTTACA
ATGGGTGTGTTTGCTGTCGGTCAATTCTCAGGTGCACATTTAAACCCAG
CGGTGTCTTTAGCTCTTGCATTAGACGGAAGTTTTGATTGGTCATTAGT
TCCTGGTTATATTGTTGCTCAAATGTTAGGTGCAATTGTCGGAGCAACA
ATTGTATGGTTAATGTACTTGCCACATTGGAAAGCGACAGAAGAAGCT
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GGCGCGAAATTAGGTGTTTTCTCTACAGCACCGGCTATTAAGAATTAC
TTTGCCAACTTTTTAAGTGAGATTATCGGAACAATGGCATTAACTTTAG
GTATTTTATTTATCGGTGTAAACAAAATTGCCGATGGTTTAAATCCTTT
AATTGTCGGAGCATTAATTGTTGCAATCGGATTAAGTTTAGGCGGTGC
TACTGGTTATGCAATCAACCCAGCACGT 
4) gmk  
CGAATATTTGAAGATCCAAGTACATCATATAAGTATTCTATTTCAATG
ACAACACGTCAAATGCGTGAAGGTGAAGTTGATGGCGTAGATTACTTT
TTTAAAACTAGGGATGCGTTTGAAGCTTTAATCAAAGATGACCAATTT
ATAGAATATGCTGAATATGTAGGCAACTATTATGGTACACCAGTTCAA
TATGTTAAAGATACAATGGACGAAGGTCATGATGTATTTTTAGAAATT
GAAGTAGAAGGTGCAAAGCAAGTTAGAAAGAAATTTCCAGATGCGCT
ATTTATTTTCTTAGCACCTCCAAGTTTAGAACACTTGAGAGAGCGATTA
GTAGGTAGAGGAACAGAATCTGATGAGAAAATACAAAGTCGTATTAA
CGAAGCGCGTAAAGAAGTTGAAATGATGAATTTA 
5) pta  
GCAACACAATTACAAGCAACAGATTATGTTACACCAATCGTGTTAGGT
GATGAGACTAAGGTTCAATCTTTAGCGCAAAAACTTGATCTTGATATT
TCTAATATTGAATTAATTAATCCTGCGACAAGTGAATTGAAAGCTGAA
TTAGTTCAATCATTTGTTGAACGACGTAAAGGTAAAGCGACTGAAGAA
CAAGCACAAGAATTATTAAACAATGTGAACTACTTCGGTACAATGCTT
GTTTATGCTGGTAAAGCAGATGGTTTAGTTAGTGGTGCAGCACATTCA
ACAGGAGACACTGTGCGTCCAGCTTTACAAATCATCAAAACGAAACCA
GGTGTATCAAGAACATCAGGTATCTTCTTTATGATTAAAGGTGATGTA
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CAATACATCTTTGGTGATTGTGCAATCAATCCAGAACTTGATTCACAA
GGACTTGCAGAAATTGCAGTAGAAAGTGCAAAATCAGCATTA 
6) tpi 
CACGAAACAGATGAAGAAATTAACAAAAAAGCGCACGCTATTTTCAA
ACATGGAATGACTCCAATTATTTGTGTTGGTGAAACAGACGAAGAGCG
TGAAAGTGGTAAAGCTAACGATGTTGTAGGTGAGCAAGTTAAGAAAG
CTGTTGCAGGTTTATCTGAAGATCAACTTAAATCAGTTGTAATTGCTTA
TGAGCCAATCTGGGCAATCGGAACTGGTAAATCATCAACATCTGAAGA
TGCAAATGAAATGTGTGCATTTGTACGTCAAACTATTGCTGACTTATCA
AGCAAAGAAGTATCAGAAGCAACTCGTATTCAATATGGTGGTAGTGTT
AAACCTAACAACATTAAAGAATACATGGCACAAACTGATATTGATGG
GGCATTAGTAGGTGGCGCA 
7) yqil 
GCGTTTAAAGACGTGCCAGCCTATGATTTAGGTGCGACTTTAATAGAA
CATATTATTAAAGAGACGGGTTTGAATCCAAGTGAGATTGATGAAGTT
ATCATCGGTAACGTACTACAAGCAGGACAAGGACAAAATCCAGCACG
AATTGCTGCTATGAAAGGTGGCTTGCCAGAAACAGTACCTGCATTTAC
AGTGAATAAAGTATGTGGTTCTGGGTTAAAGTCGATTCAATTAGCATA
TCAATCTATTGTGACTGGTGAAAATGACATCGTGCTAGCTGGCGGTAT
GGAGAATATGTCTCAGTCACCAATGCTTGTCAACAACAGTCGCTTCGG
TTTTAAAATGGGACATCAATCAATGGTTGATAGCATGGTATATGATGG
TTTAACAGATGTATTTAATCAATATCATATGGGTATTACTGCTGAAAAT
TTAGTGGAGCAATATGGTATTTCAAGAGAAGAACAAGATACATTTGCT
GTAAACTCACAACAAAAAGCAGTACGTGCACAGCAA 
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(D) Clone types of P. aeruginosa isolates 
Strain Source Hexa code
a 
Clone type
b 
96004 Bristol 4822 novel
c 
96009 Bristol F469 D 
96024 Bristol F4A9 novel
c
 
96034 Bristol F429 I 
96035 Bristol F429 I 
96036 Bristol D421 A 
96037 Bristol F469 D 
96043 Bristol 1BAA novel
c
 
96044 Bristol 2422 novel
c
 
96045 Bristol E429 B 
96046 Bristol FE69 novel
c
 
96056 Bristol D421 A 
96062 Bristol F469 D 
96063 Bristol 2F82 novel
c
 
96064 Bristol 3C2A U 
96066 Bristol E429 B 
96074 Liverpool C40A C 
96076 Bristol 3C2A U 
106003 Bristol D421 A 
106011 Liverpool 2598 novel
c
 
106012 Liverpool C40A C 
106019 Liverpool 2C22 novel
c
 
106022 Bristol 042E novel
c
 
106026 London D421 A 
106028 London 0C8A novel
c
 
106029 London 0812 V 
106033 London F421 A2 
106042 London B428 novel
c
 
106044 London D421 A 
106053 London F469 D 
106054 London EC2A J 
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106055 London 2F82 novel
c
 
106056 London F460 novel
c
 
106057 London 85AA A4 
106065 London 0812 V 
106068 London EA0A A3 
106074 Bristol 9421 novel
c
 
106075 Bristol EC29 novel
c
 
106080 Manchester E429 B 
106083 Manchester 4612 novel
c
 
106094 Bristol F421 A2 
106103 Birmingham 3C1A novel
c
 
106107 Bristol C40A C 
106120 Bristol D421 A 
106122 Birmingham FD9A novel
c
 
106123 Birmingham 241A novel
c
 
106124 Birmingham C40A C 
106125 Birmingham D421 A 
106146 Bristol C429 novel
c
 
106147 Birmingham ED9A novel
c
 
106149 Birmingham E429 B 
106151 Birmingham C40A C 
106152 Birmingham 0812 V 
106154 Birmingham EC2A J 
106161 Bristol EC21 novel
c
 
106181 Bristol 2C22 novel
c
 
106183 Birmingham F429 I 
106188 Liverpool E429 B 
106215 Bristol 4992 novel
c
 
106221 Birmingham 2F02 novel
c
 
a Hexadecimal code generated from AT SNP analysis 
b Clone type identified in database  
c Hexadecimal codes of novel clones were not assigned a clone type in database 
na: not applicable 
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(E) Members of The MOG  
Stephen Kaye, Craig Winstanley, Mal Horsburgh, Amanda Hall, Henri Sueke and 
Timothy Neal (Royal Liverpool University Hospital); Stephen Tuft (Moorfields’ 
Eye Hospital); Derek Tole and John Leeming (Bristol Eye Hospital); Peter 
McDonnell (Birmingham and Midlands Eye Hospital); Francisco Figueiredo and 
Manjusha Narayanan (Royal Victoria Infirmary, Newcastle); Andrew Tullo, Fiona 
Carley, Hannah Lloyd and Malcolm Armstrong (Manchester Royal Eye Hospital); 
Colin Willoughby, Johnny Moore and Grace Ong (Royal Victoria Hospital, 
Belfast). 
